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Abstract 
Advances in mammalian cell culture have led to significant increases in cell concentrations 
and product titres. This has placed considerable demands on primary recovery and 
purification operations through associated increases in solids and impurity loads. These 
pose an additional challenge for the development of efficient and cost-effective processing 
strategies for the future. The work presented in this thesis focuses on the development of a 
methodology for the identification and selection of future-proof primary recovery 
technologies for the harvest of high cell concentration mammalian cell cultures.  
 
A survey questionnaire was developed to define industry needs in terms of desired primary 
recovery operational criteria as well as changes in cell culture material expected over the 
next decade. The industrial responses were used to form the base assumptions for the cell 
culture conditions used in the experimental work. The cell concentration and product titre 
expected in 2020 ranged up to 100x106 cells/mL and 20 g/L respectively. Impurity removal 
targets for the future primary recovery technologies were also quantified, where HCP 
removal was found to be of highest priority, followed by DNA and then aggregate removal.  
 
An integral element of the research focused on establishing a methodology to mimic future 
feed profiles to primary recovery stages. This resulted in the creation of a set of cell culture 
test materials (CCTM) where key variables including cell concentration, cell viability, product 
and host cell protein (HCP) load could be manipulated individually. The methodology 
involved using tangential flow filtration (TFF) to generate a range of target cell 
concentrations, induced cell apoptosis to achieve the target viabilities and ultrafiltration of 
purified harvests to create a range of Immunoglobulin G1 (IgG1) and HCP concentrations. 
The CCTM methodology was used at the 70L scale to quantify the reproducibility of the 
material, which was found to be within 10% of the target cell and HCP concentrations and 
15-20% of the target cell culture viability.   
 
The CCTM methodology was then integrated with scale-down experimentation, multi-
attribute decision-making, process economics and facility fit considerations to provide a 
systematic framework for the screening of primary recovery technologies with the potential 
for future use.  These included three current (centrifugation and depth filtration combinations 
including 05SP, 10P and 30ZA) and two alternative technology options (charged TFF hollow 
fibre modules including Bio-Optimal MF-SL and QSD). HCP removal levels of approximately 
10% were reached across all the tested technologies, however removal of specific HCP 
groups varied. Up to 99% DNA removal was achieved using the QSD, with lower levels of 
DNA removal using the other options. 
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MADM analysis as well as a selection based on current technology performance criteria 
showed that only two options met the yield and purity criteria: Bio-Optimal MF-SL and the 
QSD. The centrifugation and the 30ZA option met the purity criteria but not the yield criteria. 
Further economic evaluation of the options showed the centrifugation and 30ZA option to be 
the least cost-effective across the 2,000L, 10,000L and 20,000L scale scenarios and to not 
fit the facility constraints, which were set based on a typical existing large-scale facility. The 
Bio-Optimal MF-SL option was the most cost-effective option across the 2,000-20,000L 
scales of operation.  
 
Economic and MADM analyses of the alternative technologies were used to identify primary 
recovery options for the future. The QSD was found to provide greater capability for DNA 
removal prior to purification operations, however remained a costly option. The Bio-Optimal 
MF-SL offered a similar level of solids removal but was more cost-effective. Specific process 
requirements as well as other technology alternatives have to be taken into account 
indvidually to further select a cost-effective and appropriate technology choice.  
The effects of cell concentration, cell culture viability and HCP concentration on primary 
recovery performance were  then quantified using a Design of Experiments (DoE) approach. 
Multivariate data analysis wasused to determine predictive correlations capturing the impact 
of changes in cell culture composition on primary recovery performance. Ultimately this 
allowed identification of the most cost-effective primary recovery technology options to be 
centrifugation and depth filtration at cell concentrations below 50x106 cells/mL, the Bio-
Optimal MF-SL at cell concentrations in the range of 60-80x106 cells/mL and titres below 8 
g/L, and the QSD at cell concentrations above 80x106 cells/mL and titres above 12 g/L.. The 
work in this thesis  demonstrates a systematic integrated economic and experimental 
approach to identifying robust primary recovery technologies for future mammalian cell 
culture processes. 
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t Time s 
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MWC Wet mass per cell g 
SR Solids fraction remaining % 
SH Solids holding capacity kg 
U Number of centrifuge units  
QCin Maximum feed flowrate to a large scale 
centriguge 
L/h 
mPin Product mass kg 
Vmax Maximum throughput through a depth filter L/m2 
SF Safety Factor  
AM Membrane area per filter module  
NMSK Number of filter modules per skid  
VDFhup Hold up volume L 
YCP Unit specific product concentration yield g/L 
OPA Minimum space required for operation m 
MLW Mass of liquor in the sediment kg 
NP Number of discharge operations  
VW Total liquor loss in the sediment L 
tPCent Processing time H 
VDFin Volume in (depth filtration) L 
ADF Total membrane area required (depth filter) m2 
Nm Number of modules required  
YDF Product Yield (depth filtration) g/L 
AFSP Floor space required m2 
ATFF Total membrane area required (TFF filter)  
VTFFp Permeate volume (TFF) L 
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YTFF Product Yield (TFF filtration)  
   
Greek Symbols Description Units 
α Half the canonical angle of the disc in a 
centrifuge 
o 
β Membrane specific constant  
Δρ Density difference kgm-3 
μ Dynamic viscosity kgms-1 
Σ Equivalent clarification area in the centrifuge m2 
ω Angular velocity rads-1 
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1. Chapter 1: Introduction 
The high demand for cost-effective therapeutic protein products has been a continuing driver 
for process improvements, especially in the case of monoclonal antibody production. Due to 
the biological similarity and the complexity of these products, platform processes based 
largely on mammalian cell culture have been designed and implemented for the majority of 
the products over the last 20 years. Advances in cell culture methods and technologies have 
resulted in significant increases in cell culture titres and densities. The current workhorses of 
primary recovery operations can struggle to perform effectively with these high cell 
concentration cultures. This challenge potentially calls for a new strategy to cope with 
increased biomass, product and impurity levels from cell culture. This thesis describes the 
development of a methodology to screen rapidly and evaluate primary recovery technologies 
for their capacity for robust and cost-effective operation in the context of high cell 
concentration cultures. This introductory chapter provides an overview of the historical 
developments in the biopharmaceutical industry, an analysis of the current and future 
challenges in primary recovery of mammalian cell culture broth, as well as an overview of 
key primary recovery unit operations and cost modelling considerations.  Section 1.2 
provides an overview of the past and current trends in recombinant protein production. 
Sections 1.3 and 1.4 discuss key trends in mammalian cell culture and primary recovery 
methods and Section 1.5 discusses the main considerations which apply to recombinant 
protein production. Bioprocess cost modelling considerations are discussed in Section 1.6. 
Finally, the aims and organisation of the thesis are presented. 
1.1 Trends in recombinant protein production 
This section will explore the recent trends in recombinant protein production and some of the 
reasons behind them. The section will begin with a discussion of the recent production 
trends in terms of market demand, as well as more specific manufacturing trends, such as 
the recent issues experienced in the contract manufacturing industry. This will be followed 
by an overview of the steps involved in a typical mammalian cell culture process as well as 
some of the drivers behind the volume requirements and other trends observed in 
processing over the years. The section will conclude with an overview of the regulatory 
requirements in the biotechnology industry and their implications for processing. 
1.1.1 Trends in recombinant protein production 
The age of recombinant proteins began with the arrival of insulin between 1982 and the 
early 1990’s, which soon became the fastest growing branch of the biopharmaceutical 
market (Johnson, 2003; Jenkins, 2007). By 2000, investment in biotech was at the highest 
point ever observed before this poing, resulting in a large number of products entering 
clinical trials (Huggett et al., 2009). However, shortly following the market successes, the 
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demand for Enbrel (Fc-fusion protein, produced by Immunex) exceeded the manufacturing 
capacity to the extent that the drug had to be rationed, leading to the acquisition of Immunex 
by Amgen.  (Mallik, Pinkus, and Sheffer, 2006). The fear of such potential underproduction 
had caused many biopharmaceutical companies to start mammalian cell construction 
projects, and was believed to have led to an increasing trend towards outsourcing 
production (Ransohoff, 2007). Today it is very common for biopharmaceutical companies to 
source capacity from contract manufacturing organisations (CMOs) so as to mitigate risks 
and either to delay the significant capital outlays required to build a manufacturing facility or 
to supplement existing in-house facilities (Kelley, 2009). Therefore, considerations and 
assumptions made throughout these studies will come from the stand point of a CMO as 
opposed to a bioprocess developer, when considering strategies for technology changes 
and facility scenarios.  
 
Today, monoclonal antibodies (mAbs) are the most prevalent class of recombinant protein 
(Kelley, 2009). The majority of mAb products target chronic diseases where the biggest 
sector is oncology (Pavlou and Belsey, 2005), requiring long term treatment (see Table 1.1). 
An intermittent high dose is typically required (e.g., every 4-6 weeks), which over the course 
of a year can result in a demand of 1-20 g of mAb per patient. This is considered to be a 
high long term dose requirement. The next section provides an overview of the processing 
trends in mAb production which will allow the industry to meet these dose requirements and 
demands in the past. 
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Table 1.1: An overview of the top 4 current mAbs, their target dose, administration method and predicted performance in the near future (Bloomsberg consensus forecast, 2011, sales of 
mAb from primary companies: Janssen (J&J), Roche and Abbott). 
Predicted 
Position 
mAb 
(commercial 
name) 
Company Type Targets 
Maximum dose 
(g/person/ year) 
Administration 
method 
Predicted sales in 
2015 ($ m) 
1 Humira Abbott 
TNF- 
inhibitor 
Rheumatoid Arthritis 2 
Pen, Prefilled Syringe 9,875 
Juvinile Ideopathic Arthritis 
1 
Psoriatic Arthritis 
Ankylosing Spondilitis 
Crohn's disease 
Plaque Psoriasis 
2 Avastin Roche VEGF-A 
Metastatic Colorectal Cancer 
(mCRC) 
11 
Intravenous 8,046 
22 
Non–Small Cell Lung Cancer 
(NSCLC) 
Metastatic breast cancer 
Glioblastoma (GBM) 
Metastatic Kidney Cancer(mRCC) 
3 Herceptin Roche anti HER2 
Adjuvant treatment for breast 
cancer 
9 Intravenous 6,352 Metastatic treatment for breast 
cancer 
Metastatic treatment gastric cancer 
4 Remicade Janssen (J&J) 
TNFα 
inhibitor 
Crohn’s Disease 
3 
Intravenous 3,009 
Ankylosing Spondylitis 
Psoriatic Arthritis 
Plaque Psoriasis 
Ulcerative Colitis 
1 
Rheumatoid Arthritis 
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1.1.2 Trends in mAb production 
The first mouse mAb to reach clinical practice in 1986 (OKT-3), presented significant 
challenges for manufacturing and commercialisation as many of the early clinical trial 
patients experienced immune reactions due to the generation of their own anti-mouse 
antibodies (Human Antimouse Antibody response-HAMA). The emergence of mAbs as a 
major, established biopharmaceutical class was due to the development of humanisation 
technology combined with efficient and cost-effective mammalian cell culture production and 
recovery methods (Ezzell, 2001). 
Following the success of the first antibodies in the market, there was a need to identify a 
strategy for the quick transition of the emerging molecules into the clinic. Several of the 
larger biotech companies, including Amgen (who had just acquired Immunex), designed and 
implemented a platform approach to mAb process development (Gombotz and Shire, 2010). 
A platform approach requires definition of a set of robust unit operations and methodologies 
to yield consistent results when used for the production of different products or cell lines. 
The typical platform seen today in mammalian cell monoclonal antibody production includes 
fed-batch cell culture, followed by primary recovery, protein A chromatography, polishing 
chromatography steps, viral filtration and ultrafiltration before progressing further to 
formulation (see Figure 1.1) (Kelley, 2009). Cell culture operations typically fall into upstream 
operations (in some cases primary recovery operations are included as well), primary 
recovery and purification operations are typically considered part of downstream operations. 
These are designed to purify the product to meet the regulatory requirements for human 
administration. However, 2007 survey results showed that the greatest concern across 
CMOs was “the physical capacity of downstream equipment” (Langer, 2009). This implied 
that the contract manufacturing industry was experiencing strain on the performance of 
downstream operations as well as pressure to increase capacity. This pressure on 
purification can be critical as the failure to meet regulatory requirements automatically 
precludes a product from the market. Although downstream unit operations are typically 
designed to carry out a specific role (e.g. cell removal, DNA removal etc.) the process as a 
whole must also be designed to meet the relevant regulatory requirements. These will be 
discussed in the following section, which provides a summary of the key regulatory aspects 
directly related to the processing trends discussed in this chapter. 
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Primary Recovery
pH Hold
Anion –Exchange 
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Chromatography
Virus Retentive 
Filtration
UF/DF
Protein A 
Chromatography
 
 
 
1.1.3 Requirements in the Biotechnology Industry 
Recombinant protein production processes are designed not only to fulfil the market demand 
of the particular product in terms of product yield and yearly volume requirement, but equally 
to fulfil requirements regarding product quality.  
Primary requirements for pharmaceutical protein products mainly focus on minimal 
requirement levels for host cell proteins, product variants (aggregates, glycosylation 
variants), DNA, viruses, endotoxins, leachables and small molecules added during the 
fermentation/cell culture and the purification processes. Host cell protein (HCP) acceptance 
levels are within micrograms per gram of product (Jin et al., 2010).  If levels of these 
impurities in feed streams to processes increase, higher removal capacity will be required by 
the downstream operations to match set criteria levels. Thus, any inconsistency or increase 
in HCP production upstream may require a change of technology or increase in downstream 
operational performance. Alternatively, host cell engineering or more appropriate cell line 
selection can be implemented as a long term strategy. 
Figure 1.1: Conventional mAb process flow sheet for bulk drug substance. Typically titres reached during 
fermentation are in the range of 2-5 g/L. Typical yields after the protein A capture step yields 70-80% (Adapted from 
Kelley et al., 2009). 
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Product aggregates cause varying levels of immunogenic response and therefore are also 
considered an impurity. The allowed content of product aggregates depend on the product, 
however on average the final product should contain <5% of protein product variants (these 
may include deaminated, oxidised and incorrectly glycosylated forms). The acceptable levels 
depend on the bioactivity shown during clinical trials. The DNA levels set by the World 
Health Organisation (WHO) are at ≤10 µg per dose.  In terms of virus particles, regulation at 
the moment states that the viral levels should be less than 1 virus particle per million doses. 
Viral removal is typically achieved by nanofiltration and low pH hold steps.  Endotoxin levels 
are usually set to less than 5EU/kg of patient weight, whilst leachable levels are set typically 
at ≤1-10µg/mL (Rosenberg, 2006). The current reported improved analytical methods are 
able to provide an increasing amount of detail in terms of impurity characterisation as well as 
allowing a greater sensitivity in detection (Jin et al., 2010; Wang et al., 2010.). This can 
potentially put greater pressure on downstream operations in setting higher specification 
targets for impurity removal (HCP removal in particular), subsequently requiring a greater 
level of impurity clearance from the unit operations used. Increases in impurity levels have 
been associated with increases in cell culture titre and cell concentration. In order to discuss 
the role of primary recovery operations in meeting regulatory requirements in mAb 
production processes, cell culture and primary recovery operations will be discussed in detail 
in the following sections, beginning with an introduction to mammalian cell culture 
expression systems. 
1.2 Trends in mammalian cell culture 
Prior to discussing primary recovery operations this section will explore the key properties of 
the typical types of feed to primary recovery operations. For the purpose of this research it is 
important to review the trends in titre increase as well as the methodologies used to achieve 
them. 
 
Mammalian cells are predominantly used for recombinant protein production due to their 
effective protein folding mechanisms and consistent ability to perform complex post 
translational modifications (Jenkins, 2007). Consistency in glycosylation pattern is analogous 
to product consistency and is essential for regulatory process approval. Those 
biopharmaceutical proteins that undergo simple modification can be produced using yeast or 
bacteria, e.g. albumin (Recombumin by Novozymes) and insulin (Lispro by Elli Lilly and 
Novo Nordisk) (Roach and Woodworth, 2002). However, molecules with more complex 
glycosylation requirements are more commonly produced using mammalian cell lines. There 
is a range of mammallian cell lines approved for expression of recombinant proteins, some 
derived from mouse myeloma (NS0 or SP2/0), baby hamster kidney cells (BHK), Chinese 
hamster ovary cells (CHO), and a humanised cell line PER.C.6. However 70% of all 
recombinant protein production is carried out in CHO cell lines which includes all currently 
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approved monoclonal antibody products (Jayapal, 2007). The reason for this likely stems 
from early development of recombinant technology being based on expression in heavy and 
light chains of CHO cell antibodies. Platforms for transfection and selection of high producer 
cell lines using CHO cells waere well developed which allowed mAb production to take 
advantage of already established technology used for other recombinant products such as 
erythropoietin, Factor VIII, plasminogen activator.  At the time these recombinant products 
typically were produced at low expression levels, approximately <1 g/L (Birch, 2005). 
Consequently, rapid growth in market demand for mAbs and other recombinant proteins 
(e.g. Fc-fusion proteins) was  a key driver to increase scale of the production facilities 
resulting in large culture volumes of >10,000L (Kelley, 2009). 
 
Reported product titres using CHO cell culture have been increasing over the years, from 
the 50mg/L region, which the original platform processes were designed for, to 2g/L by mid 
90s, reaching greater than 12g/L in 2010 (Bibila and Robinson, 2000; Charaniya et al., 
2010). This is thought to be due to the improved understanding of gene expression, growth, 
metabolism and apoptosis delay (Wurm, 2004).  
 
This section provided examples of significant increases in cell culture titre over the last 
decade. These increases may have been achieved by increasing specific cell productivity as 
well as the cell concentration. Both of these mechanisms can impact the load on primary 
recovery and downstream applications. 
 
In order to explore the range of cell lines likely to require primary recovery processing in the 
future, the next section will provide a discussion on the expression systems used for mAb 
production in the past and the key mechanism by which they work. 
 
1.2.1 Mammalian Cell Expression Systems 
During the transfer of recombinant DNA, which results in the production of the protein of 
interest, the efficiency with which the DNA is taken up varies between cell types and 
selection methods (Kucherlapati and Skoultchi, 1984). Selectable markers are used either to 
complement host cell deficiencies or to provide resistance to otherwise toxic agents 
therefore facilitating the detection of the plasmid containing the gene of interest. Several 
such selection markers have been identified including xanthine, guanine 
phoshoribosyltransferase, adenosine deaminase, multiple drug resistance (e.g., colchicines, 
adriamycin, actinomycin), asparagine synthetase, glutamine synthetase (GS) and 
dihydrofolate reductase mutants (DHFR) (Chapman et al., 1983; Cartier and Stanners, 1990; 
Choi et al., 1988). Most commonly, commercial cell lines utilise either the DHFR or the GS 
expression systems. 
Chapter 1 
29 
 
 
The DHFR enzyme catalyzes the NADPH-dependent reduction of folate to tetrahydrofolate, 
which is an essential cofactor in the synthesis of glycine, purines, and thymidine. Enzyme 
synthesis can be inhibited by the addition of a folate analogue- methotrexate, which leads to 
a deficiency of thymdylate resulting in cell death (Blakely, 1969). When used as a selection 
marker, DHFR is introduced into DHFR deficient hosts (which otherwise can only be grown 
in supplemented media), those which have taken up the plasmid can have resistance to the 
methotrexate by amplifying the DHFR gene. If the gene of interest is located on the same 
expression vector it is co-amplified and its presence is detected with the presence of 
resistance during the addition of methotrexate. One of the advantages of using the DHFR as 
a selectable marker is the ability to modulate selective pressure by inhibiting gene 
expression with methotrexate (MTX). The same effect can be achieved also by reducing the 
enzyme activity which can result in a compensatory increase of expression via an alternative 
pathway (e.g. copy number increase) (Simonsen and Levinson, 1983).  
 
Codon optimisation has been used in the past as a strategy to increase gene of interest 
expression, by increasing the translational efficiency of the gene of interest, thus achieving 
titre increases during the cell line development stage. More recently a different approach 
emerged which involved “codon deoptimisation” of the DHFR gene in combination with 
increasing selection pressure by altering the internal mRNA to decrease expression of the 
DHFR gene (Wernicke and Will, 1992). 
 
GS is another widely used expression system. Glutamine synthetase enzyme converts 
glutamate and ammonia to glutamine, which is not only an essential amino acid but also is 
vital for nitrogen detoxification and plays a role in purine biosynthesis. The system works 
when glutamine is omitted from the media, while maintaining low concentrations methionine 
sulphoximine (MSX), approximately 50mM, which inhibits indigenous glutamine synthetase 
favouring the survival of transfected cells. However cells which have acquired the additional 
copies of glutamine synthetase (also expressing the gene of interest) will survive (Schlokat, 
1997). 
 
The GS system was made commercially available by Lonza Biologics in the late 1980s, for 
use with CHO and NS0 cell lines. By the end of the 90s research showed that the GS 
system in NS0 cell lines was yielding higher titres than CHO cell lines when optimised (up to 
510mg/L in batch culture while in CHO only 270 mg/L) (Birch et al., 1993; Bebbington 1991).  
The following section will provide an overview of the current trends in titre increases and 
highlight the systems and cell lines used to achieve the current high titre processes, noting 
however that CHO cell lines are still one of the most common cell types used today. 
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1.2.2 Trends in Titre Increases 
Improvements in cell line development, media and process optimisation have enabled 
continuing titre increases in mammalian cell processing. In the 80’s reported product titres 
were reaching 100 mg/L in batch cultures, which increased to 1 g/L over the next 10 years 
with the development of fed-batch culture (allowing the culture period to double) (Wurm, 
2004). Recently titres of up to 12g/L have been reported (Huang et al., 2010). 
 
Reported titre increases have been achieved by increasing the culture time, the specific 
productivity of cells, increasing the viable cell concentration and a combination of the two 
effects. Currently the highest reported titre of 13g/L has been achieved in a Fc fragment 
producing CHO cell line through media optimisation. Non glycosylation mAb producing CHO 
cell line through medium optimisation also yielded a high titre of 12 g/L. The achieved titre 
was stated, but no data was provided. In the same sets of experiments, the highest achieved 
total cell concentrations ranged between 13-15 x106 cells/mL with specific productivities in 
the range of 30-50 pg/cell/day. The high titre process was optimised by implementing a 
screening method to identify the effect of components in three different basal media and four 
feed media. The screening method reported in this case was aimed at increasing cell mass, 
enhancing specific productivity and longevity of the cells, which requires balancing increases 
in specific productivity with the effects on the viability and density of culture (Huang et al., 
2010). This is one of the potential reasons for the choice of a lower specific productivity over 
the maximum reported back in 2004 of 90pg/cell/day (Wurm, 2004).  
 
An increase in specific productivity can be induced by the addition of sodium butyrate to the 
media. Sodium butyrate is a short chain fatty acid, histone deacetylation inhibitor, and has 
been used to increase specific productivity of secreted proteins in mammalian cells, 
including CHO and hybridoma cells (Sung et al., 2004). However, the addition of sodium 
butyrate causes a depletion of viable cells and an increase in the number of apoptotic cells 
(Mimura et al., 2001). The addition of sodium butyrate yields most favourable results when 
introduced in the late exponential phase as the inhibitory effect on cell proliferation is 
minimised (Hunt et al., 2002). The molar concentration of sodium butyrate also affects the 
degree of growth arrest observed. Low concentrations of 0.25- 0.5mM have been reported to 
have no significant effect on cell viability and growth. However higher concentrations of 1-
4mM resulted in slow growth and a decrease in cell viability, overall resulting in a maximum 
of a two-fold decrease in cell concentration at high sodium butyrate concentrations only 
yielding a cell concentration of 2x106 cells/mL (Goulart et al., 2010). Overall, moderate 
concentrations of sodium butyrate have been shown to result in up to three-fold increases in 
titre (Mimura et al., 2001) which suggests a compromise must be struck between the impact 
its addition has on specific productivity increases, cell concentration and viability. 
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The following section will discuss the cell concentrations which have been observed over the 
years and highlight the typical cell concentrations which have been reached to date. 
 
1.2.3 Trends in Cell Concentration Increases 
Currently, two culture formats are available for mammalian cells: adherent and suspension. 
The latter is widely used for industrial recombinant protein production, where three modes of 
operation can be applied:  batch, fed-batch and perfusion. CHO cell culture is predominantly 
carried out using fed-batch fermentation. Although perfusion culture has been promising in 
terms of high titre and cell concentration production, product dilution still remains a downside 
of this mode of operation. Controlled rate perfusion methods have been shown capable of 
reaching and maintaining cell concentrations of >150x106cells/mL over the course of 30-60 
days, however this cell concentration has only been achieved using the PER.C.6 cell line 
(Schirmer et al., 2010; Clincke et al., 2013a; Clincke et al., 2013b; Karst et al., 2016). Cell 
cultures carried out using fed batch processes have also been reported to achieve cell 
concentrations in the range of 10-40x106 cells/mL (Singh et al., 2013). The cell 
concentrations achieved by these different processes vary along with the definition of “high 
cell concentration culture”.  In order to capture the full range advancements, independent of 
the technology used, cell concentrations over 1x107 cells/ mL tend to be referred to as “high 
cell density” in this thesis (Westoby et al., 2011).  
 
As discussed above, the current range of titres achieved during cell culture ranges by 
roughly 100 fold. Primary recovery operations used today were designed during the first 
platform development movement, when cell concentrations and titres reached maximum of 
1x106 cells/mL and cell culture titres averaged 1g/L (Wurm, 2004). Increases in cell 
concentration lead to an increase in solids content, impurities as well as cell debris, 
presenting challenges to both primary recovery and purification operations.  
 
Although significant increases in cell concentrations have been achieved, there has been 
little move towards implementing changes in the technologies used in primary recovery. This 
implies that current primary technologies provide sufficient efficiency for current processing. 
However if it is assumed that the trend of increasing cell concentrations and titres continues 
(Immarino et al, 2007; Singh et al, 2013; Westoby et al., 2011), the pressure to identify 
alternative primary recovery operations that may present more cost-effective process 
options in the future will present an opportunity for future process development (Singh et at., 
2013). It is this perceived pressure that forms the motivation for the studies reported in this 
thesis and leads this introduction to provide an overview on primary recovery operations 
currently used as platform processing options as well as those seen as alternative 
technology options. 
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1.3 Primary recovery of mammalian cell culture 
The first steps following mammalian cell culture in recombinant protein processing are 
traditionally designed to remove the insoluble components of the cell culture broth. This 
means that the main role of primary recovery operations has been to achieve a sufficient 
level of clarification to prepare the material for progressing to purification. Centrifugation and 
depth filtration are the most commonly implemented harvest operations, with tangential flow 
microfiltration options also considered for use in some cases.  The following section will 
review the typical primary recovery operations as well as the potential alternatives in terms 
of their theoretical principles and their key features. 
 
1.3.1 Centrifugation 
Principles 
Centrifugation is a preferred method of solid-liquid separation due to the ease of its 
scalability and economical operation for large volumes (Maybury et al., 2000). Therefore it 
tends to be used for scales of 2000L and above (Yavorsky et al., 2003). Although 
multichamber and tubular bowl centrifuge designs are available, the disc-stack centrifuge is 
the most commonly used as it accommodates for intermittent discharge of solids during 
operation and therefore is more effective in clarification of large volumes and higher solid 
feeds. The centrifuge is able to remove a high percentage of cells and cell debris prior to 
secondary clarification and subsequent product clarification steps. However it is typically not 
effective at removing small particles in mammalian cell broths (1-6µm) which will cause 
fouling of the chromatography column. This is also the reason behind the common  
utilisation of depth filtration post centrifugation (Kempken et al., 1995). Any improvement in 
centrifuge performance, regarding increased levels of solids removal or reduced levels of 
cell disruption during processing, will translate to a reduction in the filter area required to 
protect the chromatography column. Figure 1.2 provides a cross sectional view a typical 
disc-stack design. 
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Figure 1.2: Schematic of key flow paths inside the disk stack centrifuge. Liquid feed flows through inlet A, out to the side of 
the bowl and up between the discs. The solids settle on the disc, making their way back down and up to outlet C, while the 
clarified liquid flows through to outlet B. 
 
The settling area of a continuous disk stack centrifuge is defined as follows: 
(1.1) 
 
Where Σ is the equivalent clarification area in the centrifuge (m2), g is the acceleration due to 
gravity (ms-2), ω is the angular velocity (rads-1), N is the number of disks, α is half the conical 
angle of the disk (o), ro is the outer disk radius (m), ri is the inner disk radius (m).  Sigma 
theory can be used to predict the performance of the same feed in different centrifuges and 
at different scales: 
and                                                                                                                        (1.2) 
 
Where Vg is the particle settling velocity and Q is the volumetric flowrate into the centrifuge 
(m3s-1). The minimum diameter of particles which can be separated (dmi,, m) can be 
calculated as stated below: 
(1.3) 
 
Where µ is the dynamic viscosity of culture medium (kgms-1), Δρ is the density difference 
between cells and medium (kgm-3) and g is the acceleration due to gravity (ms-1). 
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Centrifugation features 
Through CFD analysis, the feed zones of disk- stack and multichamber centrifuges have 
been identified as the area resulting in high shear due to the presence of air- liquid 
interphases. Levels of energy dissipation in a non-hermetic feed zone may reach up to 
0.37x106W kg-1 where 99% of the energy has been shown to dissipate to the liquid phase 
due to the higher density of the liquid in comparison to the air phase (Hoare et al., 1992; 
Boychyn, 2001). High-energy dissipation results in high shear during operation and 
subsequent cell breakage and decreased clarification performance. The minimum particle 
size which can be removed by a centrifuge is a function of the centrifuge bowl design, cell 
culture properties (viability, density), feed rate and rotational speed (consider equations 1.1, 
1.2 &1.3) but is typically >0.5µm. 
Shear in the feed zone can be reduced by introducing a hermetic seal, thereby eliminating 
the air- liquid interphase in the feed zone. This reduces the energy dissipation rates typically 
to a maximum of 0.019x106W kg-1 and reduces cell breakage, thereby also reducing the 
number of fine particles present post centrifugation (Hoare et al., 1992; Tait et al., 2009). 
Studies using a Westfalia CSA-1 model with hermetic seal, with a working volume of 600 mL 
showed that the concentration of non-viable cells in the feed broth was linearly correlated 
with the decrease of clarification efficiency. In addition, centrifugation conditions were shown 
to have no impact on the quantity of impurities present post centrifugation indicating that 
shear levels are uniform across the range of centrifugation generating conditions and that 
the key parameter causing variation is the condition of the feed. Finally it was noted that the 
% of clarification converged for cell viability levels above 80%. Iammarino et al. (2007) 
suggested to set a minimum viability at >50% for efficient clarification. 
Hermetically sealed feed zones are currently available in disk stack and CARR Powerfuge 
models. The performance of these models has been investigated in terms of levels of shear 
produced. All models of the CARR Powerfuge showed 69-76% recovery and little shear 
damage by comparing the DNA concentrations in the centrate to the concentrations in the 
original cell broth (Lander et al., 2005). Another technique which is easily implemented in 
most centrifuge designs is the full bowl start up, which reduces the air- liquid interphase, 
reducing the shear encountered during start up (Hoare et al., 1992). 
A study examining the effects of solid content increase in cultures of Pichia pastoris on 
centrifugation performance showed that although some product loss was encountered when 
increasing the solids content from 2% to 15%, the loss can be offset by the higher 
dewatering levels achieved from higher solids content feeds. The same study also proposed 
a method for establishing a window of operation for higher solid content feeds, which can be 
applied to other host organisms (Salte et al., 2006).  
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At average cell concentrations relatively low discharge frequencies are typically required, 
therefore the contribution to product loss is minimal (Maybury et al., 2000). However 
increasing cell concentrations results in an increase in the solid content of the culture broth 
which in turn required a greater frequency of desluge, potentially leading to a greater degree 
of product loss. These inter-relationships emphasise the strong level of interactions that exist 
between the unit operations engaged in a typical mammalian cell culture based 
manufacturing process. 
1.3.2 Filtration Principles 
Pore blockage 
Filter capacity is determined by the fouling characteristics of the feed solution, which causes 
a decay in flowrate during constant pressure operation or an increase in pressure during 
constant flux operation. Flux decline is said to be caused by one or a mixture of mechanisms 
including pore blockage, intermediate pore blockage, pore constriction and cake filtration 
(Hermia, 1982). 
Initial flux decline is typically associated with pore blockage or constriction, which is followed 
by cake filtration. The model developed to reflect this has been demonstrated (Ho and 
Zydney, 2000), (see equations 1.4-1.6). This model is considered to provide a more 
accurate description of fouling than the classical filtration models, which are based on just a 
single pore blocking mechanism (Reis and Zydney, 2007). 
(1.4) 
(1.5) 
(1.6) 
 
Where Q is the volumetric flowrate (m3s-1) at time t, Q0 is the initial flowrate (m3s-1), t is the 
filtration time (min), Rm is the clean membrane resistance, Rp is the resistance of the growing 
deposit, Rp0 resistance of the initial deposit and Lp is the membrane hypraulic permeability.  
1.3.3 Depth Filtration 
Principles 
Depth filtration is designed to achieve cell and cell debris removal through the filter media as 
opposed to surface removal observed in microfiltration membranes (Yavorsky et al., 2003). It 
is typically employed in place of, or in combination with, centrifugation in the clarification of 
mammalian cell culture broths in monoclonal antibody producing processes as well as in the 
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Figure 1.3: Cross section of a depth filter medium demonstrating removal mechanisms (Shukla and 
Kandula, 2008) 
removal of acidified protein solutions prior to chromatographic processing often employed as 
prefilters (Singhvi et al., 1996). Depth filtration has also been demonstrated to remove DNA 
and host cell proteins during clarification of animal cell cultures when using charged depth 
filtration medium (Yigzaw et al., 2006; Charlton et al., 1999). However where large cell 
culture volumes are concerned, providing the required membrane area for clarification is 
economically and operationally inefficient, therefore centrifugation followed by depth filtration 
tends to be employed during clarification at scales above 2000L (Yavorsky et al., 2003). 
Particle removal is achieved by a combination of mechanisms which also contribute to 
membrane fouling (see Figure 1.3). Cells and cell debris are removed by capture inside pore 
spaces (pore constriction and plugging), also referred to as depth straining. This occurs 
when a particle travels down the narrowing pore until it becomes trapped or lodged inside 
the pore. This applies not only to particles which are the same size as the pore but also to 
those smaller through a mixture of physical mechanisms (McCabe et al., 1976). This is 
exploited especially well in graded filter modules, where a mixture of grades is used to form 
a network of pores that decrease in size through the depth of the filter material. Therefore 
different sizes of particles are removed at distinct portions within the body of the filter.  
 
 
 
 
 
 
 
 
 
 
A large portion of the particles present in any given feed are retained at the filter surface. 
These are typically cells or particles which are larger than the pore size. In turn, other cells 
or debris which are brought in contact with the pores and particles already attached to the 
pores, also become attached by van der Waal and other forces. Flow through larger pores is 
restricted by the presence of smaller particles which collect in the pores, allowing cake to 
form on top of the membrane, which in turn acts as an additional filter medium. The positive 
charge often provided by the material effectively binds some DNA, viruses and endotoxins 
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(Charlton et al., 1999).  As a consequence of these multiple mechanisms it is possible for a 
certain pore size to allow capture of smaller particles than might be expected solely based 
on the basis of the surface pore rating. 
Recovery operations where depth filtration is used generally involve a high-solid containing 
feed load to the filter where cake filtration by surface retention dominates. A similar situation 
applies at small scale mammalian cell clarification operations where depth filtration is used 
as the pre-clarification step. However in larger scale operation (as previously described) 
where depth filtration is preceded by centrifugation, the feed consists of mainly debris, 
implying lower solids content and a smaller average particle size. 
Filter Media 
Typically the filter media used in bioprocessing includes cellulose or polypropylene fibres, 
where filter aids can be added (e.g., diatomaceous earth, perlite, activate carbon etc). 
Alternatively, charged filters are manufactured by incorporating charged polymers or ion 
exchange particles within the material (Reis and Zydney, 2007). Depth filter media does not 
typically come with an absolute pore size rating unless a membrane layer at the end of the 
flowpath is included. However the depth filter tends to be followed by an absolute pore size 
rated filter (typically 0.45µm or 0.2 µm) that ensures the removal of solid particulates (also 
bacteria in case of the 0.2 µm filter) from the cell culture harvest supernatant. 
Modules 
Depth filtration units utilised in mammalian cell culture fluid clarification are typically 
composed of circular replacement cartridges. The lenticular disc arrangement has been 
common in pre-clarification, where each disc is made from two circular layers of thick filter 
media bonded together at the outer edge. For example the Zeta PlusTM, 3M (previously 
known as Zeta PlusTM, CUNO) depth system first widely advertised in 1997 demonstrates 
this configuration and are said to provide a 1-2 log removal of DNA (Dorsey, 1997). However 
these systems were recognised to present some operator, CIP and scaling issues in reviews 
by competitors and independent review articles. As the discs are stacked vertically hoists 
may be required in some cases to change the discs. In some cases the filter medium 
between the discs sagged resulting in contact between the discs.  
Product innovation in the depth filtration market has most recently aimed at combating these 
problems. For example, Millipore had offered the Millistak system to combat the operator 
problems of vertical stacking configuration. The system comprises of filter graded cassettes 
stacked in a horizontally placed housing. In the early 2000’s the advantages of single use 
systems had become more widely recognised (Reis and Zydney, 2001), which included a 
move towards single use depth filtration equipment. Millipore’s POD system, similar in 
configuration to the Millistak was introduced and adopted widely at this time (Lambalot et al., 
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2006). Similarly the CUNO Zeta PlusTM system evolved to allow single use of the lenticular 
discs, which were advertised to also achieve HCP removal. The current design of the 
housing still utilises vertical configuration, which provides greater space efficiency, having 
improved upon the previous design by incorporating a mechanical system allowing the discs 
to be loaded in the horizontal position and then mechanically moving the stack into its 
vertical configuration.  
1.4 Alternative Primary Recovery of Mammalian Cell Culture 
Optimisation and the development of new, improved primary recovery methods is driven by 
the possibility for non-protein chromatographic separation (Roush and Lu, 2008). A variety of 
approaches have been described, roughly dividing into two types of alternatives: 
 Those which aid the performance of current operations; and 
 Those which offer an alternative operational option. 
 
1.4.1 Tangential Flow Filtration (TFF) 
Principles 
Tangential flow microfiltration is a competing unit operation to centrifugation and depth 
filtration in the clarification of mammalian cell culture broths. One of the key advantages it 
provides is the production of a particle free harvest stream in one unit operation which 
requires little further clarification prior to application of the clarified material to 
chromatography as opposed to centrifugation operations which can result in the introduction 
of additional debris into the stream (Reis and Zydney, 2001).  
In tangential flow mode the cells and debris present in the feed flows at a tangent to the filter 
medium as opposed to directly through it. An applied pressure forces the liquid through the 
filter medium forming the permeate stream. Particles larger than the pore size remain in the 
original flow and are swept across the surface of the membrane, forming the retentate. In 
operation, tangential flow membranes are dominated by concentration polarisation and 
fouling effects. The filtrate flux through the membrane is limited by the accumulation of a gel 
layer of cells and debris along the flow path through the membrane. However this can be 
avoided by exploiting a low flux in the system or taking advantage of inertial lift effects which 
would help combat the gel effect (Belfort et al., 1994). The consequence of this solution is 
increased processing times as well as the risks associated with it, including potential effect 
on product stability, cell viability, impurity release and clarification efficiency. 
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Membrane media 
Tangential flow microfiltration is most commonly accomplished in flat sheet and hollowfibre 
membranes. Flat sheet membranes are typically cast on non- woven substrate and either 
have an isotropic or asymmetric structure. Commercially available membrane material 
includes polysulphone, polyethersulfone, cellulose and hydrophilized polyvinylidene fluoride, 
which are often modified to provide the required surface properties (e.g., hydrophobicity) 
(Zeman and Zydney, 1996).  Hollowfibre modules are also typically made from 
polyethersulfone, polysulfone, and polyvinylidien fluoride as well as mixed cellulose esters 
and polypropylene.  Structurally hollow fibers are self-supporting and dense at the lumen, so 
can be easily cleaned (Reis and Zydney 2007). Polysulphone material tends to be favoured 
for mammalian cell clarification stages. 
Membrane technology can aid fast process development as small scale cassettes are 
readily available for primary recovery (0.1 m2 membrane area). However, much like 
centrifugation the technology is sensitive to culture properties such as cell viability, density 
and medium components (Westoby et al., 2011). High cell concentrations and low cell 
viabilities have been suggested to result in high transmembrane pressures. An application of 
membrane cascades using a series of membrane processes has been suggested to achieve 
separation of a soluble biologic by exploiting the difference in sieving coefficients at each 
step resulting in improved separation factors (Lightfoot et al., 2008). 
1.4.2 Flocculation 
The addition of a flocculation step directly following cell culture is aimed at improving the 
clarification efficiency during primary clarification, reducing the need for secondary 
clarification by aggregating the smaller debris. This step has not been widely used in the 
biotechnology industry as its wide application originates in waste water treatment, however it 
is expected to bring applied benefits in the future (Shukla and Kandula, 2008). This lack of 
translation into industrial use may stem from the need to add a processing step that 
enhances the following filtration stages, however it does not provide a replacement for the 
filtration operation. Polyelectrolyte induced flocculation has been proposed as an alternative 
to Protein A chromatography in the separation of a humanised monoclonal antibody from 
cell culture fluid. This process was shown to achieve similar purity levels to current 
chromatography based processes and demonstrated the removal of the added agents post 
product capture using anion exchange chromatography (McDonald et al., 2009). 
Flocculation processes have been shown to be highly sensitive to feed stream composition 
and operating conditions, including pH, ionic strength, depending on the choice of flocculant 
(Habib et al., 2000). Flocculation is driven by the collisions between the polymer and the 
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particle, however increased shear rates can cause the flocculated particles to break up into 
small particles, which have a low re-growth rate after the shear is reduced (Kim, 2001; 
Yukselen 2004). CHO cell flocs were found to be more shear sensitive in comparison to E. 
Coli, potentially leading to the presence of a large number of small particles within the broth 
(Han et al., 2003).  
Flocculating agents 
Cationic polymers tend to be most effective for mammalian cell culture flocculation, to match 
the overall negative charge of the cells. Therefore the addition of cationic polymers into the 
cell culture fluid results in electrostatic interactions between the negatively charged cell 
debris and whole cells in the culture. Examples include polyamines, cationic 
polysaccharides, chitosan and diallyldimethyl ammonium chloride. The use of polyamines, 
including polyethyleneimine (PEI) and polyallyamine as cationic polymers to induce the 
flocculation of host cell impurities as an alternative to column chromatography has been 
demonstrated. The removal of CHO HCPs has been shown (Ma et al., 2010). PEI was also 
effectively used for the flocculation of E. Coli, (Salt, 1995; Barany and Szepesszentgyörgyi 
2004) and yeast cultures (Milburn et al., 1990; Habib et al., 2000). Molecular weight and rate 
of agitation greatly impact the flocculation efficacy, as opposed to mixing time which has little 
effect (Habib et al., 2000). The advantages of PEI in industrial application include small 
volume requirements and low material cost, however the subject of PEI removal from 
processing streams post clarification is generally avoided in the reviewed publications. It is 
important to note that PEI removal is required in order to fulfil regulations on human 
administration in the US and EU. 
The use of chitosan as a flocculant in NS0 culture was shown to improve dramatically the 
clarification achieved by the following centrifugation and increase the capacity of the 
following depth filter with no adverse effects on the monoclonal antibody recovery or purity. 
The process was shown to be relatively robust under operation in a pH range of 5-7.5 (Riske 
et al., 2007). Chitosan has additional benefits in application in biotechnology as it is sourced 
from non- mammalian in origin and is available in a highly pure form. 
1.4.3 Acid Precipitation and Cell Settling 
Acid precipitation of cells and cell debris has been explored over the past 20-30 years. 
Induction of flocculation with the decrease of pH has been shown using centrate derived 
from hybridoma cell culture. In addition it demonstrated the precipitation of DNA and the 
combination of clarification with viral inactivation early on in the process (Lydersen et al., 
1994). Later it was suggested that it can be carried out directly inside the bioreactor, 
followed by centrifugation and depth filtration resulting in removal of the precipitate. This was 
shown to increase capacity of the depth filtration operation. Acid precipitation was also 
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carried out prior to a centrifugation and a microfiltration step where the flux of the 
microfiltration operation was shown to be dramatically improved (Roush and Lu, 2008). 
Acid precipitation followed by cell settling has been tested by Westoby et al., (2011) for a 
range of CHO cell lines prior to hollowfibre microfiltration. The combination of low pH with 
the addition of cobalt chloride showed an increase in product yield, a 3 log removal of DNA, 
as well as a consistently low TMP at 15 LMH in comparison to non-precipitated culture fluid. 
HCP reduction was also achieved, however the reduction was insignificant, which was 
attributed to the hetrogenous nature of the HCP pI as opposed to DNA (Westoby et al., 
2011). Although the cell line to cell line variability was not clearly explored, the results 
showed a promising prospect for the future of cell settling options. 
1.4.4 Expanded Bed Absorption (EBA) Chromatography 
Expanded bed adsorption has attracted some interest over the years; however it has found 
little industrial application in recombinant protein recovery operations so far. Drager and 
Chase first introduced the idea of a fluidised bed in the 1990s, later expanding its use to 
protein purification (Drager and Chase, 1991).  More stable adsorbents were introduced by 
Amersham Pharmacia Biotech in 1993 named STREAMLINETM, which were later assessed 
in their ability to clarify mammalian cell broths. Protein A was rated most efficient in all 
aspects of performance followed by the Chelating matrix which rated highly in CIP 
performance but exhibited poor cell and debris clarification (Lütkemeyer et al., 2001). 
However, when human embryonic kidney cell culture was loaded onto a Chelating adsorbent 
it was shown that cell high cell recovery was achieved in terms of cell number and viability, 
exhibiting little cell breakage during the process (Poulin et al., 2008). Single use adsorptions 
chromatography columns have also become available (Lihme et al., 2015), and EBA is still 
considered in microbial and whey process purification stages (Du et al., 2014; Xu et al., 
2014; Hansen et al., 2013) 
1.4.5 Counter Current Tangential Chromatography (CTC) 
This technology was newly patented in 2009, with an initial demonstration for the separation 
of bovine serum albumin (BSA) from a protein mixture provided using Macro Prep 25Q anion 
exchange resin. The resin flows through a series of static mixers and hollowfibre modules. 
The hollowfibre membranes retain the large resin particles, letting the dissolved species flow 
through. The solution containing the protein of interest is then released and protein binds to 
the slurry molecules, while the impurities are removed as waste. Binding, washing and 
elution buffer flow is counter current to the resin through multiple hollowfibre modules which 
enables high resolution separation and increase in product yield. Myoglobin impurity removal 
was shown to be >99% and the product yield to be 94% (Shinkazh et al., 2011). This 
Chapter 1 
42 
 
technology has potential in cell clarification or perfusion if the design is modified for cell 
accommodation. 
1.4.6 Alternating Tangential Flow Filtration (ATF) 
Alternating tangential flow (ATF) filtration has been used in perfusion and concentrated fed-
batch modes to achieve high cell concentration cultures of >150x106 cells/mL. The 
processes using a number of cell lines have been shown, including HeLa cells for production 
of recombinant vaccinia virus (Bleckwenn et al., 2005), PER.C.6 cell line in a process 
referred to as the XD (Schirmer et al., 2010), and an IgG1 producing CHO cell line (Clinke et 
al., 2013). There is currently no publically available data for its implementation specifically as 
a primary recovery step, however manufacturers have seen to have potential in the area. 
The following information has been obtained through discussions with the manufacturers of 
the ATF. 
The mechanisms by which the process works ensures low shear processing which is 
advantageous for processing both high and low viability cultures, however the system is 
designed for low cross flow rates, which does not cause a problem during cell culture 
operations.  
There are two potential methods of ATF implementation in primary recovery: reduced time 
harvest and the long harvest. Reduced time harvest involves harvesting over approximately 
3-4 hours at high cross flow rates and is suitable for high viability harvests (>50%). However 
this methodology is not thought to exploit the full potential of the system. In addition it is 
possible that a secondary clarification stage may be required post ATF.  
The long harvest methodology requires a degree of integration of cell culture process and 
the primary recovery process. The primary recovery operation is thought to commence on 
the day of harvest, however the process is likely to take more than 20 hours. This 
methodology is predicted to increase cell culture times as product expression carries on 
throughout the harvest operation, ensuring that viable cells are intact and producing whilst 
clarified material is harvested at low cross flowrates. The methodology would be most suited 
to concentrated batch operations, however it may prove beneficial when implemented within 
fed-batch cell culture modes of operation. 
1.5 Ultra Scale-Down (USD) of Primary Recovery Unit Operations 
During early stage bioprocess development, validation, implementing process changes, 
quality by design principles (QbD), and other work requiring the running of a large number of 
experiments can result in high investment due to large quantities of material required. 
Therefore the value of scale down of unit operations has been long recognised and desired 
(Boychyn, 2001). Although small scale models of a variety of units are available (Maybury et 
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al., 2000), many require a relatively large volume and only allow single experimental runs at 
a time contributing to cost and time issues related to such studies. Ultra scale-down 
techniques of unit operations across processing areas have been demonstrated, including 
cell culture (Korin et al., 2009), clarification (Tait et al., 2009) as well as purification 
operations (Neal et al., 2003). 
 
1.5.1 USD Centrifugation 
Early scale down techniques of centrifugation processes were based on decreasing the 
volume requirements in a centrifuge by introducing blank/ dummy discs which was shown to 
reduce the throughput requirements by a factor of 10 (Hoare et al., 1992). However the 
volume reduction achieved by a direct mimic of centrifugation did not achieve sample 
requirement reduction to the degree where significant changes to experimental procedure 
and experimental cost were made. Methods to mimic large scale centrifugation in terms of 
recovery and performance using a lab scale centrifuge have been described. This method 
was shown to predict large scale performance well in the case of polyvinyl acetate particles, 
but not protein precipitates which showed solids breakup during centrifugation (Hoare et al., 
1992). However, mimicking centrifugation in a way which incorporates the full functionality of 
the large scale centrifugation as well as the discontinuous discharge feature has not been 
carried out to allow small volume utilisation. The smallest currently available model 
(Westfalia CSA-1) requires a volume of 600 mL, allowing for 250 mL of solids holding 
(Roush and Lu 2008). Subsequent scale down methods focused on reproducing the shear 
which the material experiences during the centrifugation operation.  Multiple assessments of 
this scale down techniques have been carried out and improved methods have been 
introduced. Ultra scale-down of centrifugation has achieved the smallest required sample 
volume of 20 mL. The principle is based on mimicking shear cell culture is exposed to in a 
full scale centrifuge and subjecting cell culture to the equivalent shear force by using a 
rotating disk device (Tait et al., 2009).  
Scale up of centrifugation has been carried out using the sigma concept-or the equivalent 
setting area. A typical scale down model used in a number of scale down studies in 
described below (Boychyn et al., 2004; Hutchinson et al., 2006; Levy, 1999; Tait et al., 
2009). Remaining solids after large scale continuous centrifugation can be determined using 
equation 1.7.  
(1.7) 
 
This is related to the bench scale test tube centrifugation using equation 1.8: 
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(1.8) 
 
Where Cc is an experimentally derived factor 1, Cb is an experimentally derived factor 2, VB   
is the volume of material (L), tB is the centrifugation time (h). 
The relationship used to determine the Sigma of a laboratory scale centrifuge was described 
by Maybury et al., (2000): 
(1.9) 
 
 
Where ΣB is the equivalent settling area of a bench top centrifuge, VB is the volume of 
sample used (mL), ω is the angular velocity (rads-1), x is the time required for acceleration 
(h), y is the time required for deceleration (h),  ri= inner radius (m), ro= outer radius (m). 
ri and ro are determined using the following relationships: 
(1.10) 
(1.11) 
 
 
Where p is the horizontal length of the rotor (m), q is the length to base of the centre (m), θ 
is the angular deviation from 90o, L is the average height of the suspension, a is the vertical 
position from centre (m).  
A well plate can be used for the last stage of the mimicking process which allows a high 
throughput of a large range of conditions at once (Tait et al., 2009). However use of the 
Sigma approach for scale down can result in significant differences in performance as 
different centrifuge design are often employed during scale up, sometimes resulting in a 
large reduction in Q/Σ (Hutchinson et al., 2006). 
1.5.2 USD Filtration 
A range of ultra scale-down filtration operations have been described including 
microfiltration, ultrafiltration (Brou et al., 2003), diafiltration (Ma et al., 2010) and depth 
filtration (Belfort et al., 1994), (Pampel et al., 2008). These ultra scale-down methods are 
achieved using rotating disc filter designs (RDF). 
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The RDF is a non-linear approach to the prediction of large- scale filtration performance. 
Correlation between shear rate on the membrane surface and the disc rotating speed as 
well as the correlations between the wall shear rate on the membrane surface and inlet flow 
rate in lab scale cross flow cassette systems have been established (Ma et al., 2010). 
Typically a rotating disc is placed ~1 mm from the membrane (sample material from the 
large scale membrane), which generates controlled levels of shear across the surface of the 
membrane.  
 
A correlation was established between shear rate and RPM for the disc device, valid for 
cases when the viscosity is constant during the operation. Therefore the correlation does not 
apply to dead end more filtration 
(1.11) 
 
Where γ is the shear rate (s-1), µ is the viscosity (Pa.s), a is an experimentally determined 
constant and b is also an experimentally determined constant. 
In tangential flow more at lab scale, shear rate at a given time is dependent on the flow rate 
(Q) and any additional viscosity increase is due to increase in cell concentration and the 
channel pressure drop. 
 
(1.12) 
 
 
 
Where Q is the flowrate (ms-1), A is the membrane area (m2), K is a dimensionless 
coefficient, µ is the specific viscosity (Pa.s), L is the channel length (m) and ω is the effective 
channel width (m). Bouzerar, et al. (2000) pointed out that although the average shear rate 
is RPM dependent, the shear rate that cells are exposed to inside the RDF depend on their 
position with respect to the disc diameter (Bouzerar et al., 2000).  
 
(1.13) 
 
Where K is the velocity entrainment factor, ω is the disc angular velocity and τwt is the wall 
shear stress (Pa). Bouzerar et al. (2000) also established that flow can be laminar near the 
centre of the disc and turbulent near the periphery. Therefore in order to avoid differences 
between in flux behaviour in a USD and a lab scale system, two key considerations are 
applied: 
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1. Shear stress and rate is dependent on the distance from the disc centre, where γ=0, 
unlike the lab scale system, where the shear stress is uniformly distributed over the 
membrane area. 
2. Flux differs depending on the distance from the centre, unlike in the lab scale 
system, where flux is more uniform. 
Overall it is clear that there are available methods to be implemented as tools for scaling 
down conventional primary recovery operations. These principles can be implemented 
during the research in order to maximise the efficiency of the experimental work. However in 
each case reliable scale up data will have to be shown as some ultra scale-down methods 
can yield poor results. For example using a small area for determination of depth filter 
performance may not be truly representative of the large scale operation due to 
inconsistency in the filter media which resulted from the initial manufacturing process.         
The final introductory section will discuss the economic considerations which apply to the 
bioprocessing area. In particular, unit operation cost assessment methods will be discussed, 
including cost modelling methods. 
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1.6 Economic Considerations  
Economic modelling in the biotechnology industry has focused on addressing cell culture 
decisions (e.g., selecting between fed-batch and perfusion processes) (Lim et al., 2005; 
Pollock and Farid 2013), and chromatography operations (Stonier et al., 2012, Pollock et al., 
2013b; Allmendinger et al., 2014). Modelling tools for addressing the choice between 
stainless steel and single use technologies have also been reported (Farid et al., 2005; 
Sinclair 2008). In comparison, there are few examples addressing the primary recovery area 
(Felo et al., 2013; Pegel et al., 2011). 
Cost modelling in the biotechnology industry has been carried out using a variety of 
modelling options. Depending on the scope and the complexity of the model a choice 
between a static and a dynamic model can be made. Static models are faster to build and 
provide a basic comparison for a small number of worksheets. These have been applied to 
generate process cost estimates (Farid 2007; Paz and Puich et al., 2004; Shaklin et al., 
2001;). Dynamic models are more suitable for complex scenarios, capable of encompassing 
parallel events as well as discrete event simulation e.g., impact of manufacturing delays, 
resource constraints, etc. (Banks, 1998; Paz and Puich et al., 2004 Pollock et al., 2013; 
Stonier et al., 2012; Stonier et al., 2009). A deterministic model is suitable for clear cut 
scenarios involving a limited number of inputs as it is based on carrying out a sensitivity 
analysis and measuring impact on key outputs by introducing an x% change to the input 
variables (Farid et al., 2005; Lim et al., 2006; Biwer et al., 2005). Accounting for more 
complex and random events such as risk adjustment, is most commonly done by using 
Monte Carlo simulations (Hayes and Wheelwright, 1984).  
A range of commercial software packages is available which provide cost modelling options 
including SuprerPro Designer (Intelligen Inc, Meryland, USA) and BioSolve 
(Buckinghamshire, UK). These offer benefits in terms of graphical representation and 
process design as well as ability to carry out material balances, equipment sizing and 
economic evaluation in a speedy manner. However novel technologies may not be captured 
by these packages and they do not allow incorporation of empirical models into the 
evaluation. 
Due to the scope of this thesis and the use of alternative technologies in combination with 
empirically derived data a static deterministic model will be most appropriate for direct 
comparison of recovery unit operations. Key costs to be accounted for in the model tend to 
fall into two categories: capital investment required and production costs. 
1.6.1 Capital Investment 
Capital investment is often considered as the capital required to build a new production 
facility, including construction, validation and licencing. When calculated for a new build 
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facility this generally includes equipment costs, utility costs, piping and instrumentation 
costs, as well as HVAC systems and costs associated with validation, design, engineering 
and licencing. Previous studies have described typical capital investment costs in the range 
of £2 M to £750 M required to build a new facility, with typical times in the range of 2-4 years 
required for building and validating. The most representative method for estimation of capital 
investment has been suggested to be achieved by using factorial estimates which are based 
on previous similar projects. The Lang factor (Lang 1948) is often used in conjunction with 
calculated equipment costs to estimate capital investment where values in the range of 3.3-
8.1 have been used for stainless steel biopharmaceutical facilities and values up to 23.7 for 
single use biopharmaceutical facilities (Farid 2007; Novais et al., 2001; Pollock et al., 2013) 
1.6.2 Cost of Goods (COG) 
Cost of goods (COG) generally include the operating costs associated with the production of 
a product. COG can be broken down into direct (e.g. raw materials, utilities etc.) and indirect 
costs (equipment and facility depreciation, equipment maintenance etc.). Labour costs can 
be included in either category, however is most commonly included in the direct costs as an 
hourly rate related to the processing time. The impact of each of these cost factors in 
mammalian cell processing have been described by Farid (2009). For example, an increase 
in annual production has been shown to decrease the COG/g, while material costs begin to 
dominate compared to the labour and indirect costs. Therefore reduction in material costs at 
large scale will significantly impact the COG/g, especially in downstream operations (DSP) 
as DSP cost has been shown to increase significantly with annual production (Farid 2009). 
This pattern is typically described as a downstream bottleneck and has been exacerbated by 
the increase in cell culture titre (Langer, 2012). 
Although the trends in USP and DSP COG have been well described for mammalian 
processes, isolating the impact of trends in mammalian cell bioprocessing on individual 
processing steps is less available. Therefore creating an economic model to look specifically 
at COG in primary recovery operations would be necessary in order to fully describe the 
impact of any proposed changes to the current platform. 
 
Chapter 1                                      
49 
 
1.7 Aims and Thesis Structure 
Published literature discussed in the previous sections has shown a continuing demand for 
improvements in primary recovery operation efficiency. It also highlighted that limited data is 
available on the future strategies for the area. This thesis aims to develop a robust 
methodology for the identification and selection of a future-proof primary recovery 
technology for the harvest of high cell concentration mammalian cell culture in mAb 
processing. In order to achieve this, the work will cover the identification of industry needs, 
creation of representative test material, primary recovery technology screening as well as 
detailed performance and economic assessments. This section details the aims and 
structure of the individual results chapters included in this thesis. 
The first step in the identification of potential future proof technologies for primary recovery 
was assessing the current and future needs of the industry. The work described in Chapter 
3 of the thesis aimed to identify the current and future demands on primary recovery 
operations by surveying expert opinion across the key processing areas on the current and 
expected trends in cell culture, primary recovery and purification. This will identify numerical 
values for the worst and best case conditions, representative of the potential future and 
current cell culture feed profiles. The chapter results will also aim to collate the industry 
desired criteria for the performance of the future primary recovery technologies in order to 
identify the optimal assessment criteria for the technology selection process. 
Chapter 4 aimed to describe a novel methodology for the generation of cell culture test 
material (CCTM) which will allow the test conditions identified in Chapter 3 to be achieved. 
This methodology will aim to allow independent control of key cell culture variables in order 
to decouple the resulting effects. The methodology will aim to produce test materials for the 
following studies involving the testing of primary recovery technologies described in this 
thesis. It will be designed for the generation of a greater level of information, in turn allowing 
empirical correlations to be derived that link cell culture variables to the performance of 
primary recovery technologies tested.  
Chapter 5 aimed to describe the use of CCTM to screen current and alternative primary 
recovery technologies, identified to have the potential to cope with predicted future feed 
profiles identified in Chapter 3. The technologies will be evaluated based on the following 
performance criteria: solids removal, yield and impurity removal. Selected current and 
alternative technology candidates will then be ranked using a multi-attribute decision-making 
(MADM) technique and the successful candidates will be assessed further using an 
economic evaluation and facility fit criteria.  
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Chapter 6 aimed to assess the performance of the successful technology candidates 
identified in Chapter 5, as a function of key cell culture variables. The chapter will aim to 
identify the most cost effective technology option for each cell concentration and product titre 
combination expected over the next decade in order to allow for the formation of a 
technology strategy for given aims of cell culture performance in terms of cell concentration 
and titre combinations. 
The following chapter (Chapter 2) will describe the general materials and methods used in 
the course of this work. The materials and methods included in this chapter will cover 
detailed descriptions of the general techniques applied. Each results chapter will also 
include individual materials and methods sections which will focus on describing the chapter-
specific experimental set up and methods used to generate the data in each chapter. 
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2. Chapter 2: Materials and Methods 
2.1 Introduction 
This section provides a description of the general methods and procedures used to obtain 
the results discussed in this thesis. The experimental designs adopted are discussed in the 
corresponding chapters and reference made to the relevant procedures described below. 
2.2 Cell culture 
Cell culture material was generated using an IgG4 producing GS-CHO cell line - CY01 kindly 
provided by Lonza Biologics Plc (Slough, UK). The cell line was cultured at 5 L (bench) and 
70 L (pilot) scales using stirred tank reactor (STR) systems in order to produce a cell culture 
material representative of commonly used large scale cell culture operations. The following 
sections describe the general methods used for cell recovery using the selected scales and 
systems.  
2.2.1 Cell Line Recovery and Propagation 
A working cell bank was created at passage number 8 and was stored at a concentration of 
10x106 cells/mL in 10% DMSO in liquid nitrogen storage. The cells from this working cell 
bank were used throughout all of the experimentation described in this thesis. When 
required a vial was removed from the liquid nitrogen store and thawed at 37°C using a water 
bath. The contents of the thawed vial (~10x106 cells) were added to 9mL of sterile CD-CHO 
(Invitrogen, Paisley, UK) medium in a 50 mL falcon tube. The cells were washed by gentle 
mixing with the medium then centrifuged at 450 g for 5 minutes. The supernatant was 
discarded and the pellet was resuspended in 20mL of fresh sterile medium and cultured in a 
125 mL shake flask for 3 days, incubated (Sanyo, Loughborough, UK) at 37°C and 5% CO2. 
The condition of the cells was checked one day after recovery from frozen stock to ensure 
that the cell viability was above 50%. If this was not the case, the wash step was repeated to 
remove any remaining DMSO and the culture was continued.  
Cell passages were carried out every 3-4 days. Cell number and viability was quantified 
using the ViCellTM (trypan blue exclusion) and cells were seeded in a new flask at 2x105 
cells/mL using fresh CD-CHO medium containing 0.1% methionine sulphoximine (MSX). 
2.2.2 Cell Culture at the 5 L Scale 
Cell expansion was carried out using 1 L shake flasks where cells were cultured for 4 days 
prior to the inoculation of the 5 L (3.5L working volume) stirred tank bioreactor (STR). This 
had an in-built control system (B. Braun BIOSTAT B-DCU control unit, Sartorius, Epsom, 
UK). 3 L of CD-CHO media was pumped into the reactor the day prior to inoculation in order 
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to preheat the media and carry out a two point calibration of the dissolved oxygen probe and 
a one point calibration of the pH probe using an offline pH reading. 
A cell count of the inoculum was carried out on the day of the inoculation. Inoculum volume 
was calculated to achieve a final inoculation density of 2x105 cells/mL. The inoculum as well 
as any remaining media required to achieve the total working volume was pumped into the 
reactor once the set point conditions were stable, as determined by the online DO, 
temperature and pH probes. 
Set points were maintained at 30% air dissolved oxygen tension (DO), 7.10 pH using CO2 
and 0.1 M base and a temperature of 37°C. A constant gas flowrate of 100 cm3/min was 
maintained using a horseshoe sparger. Agitation was set at 260 RPM using a single 45° 
pitch, three blade impeller. All cell cultures were carried out in fed-batch mode using 
chemically defined medium (CD-CHO, Invitrogen, Paisley, UK). The glucose concentration 
was measured daily with a NOVA Bioanalyser (Nova Biomedical, Deeside, UK) and 
maintained at a concentration of 2 g/L using a bolus feed of 10-fold concentrated dry powder 
CD-CHO media, adjusted to a concentration of 150 g/L glucose (Sigma, Poole, Dorset, UK). 
The culture was typically run to a maximum of 14-15 days. 
2.2.3 Cell Culture at the 70 L Scale 
Shake flask pre-culture was carried out in 1L shake flasks for 3 days and used to inoculate a 
5 L STR (3.5L working volume). The inoculation procedure followed is as described in 
section 2.2.2 and the inoculum was expanded for a further 4 days.  
45 L of CD-CHO media was made up using de-ionised grade water from powder stock of 
CD-CHO AGTTM (Invitrogen, Paisley, UK). Two days prior to the inoculation of the 70 L 
single-use bioreactor (SUB) (BIOSTAT CultiBag STR, Sartorius Stedim, UK), the single use 
bag was installed and inflated as per manufacturer’s instructions.  A Millipak 200 Gamma 
Gold 0.22 µm sterile filter (EMD Millipore,UK) was welded onto the media line using a 
BioWelderTM (Sartorius Stedim, UK). The media was then pumped into the bag at a flowrate 
of 100 L/h using a peristaltic pump (Watson Marlow, UK). Once the media transfer was 
complete, the temperature control was set to 37°C, the impeller speed was set to 150 rpm 
and air was pumped in at a flowrate of 2 L/min. The bag was left to soak for one day as per 
manufacturers instructions, at which point the dissolved oxygen optical sensor was then 
calibrated using air and nitrogen. The pH was manually brought within the range of the pH 
optical sensor using offline measurements taken with a SevenEasy pH meter (Mettler 
Toledo, UK) before the pH control was activated with a set point pH of 7.1 with a deadband 
of 0.05. Set points were maintained at 30% dissolved oxygen and a pH of 7.1 at 37°C for 
one day before inoculation, and then maintained throughout the culture. Agitation rate was 
maintained at 150 RPM unless otherwise stated for specific experiments. The feeding 
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strategy was matched to the 5 L STR condition where the glucose concentration of 2 g/L 
was maintained using a bolus feed of 10-fold concentrated dry powder CD-CHO media, 
adjusted to a concentration of 150 g/L glucose (Sigma, UK). The culture was run as 
required, typically to maximum of 14-15 days. 
2.3 Primary recovery 
2.3.1 USD Centrifugation and Shear Studies 
A rotating disk shear device developed at University College London was used to mimic the 
shear encountered in the feed zones of hermetically and non-hermetically sealed disc-stack 
centrifuge. Detailed methodologies for ultra-scale-down (USD) centrifugation have been 
described previously (Boychyn et al., 2004; Hutchinson et al., 2006; Levy, 1999). A 
microwell plate-based method described by Tait et al. (2009) which is a derivative of the 
USD method was used for these experiments. 
 
Rotating Disc Device 
A rotating shear device was used to mimic the shear experienced during the centrifugation 
step. Hutchinson et al. (2006) previously estimated the high and low energy dissipation rates 
equivalent to non-hermetic and hermetically sealed disc-stack centrifuge feed zones as 
0.37x106 Wkg-1 and 0.019x106 Wkg-1 respectively. The methodology was used as a first step 
to mimic large scale centrifugation as well as for shear studies when comparing cell culture 
material. The rotating shear device stainless steel chamber used had a diameter of 50 mm, 
height of 10 mm and the rotating disc was 40mm in diameter and had a thickness of 1 mm. 
The shear device was filled slowly with the cell culture material using a 50 mL syringe; 
excess material was used to flush out any air bubbles trapped in the chamber. The selected 
shear was then applied to the material for 12 seconds. The material was removed from the 
chamber and the set condition was repeated using fresh cell culture material as required 
after cleaning the device with water by filling and running it up to 3 times. 
 
Centrifugation 
This part of the method was used to achieve equivalent solids separation when mimicking 
pilot scale centrifugation conditions. 1 mL of the sheared material prepared using selected 
shear conditions was transferred to rows A and H of a deep square microplate (Fisher 
Scientific, UK). The plate was centrifuged at 3,000 RPM for 5 minutes in an Eppendorf 5810 
R bench top centrifuge (Cambridge, UK) with an A-4-62 swingout rotor. The centrifugation 
conditions used were set to give an equivalent feed flow rate of 100 L/h in the centrifuge to 
represent a moderate flowrate into a medium scale centrifuge - the CSA-1 (Westfalia, Oelde, 
Germany) with a sigma (Σ) value of 680 m2. After the centrifugation was complete 500 µL of 
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the supernatant was carefully collected from the top of the wells, to avoid disturbing the 
sediment. The supernatant OD was measured and the samples were pooled for further 
analysis or depth filtration experimentation. Any supernatant material stored for further depth 
filtration experiments was stored at 4°C overnight. Samples for HPLC, BCA and DNA 
analysis were stored at -20°C, samples for reducing 2D PAGE gels were stored at -80°C. 
 
2.3.2 USD Depth Filtration 
Depth filtration media discs of 05SP, 10SP and 30ZA media were kindly provided by 3M 
(Bracknell, UK). These were cut using a 0.6 mm drill piece (Tool Zone, UK) to provide a total 
effective membrane area of 0.28 cm2 and inserted into a custom made manifold. The 
manifold design and the filtration method have been described previously by Jackson 
(2011), Kong et al., (2010) and Lau et al., (2013). The device set up consisted of a collection 
plate which fitted onto the vacuum block (Tecan VacS, Tecan, UK) inside a TecanTM 
platform. The vacuum manifold (TecanTM, UK) which fitted on top of the vacuum block and 
formed a seal with the position plate which accommodated the membrane housing. The 
membrane was then inserted into the membrane holder which formed the bottom part of the 
membrane housing. The reservoir on top of the membrane housing also served as a feed 
tank (see Figure 2.1). 
 
Each new membrane was flushed with water for a minimum of 2 times at a 100 mBar 
pressure, while water flux through the membrane was measured. The water flux tests were 
repeated for a maximum of 5 times until the water flux measurements became consistent 
(±10%) indicating satisfactory wetting of the membrane. If consistency was not achieved, the 
membrane was discarded, a replacement selected, and the water flux test repeated.  
Once consistent water flux measurements were obtained 4mL of feed material was pipetted 
into the membrane housing. Pressure was then applied at 100 mBar using a vacuum. 
Simultaneously a liquid handling arm (Freedom EVO® liquid handling system, Tecan, UK) 
was set up to monitor and record the retentate volume throughout the filtration procedure, 
until the flux has declined to 80% of the initial value. The scale comparison of this method 
has been discussed previously (Kong et al., 2010, Lau et al., 2012). 
 
The results were analysed based on the Vmax methodology assuming a gradual pore 
constriction model: 
 
(2.1) 
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where V is the total filtrate volume collected over time t, Q0 is the initial flowrate, and Vmax is 
the maximum volume that can be filtered before the filter is completely blocked and the flux 
reaches zero.  
 
 
2.3.3 Tangential Flow Filtration 
Bio-Optimal MF-SLTM  and QyuSpeed DTM (QSD) (Asahi Kasei, Japan) hollowfibre modules 
with areas of 0.0004 m2 and 0.0006 m2 respectively provided by a single fibre (15 cm height) 
were run at a constant flux of 30 LMH using an AKTA Crossflow device (GE Healthcare, 
Little Chalfont, UK). The initial feed flowrate was set to achieve a constant shear rate of 
2,300 s-1 for both module types, and the backpressure was maintained positive by using a 
manually operated valve when required. The module was wetted for 30 minutes prior to the 
start of the filtration using purified water followed by 5 minutes using PBS buffer (Life 
Technologies, UK). Re-circulation was then stopped and the buffer was replaced with the 
relevant feed stock. The lines were left full with PBS prior to re-starting the circulation of the 
feed, reducing the liquid-air interface in order to minimise additional shear. Feed material 
was circulated at 2,300s-1 for 2 minutes prior to starting the permeate pump. Inlet, and 
permeate pressures were recorded using an AKTA Crossflow device (GE Healthcare, UK). 
Outlet pressure was recorded using a custom made pressure sensor built in UCL. The 
pressure sensor was used for pressure ranges between 0-2 bar and was calibrated using 
the AKTA Crossflow inlet pressure sensor. Permeate was collected in 15 mL graduated 
falcon tubes (VWR, UK), pre-weighed to 2 decimal places using a balance (Sartirus Stedim, 
UK). Approximately 2 mL fractions of the permeate were collected in this manner. Weights 
before and after filling were compared to obtain a more accurate volume of permeate in 
each fraction. Permeate pressure was kept above 0 by using a manual retentate valve. The 
operation was run until maximum recommended system pressure of 2 bar was reached. At 
Figure 2.1: USD depth filtration manifold used for constant pressure depth filtration experiments. 
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this point retentate volume was recorded and feed, retentate and permeate samples were 
collected and stored at -20°C for further analysis. 
 
2.4 Analytical Tools 
2.4.1 Cell Analysis 
During the course of the cell culture and primary recovery experiments cell concentration 
and viability, cell size and metabolite concentrations were monitored. In addition, an 
apoptosis assay was also carried out. 
2.4.2 Cell concentration and Viability 
Cell concentration and viability were measured using a Vi-Cell XR (Beckman Coulter, UK). 
The method is based on imaging of trypan blue exclusion of the viable cells. When 
necessary, sample dilutions were carried out using calcium and magnesium free PBS 
solution (Life Technologies, UK) to ensure the reading was within the detection range of the 
device. 
2.4.3 Particle Size Measurement 
Cell size during the course of the cell culture as well as pre and post primary recovery 
operations was determined using a CASYTM analyser (Innovatis, Germany). A 150 µm 
capillary orifice was used to measure the number of particles which fells in the 2.5-40 µm in 
diameter range. A minimum of 5 measurements were carried out per sample, where any 
deviations in particle size distribution greater than 10% were discarded and the 
measurement repeated. An average of the measurements for each sample was recorded. 
Sample dilutions of 10-50 µL in 10 mL of CasytonTM buffer (Innovatis, Bielefeld, Germany) 
were used. 
2.4.4 Apoptosis Assay 
A commercially available Annexin V-FITC/7ADD kit (Beckman Coulter, UK) and a Coulter 
Epics XL-MCL Flow Cytometer (Beckman Coulter, UK) were used to determine the extent of 
apoptosis during the development of the cell culture test material methodology. The assay 
used Annexin V conjugated with fluorescein isothiocyante (FITC) and 7-amino-actynomycin 
D (7-ADD). Apoptosis causes the phosphatidylserine (PS) phospholipid in the inner leaflet of 
the plasma membrane to become exposed allowing Annexin V to bind to it (van Engeland et 
al., 1998). The 7-ADD marker binds to DNA guanine and the cytosine base pair therefore 
allowing the measurement of cellular DNA when it is released into solution. The collected 
fluorescence data was analysed using EXPO 32 ADC XL Color software (Beckman Coulter, 
UK). Triplicate samples from each condition were stained and measured. 
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2.4.5 Solids Removal 
The percentage solids removal post primary recovery operations was calculated based on 
optical density (OD) at 600nm measurements of the feed solution - FOD, relevant sample 
post primary recovery - SOD and was normalised to a maximum primary recovery 
performance achieved by passing a clarified sample from each technology additionally 
through a 0.2 µm PES syringe filter (Merk Millipore, UK) - S100%, as per equation 2.2. The 
OD measurements were obtained using a Thermo Biomate spectrophotometer (Thermo 
Scientific, UK).   
 
(2.2) 
 
 
2.4.6 Solids Removal Quantification by Dry Cell Weight 
In cases where the OD of a post primary recovery sample was not possible to determine, 
solids content was determined by measuring dry cell weight. Eppendorf tubes were weighed 
using a 5 decimal place balance (Sartorius Stedim, UK). Each Eppendorf was filled with 2mL 
of the relevant sample, including feed material, post primary recovery material and post 
primary recovery material which has been additionally passed through a 0.22 µm syringe 
filter. Triplicates of each sample were aliquoted. The samples were incubated at 80°C for 24 
hours. Dry cell weight was measured and percentage solids removal during primary 
recovery was calculated using equation 2.2. 
2.4.7 Impurity Qualification 
DNA and HCP impurities were quantified post the impurity concentration stage as well as in 
feed samples and post primary recovery stages. DNA concentrations were determined using 
a Quant-iT™ PicoGreen ® dsDNA Reagent Kit (Invitrogen, Paisley, UK). The BCA assay 
(Fisher Scientific, Loughborough, UK) was used for quantifying relative HCP removal. HCP 
concentrations were calculated using the following equation: 
 
[HCP] = [TP] – [TY]                                                                                                      (2.3)                                                                                                                               
 
where TP is the total protein concentration  determined by the BCA assay and TY is the total 
product concentration in the sample, determined by HPLC analysis, described in section 
2.4.8 below. 
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2.4.8 HPLC 
IgG4 and IgG1 concentrations were determined using a 1mL HiTrapTM Protein G column (GE 
Healthcare, UK) run on an HPLC system (Agilent Technologies, UK). 100 µL of sample was 
loaded at less than 2 g/L at a flowrate of 2mL/min. Sodium phosphate equilibration buffer (10 
mM NaH2PO, 10 mM Na2HPO4, adjusted to pH 7.0) and a glycine elution buffer (20 mM, 
adjusted to pH 2.8) were used. Detection was carried out at 280 nm and the sample 
concentration was determined by integrating the elution peak and generating a standard 
curve using known quantities of IgG1 or IgG4 depending on the sample tested. 
2.4.9 2D PAGE 
Samples pre and post primary recovery were treated using a 2D Clean- Up Kit (GE 
Healthcare, UK) as per manufacturer’s instructions. 200µg of protein dissolved in rehydration 
solution was then loaded onto a 7cm IPGPhor strip pH3-10 Non-Linear (GE Healthcare, 
UK). The strips were then immediately transferred to be run in the second dimension. The 
second dimension was run using 4-20% pre-cast Bis-Tris gels 7.0 x 7.0 x 0.1 cm ZOOM IPG 
Well (Life Technologies, UK) using the X-Cell SureLock Mini-Gel System (Invitrogen, UK). 
The gels were stained using Sypro RubyTM  (Life Technologies) stain according to the 
manufacturers protocol and scanned using a Typhoon 9400 laser scanner (GE Healthcare, 
UK) with a 100µm pixel size and 600 V PMT. The images were analysed using SameSpots 
software (TotalLab, UK). Normalised spot volumes were calculated and compared across 
the gels. 
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3. Chapter 3: Defining targets for mammalian cell culture primary recovery operations in 
the future by quantifying current industry trends 
3.1 Introduction 
Key variables of a typical mammalian cell culture feed to primary recovery, which impact the 
performance of primary recovery and purification operations include cell line and process 
specific parameters: cell concentration, cell culture titre and cell viability at harvest (Tait, et 
al., 2009; Westoby et al., 2001). In turn, these affect the impurity profile present in the feed 
streams to the purification operations, including DNA and HCP concentrations. As a 
consequence final product quality, purity and yield.  
Due to the current reported constraints in primary recovery changes are impacted in the 
technologies implemented for manufacture may be required. In order to ensure a future 
proof, robust choice of primary recovery technology, it is important to define the expected 
worst case conditions over the envisaged time period for technology implementation. 
Typically, purchased equipment is expected to be utilised for a period of at least ten years 
and therefore the time period considered in this study accounted for this. Accordingly the 
likely values which cell concentration, titre, cell viability and impurity concentrations might be 
expected to reach over the next decade will be defined in this chapter. To carry out this 
definition, it will be necessary to consider the relationship between these process 
parameters.  
3.1.1 Titre Increases 
Overall, titre increases can be achieved through increases in both cell specific productivity 
and in cell concentration which in turn can be manipulated through cell line engineering 
(Tiggers and Fussenegger, 2006) and cell culture process optimisation (e.g., feeding 
strategy, cell culture mode etc.) (Jiang and Sharfstein, 2007). Titre increases achieved by 
process optimisation can potentially be characterised by carrying out a practical investigation 
quantifying the impact of bioreactor operation conditions on titre and its relationship with cell 
concentration, specific productivity, and impurity concentrations. However, predicting the 
outcome of current research in cell line engineering requires not only the collation of the 
progress made to date in cell line engineering found in literature, but more specific 
knowledge of current industrial research, aims and methodology as well as industrial 
experience to date. This information is mostly unavailable to the public and is limited to 
industrial experts working in the field. Current process development implements a 
combination of cell line engineering and process optimisation (Huang et al., 2010).  
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3.1.2 Cell concentration 
Cell concentration is generally optimised through bioreactor operation after the clone 
selection process has been accomplished (Todaro and Green, 1963). An increase in cell 
concentration achieves an increase in titre, however it can also result in an increase in % 
solids concentration, as well as the potential HCP and DNA concentrations, due to the 
increase in the number of cells present. This can also result in an increase in viscosity, 
especially at low cell viabilities, due to the release of cellular contents into solution.   
3.1.3 Cell Viability 
Cell viability at the point of harvest is generally controlled. Low viability harvests are not 
typically recommended (Iammarino et al., 2007). Shear, which is typically present during 
primary recovery operations, results in a greater degree of cell breakage when processing 
low viability cell broth (Tait, 2009).  Cell breakage in turn results in an increase of HCP and 
DNA concentrations in the subsequent processing streams, which increases the burden on 
downstream operations to achieve the required level of impurity removal. For example; a 
high cell concentration, low viability feed stream composition provides challenging conditions 
for primary recovery and purification operations. 
This chapter aims to identify the current and future demands on primary recovery operations 
by surveying expert opinion across the key processing areas on the current and expected 
trends in cell culture, primary recovery and purification. This will allow the identification of 
numerical values for the worst and best case conditions representative of the potential future 
and current cell culture feed profiles. In addition, the survey aims to collate information 
regarding the desired criteria for the performance of the future primary recovery technologies 
in order to identify the optimal assessment criteria the technology selection process. 
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3.2 Materials and Methods 
A survey was constructed which consisted of 13 questions covering topics concerning cell 
culture primary recovery and purification as well as regulatory issues (Appendix A). Each 
answer option required a confidence rating of low, medium or high, where low confidence 
corresponded to an answer based on low, medium confidence was based on general 
previous experience and high confidence was based on specific data or experience. 
In order to increase the quality of the data gathered, the participants were carefully selected 
by recommendation as industry experts. The survey was carried out in a contract 
manufacturing organisation, as it had a broad range of mammalian cell processing 
experience due and therefore a good understanding of processing requirements and trends. 
A sample group of 16 experts across the processing areas were selected by internal 
company recommendation to complete the survey, which was distributed via email. Six of 
the experts were also selected for additional 30 minute interviews, in order to expand on the 
answers they provided and  to cover the topics in greater depth. 
The experts included technical experts from upstream, downstream and analytical groups. 
As primary recovery operations fall between the upstream and downstream areas both 
points of view were captured in order to draw conclusions allowing for experimental design 
definition and criteria setting. The experts were also from different groups including process 
development and manufacturing development in order to capture any difference in the 
trends observed by the two groups. 
The survey results were analysed by incorporating an appropriate numerical value to the 
corresponding confidence rating as outlined in Table 3.1. Question 1 was designed to 
identify the key operational areas which have experienced constraints over the past 2 years. 
Question 2 aimed to determine whether bioprocess developers have become more open to 
the use of alternative technologies, as technology uptake can impact technology choice 
made by bioprocess developers. Questions 3-5 aimed to determine the cell concentration 
and product titre range that the experts were expecting to reach in the next decade. 
Question 6 then asked to specify which cell culture technology was expected to be used to 
reach these cell concentrations. As discussed in section 1.2.3, the cell concentration ranges 
are highly dependent on the technologies selected (e.g., perfusion technology may be used 
to reach up to 300x106 cells/mL, whereas fed batch culture technologies currently achieve 
cell concentrations in the range of 20-50x106 cells/mL). Questions 7-8 focused on collecting 
additional information regarding current processing constraints and the cell concentrations 
under which they have been experienced. Question 9-12 aimed to quantify the current 
desired features for primary recovery operations in terms of impurity removal. Finally, 
question 13 aimed to quantify expected changes in the regulatory guidance or product 
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release specifications in order to identify if any additional pressure on unit operation 
performance will be expected in the future. 
 
Table 3.1: Confidence ratings available to support answers in the designed survey questions and the equivalent 
numerical values, allowing to calculate confidence weighted result scores for survey data analysis. 
Confidence Rating Option Equivalent Numerical Value 
Low 1 
Medium 2 
High 3 
 
This technique is similar to assigning priority weighting to selection criteria. Subsequently, 
the results were scored based on the frequency of answer and the confidence rating given 
as described in equation 3.1: 
 (3.1) 
where FR is the confidence weighted frequency rating, f is the result frequency and CR is the 
equivalent numerical value of the confidence rating basis allowing a numerical outcome. In 
cases where answer options were compared, the percentage confidence weighted 
frequency rating (PFR) was calculated as shown in equation 3.2: 
 (3.2) 
 
 
Where fa was the frequency of option a selected in an answer to a question, CRa was the 
confidence rating of the answer in option a, fi was the frequency of option i available as an 
answer option, CRi is the confidence rating given for option i and n is the number of available 
answer options. 
3.3 Results and Discussion 
3.3.1 Trends in Upstream Processing 
The survey was completed by sixteen industry experts in a contract manufacturing 
organisation in order to quantify the current and expected trends across key processing 
areas. The full questionnaire is shown in Appendix A. Contract manufacturing companies 
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tend to have high levels of experience due to the large number of products and processes 
they encounter and therefore are qualified to serve as a representative reflection of the 
industry as a whole. Although the expert sample size was relatively small, the effect on the 
quality of the collected data was minimised by participant selection (e.g., participants with 
high levels of experience), while quantifying their level of expertise using self-assessment. 
Six of these experts were also interviewed to provide additional clarification and detail to 
their answers.  
In order to contextualise the processing constraints reported in literature (see sections 1.2.2 
1.2.3), experts were asked to state the processing areas in which operational constraints 
had been experienced over the past two years. The results showed that the majority of the 
operational constraints between the years of 2009 and 2011 had been seen in purification 
(38%), followed by primary recovery (30%) and cell culture (23%) (see Figure 3.1). This is 
consistent with literature reports and provided the impetus for this thesis (see section 1.7). 
Interview results suggested that a proportion of the purification constraints were due to high 
impurity content feed streams, causing the precipitation of impurities during the pH hold step 
(for process diagram see Figure 1.1). In situ pH induced cell settling prior to recovery by 
depth filtration or a combination of centrifugation followed by depth filtration would prove 
beneficial in this instance, as it would eliminate the need for introducing an extra filtration 
train post the pH hold step, taking advantage of the existing unit operations at primary 
recovery. At large scales, however, in situ pH change may be impractical due to the volume 
and mixing requirements. Overall, this highlights a drive to achieve a greater degree of 
impurity removal during primary recovery operations. 
 
Figure 3.1: Quantification of operational constraints experienced between 2009 and 2011 by processing area. 
Percentage confidence weighted frequency ratings have been shown and calculated as shown in equation 2. 
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The survey participants were then asked to state the titre and cell concentration at harvest 
they expected to be the norm by 2020. Although no multiple choice options were given in 
this question to avoid limiting the participants in their answers, their responses fell into 
specific groups with many participants stating the same target cell concentrations and titres. 
Individual confidence values for cell concentration and titre were averaged to give an 
average confidence rating. This was plotted against the equivalent cell concentration and 
titre combinations to help identify the most likely combination expected to be reached within 
the next decade (see Figure 3.2). Expected titres ranged between 10-15 g/L but were 
associated with low confidence values. Titres above 15 g/L were stated with medium to high 
levels of confidence. The expected cell concentration range of 40-80x106cells/mL was 
frequently stated, however the average confidence rating was low (<2) with few high 
confidence answers. Four answers were in the 80-100x106 cells/mL range with confidence 
ranging between low to medium.  
 
Figure 3.2: Cell concentrations and titre expected by industry survey participants to be reached in the next 12 
years. Equivalent confidence ratings given for titre and cell concentration values were averaged and plotted for 
each given combination. 
Areas of highest confidence included titre ranges of 10-20 g/L and equivalent cell 
concentrations of 25-100x106 cells/mL. Titres beyond 10g/L has been reported in literature 
as well as cell concentrations above 100x106 cells/mL achieved with the use of perfusion 
technologies (Huang et al., 2010; Clinke et al., 2013). Therefore the stated range can be 
considered realistic in light of these independent sources. However it must also be noted 
that a change in cell culture technology (from the current fed-batch operation) may be 
necessary in order to achieve realistically these targets. When asked for reasoning behind 
these choices in titre and cell concentration combinations, interview participants who chose 
high cell concentration high titre combinations defended their choice based on the previous 
trends and cell concentration increases seen over the years, as well as potential changes in 
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the cell culture technology likely to be applied in the future.  Interview participants who gave 
lower range figures stated that their choice was based on the currently achieved higher titres 
and cell concentrations, which they expected to become routine.  
Based on these results it is possible to state the range of expected titres and cell 
concentrations to be 10-20 g/L and 20-100x106 cells/mL respectively. This range of cell 
concentrations correlated with the current industry trends discussed in section 1.2.3, where 
cell concentrations of up to 300x106 cells/mL were achieved using perfusion technologies 
(Schirmer et al., 2010; Clincke et al., 2013a; Clincke et al., 2013b; Karst et al., 2016). 
However, cell concentrations reported using fed batch processes are in the range of 20-
40x106 cells/mL, in line with the predictions made. These titre and cell concentration 
rangeswill be simulated as a potential future cell culture material in the following work. 
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3.3.2 Quantifying Purification Processing Area Needs 
Primary recovery platform options have typically included depth filtration options or a 
combination of centrifugation and depth filtration (see section 1.1.2) (Kelley et al., 2009; Liu 
et al., 2010). Interview results confirmed this and provided a clear current scale definition for 
the application of these two options. Depth filtration is typically implemented at scales less 
than 1,000 L and centrifugation followed by depth filtration at scales greater than 1,000 L. In 
order to gauge the general industry trends and interest in alternative processing options, the 
survey participants were asked whether they had observed an increase in their customer 
interest in unit operation alternatives to the platform options offered (see Figure 3.3). 83% of 
the participants answered noted an increase in customer interest in alternative processing 
options. They were then asked to identify the processing options of interest. Protein A 
alternatives were the most sought after with a percentage confidence weighted frequency 
rating (PFR) value of 29%, followed closely by cell culture alternatives (21%) and 
flocculation options (12%).  
The use of alternative unit operations requires additional development, knowledge base 
building and extensive characterisation, the extent of which depends on the currently 
available information on a given technology. Carrying out such work requires substantial 
resources and the inevitable risk associated with unknown performance output as well as 
potential failure in the selected mode of application. Interview results hypothesised that the 
difference in customer interest is likely due to the existence of two different customer types: 
small to medium and large enterprises (SME and LE respectively). Large enterprises are 
more likely to have the resources required to invest in the development and implementation 
of alternative options. SMEs are less likely to make the investment due to the high risk, as 
well as the time and cost constraints. Overall, the quantified expressed interest shows a 
potential demand for expanding the currently offered platform options. 
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Figure 3.3: Increase in interest expressed by CMO customers in alternative unit operations. Percentage confidence 
weighted frequency rating (PFR) was calculated using Equation 2. 
In order to outline the impurity removal criteria upon which technologies with the potential for 
future use might be selected, the survey participants were asked to select the desired level 
of impurity removal to be achieved during the primary recovery stages (see Figure 3.4). The 
impurities were categorised as host cell proteins (HCPs), product aggregates and DNA  
were presented in a random order. An option of “other” was also available with a space to 
further specify any additional desired impurities. The % removal options were as follows: 1-
10%, 10-20% and 20-40% removal. 20-40% HCP removal received the highest (22%) PFR 
value. Desired aggregate removal levels of 1-10% and 10-20% received similar PFR values 
of 18% and 16% respectively.  High levels of DNA removal (2-40%) received a PFR value of 
15%, while the PFR value given to low and medium levels of DNA removal were 9% and 4% 
respectively. Although the answer to this question was aimed to provide guidance on the 
desired primary recovery operation features, the given answers may indicate that the 
participants prioritised impurity removal which would be reasonable to expect from a primary 
recovery technology. For example current technologies such as depth filtration options 
provide a higher level of DNA removal and a low level of HCP removal (Yigzaw et al., 2006; 
Charlton et al., 1999). As these options are based on non-specific selection they do not offer 
aggregate removal. Therefore the current technology ability is consistent with the desired 
primary recovery operation features, which may indicate that the expert answers were 
biased by the expectations they have for technology performance in the future. 
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Figure 3.4: Desired level of impurity removal during primary recovery operations quantified using the percentage 
confidence weighted frequency rating (PFR) calculated using Equation 2. Industry experts were asked to specify a 
range of HCP, product aggregate and DNA removal they would like to see achieved during primary recovery. The 
available impurity ranges included:  1-10%; 10-20%; 20-40%; option of “other” was also available but was 
not selected by any participants. 
These percentage removal results closely reflect the currently reported and advertised levels 
of impurity removal achieved using charged depth filtration (Lambalot et al., 2006), and 
therefore provide potential minimum levels for future performance targets. They also provide 
a basis for ranking the impurities in terms of importance of removal by selecting the highest 
PFR figures in each impurity group and using these to order the impurity groups from 
highest to lowest levels of desired removal. Impurity removal can therefore be ranked in the 
following order: HCP, DNA, and product aggregates (see Table 3.2).  
Table 3.2: Impurity removal priority criteria in terms of HCP, DNA and product aggregate removal during primary 
recovery processing stages, derived by quantification of industry expert opinion. 
 
 
 
 
Priority of Removal Impurity 
1 HCP 
2 DNA 
3 Product Aggregates 
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3.4 Conclusions 
A survey was carried out in order to quantify the current and expected trends in cell culture, 
primary recovery and purification operations. Although the significance of the results 
obtained are limited by the small sample size of survey participants, participant knowledge 
base and experience in the field was likely to result in high quality answers. The breadth of 
processes considered by the participants when completing the survey was also likely to be 
limited by the processes run by the participant company. However, as the participant 
company was a CMO, the experience of the survey participants was likely to include an 
overall industry perspective due to their knowledge of their customer requirements (i.e., 
global biopharmaceutical developers). 
The results of the survey confirmed the trends implied from the literature, including 
increased operational constraints in primary recovery and purification processing areas, as 
well as increases in impurity loads in streams passed to purification. This suggests that 
impurity removal as well as solids removal are likely to be important attributes of future 
primary recovery unit operations. 
An increase in customer interest in alternative unit operations has been observed by 
process. Interest in Protein A alternatives has been shown to be the most prevalent, 
followed by cell culture alternatives and some primary recovery alternatives. Although this 
increase in interest is likely to represent mostly large enterprises, due to the investment 
required for development and implementation of new technologies, it is an indicator of 
increased demand for new technologies across the sector. 
Expected titre and cell concentration ranges have been identified for the future cell culture 
feed to primary recovery based on the average confidence weighted expert opinion.  
Expected titre in 2020 has been estimated to be in the range of 10-20 g/L with an expected 
cell concentration projected to be in the range of 50-100x106 cells/mL. These figures are to 
be used as representative ranges for the primary recovery technologies, selected on their 
capability to be implemented robustly in the future. Impurity removal targets during primary 
recovery have also been quantified as priority criteria to be used in the assessment of 
potential technology performance. HCP removal has been identified as the primary concern, 
followed by DNA and product aggregate removal.  
This chapter has quantified the cell culture conditions expected to be reached in the future 
by providing an overview of the current expert opinion. However, these high cell 
concentration, high titre and impurity load conditions remain difficult to achieve in practice in 
order to provide representative cell culture material for experimental work. The next chapter 
will focus on addressing this challenge by describing a methodology for the production of cell 
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culture test materials aimed at achieving these high cell concentration, high titre and impurity 
conditions. 
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4. Chapter 4: Generating a cell culture test material (CCTM) 
4.1 Introduction 
The previous chapter focused on quantifying the expected ranges for future cell culture feed 
profile characteristics as well as the key variables affecting primary recovery operations. The 
results identified potential future cell concentration ranges in the order of 50-100x106 
cells/mL and titre ranges of 10-20 g/L. This chapter will address the challenge of creating 
material representative of these ranges which can be used as a test material for primary 
recovery operations. 
Current cell culture titres have been reported to have reached >13 g/L in fed-batch cultures 
(Huang et al., 2004), with current cell concentrations beyond 20 × 106 cells/mL (Westoby et 
al., 2011) (see section 1.2.3). These rises have contributed to an increase in pressure on 
primary recovery and purification operations, which have to adapt to changes in the feed 
stream. Although research into alternative downstream technology options has been carried 
out over the years (Liu et al., 2010), there has been little focus on how to generate 
representative feed materials for experimentation. 
The key variables, which define the properties of feeds to primary recovery operations tend 
to be specific to the operation in question. However, most published studies have historically 
included factors such as solids load (Hutchinson et al., 2006), cell concentration and cell 
viability (Singh et al., 2013), and more specifically particle size distribution (Tait et al., 2009). 
The impact of primary recovery and purification operations on product recovery as well as 
DNA and host cell protein (HCP) impurity removal have been discussed (Westoby et al., 
2011), most often in the context of cell line and cell culture conditions (Tarrant et al., 2012). 
Research focused on increasing the understanding of primary recovery technologies such 
as centrifugation (Boychyn et al., 2004; Maybury et al., 2000), depth filtration (Lau et al., 
2013; Riske et al., 2007) and tangential flow filtration (TFF) options (van Reis et al., 1982), 
have typically used cell culture material harvested directly from bioreactors. In these cases 
harvest conditions have been stated, such as day of harvest, cell concentration at harvest or 
viability at harvest, but little evidence of control over these feedstream conditions were 
shown. Some studies have focused on just one of the variables, for example cell viability, by 
harvesting material at different days from the cell culture bioreactor to obtain feed material 
with varying levels of viability (Tait et al., 2009). However, adopting such a methodology can 
make it difficult to contextualize the results when relating to other cell lines or cell culture 
processes. For example at identical cell culture days different cell lines or processes can 
yield a range of viabilities. In addition unique cell death pathways can result in differing 
particle size distributions being passed onto the primary recovery operations (Velez-
Suberbie et al., 2013). 
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Spiking of impurities as well as product has also been used in the past to mimic different 
levels of impurity loads (Kong et al., 2010; Shirataki et al., 2011) or to provide a measurable 
concentration, which can be quantified prior to and post-technology or condition 
implementation. However, the stability of the spiked material in solution must be verified to 
ensure the spiked material can be accurately quantified. 
Comparing the cell culture material produced using different cell lines for primary recovery 
studies and purification has also been previously shown (Westoby et al., 2011; Singh et al., 
2013). However, this method can have limitations when deriving correlations or empirical 
models, as potential biological expression differences can create a large set of unknowns, 
especially where HCP profile differences are significant. 
The level of control required to achieve specific properties in cell culture feeds to 
downstream operations can cause considerable strain on the cell culture material generation 
even prior to the material reaching primary recovery stages. Other variables can also 
contribute to the number of unknowns which in turn could potentially affect the downstream 
experimentation including cell culture scale and scale up methodology, feeding strategies, 
and metabolite profiles during processing. 
This chapter describes a novel methodology for the consistent creation of materials with a 
defined set of process-relevant characteristics and is aimed at producing material for the 
primary recovery studies described in the following chapters. The approach is to control 
tightly key cell culture variables and to ensure they are maintained independently so as to 
decouple effects from one another. Such an approach is difficult to achieve when using cell 
culture material sourced directly from a cell culture operation. The methodology aims to 
increase the level of information which can then be derived from carrying out primary 
recovery and purification studies and to provide a new avenue for deriving empirical 
performance correlations for novel processing technologies, in particular those designed to 
handle high cell concentration feeds. 
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4.2 Materials and Methods 
4.2.1 Cell Culture 5 L Scale 
Cell culture material was generated using  as described in section 2.2.2. 
4.2.2 Cell Culture 70L Scale 
The CY01 cell line was also used to produce material at the 70L scale using a single-use 
bioreactor (SUB) (BIOSTAT CultiBag STR, Sartorius, UK). Set points were maintained at 
30% dissolved oxygen and a pH of 7.1 at 37°C. Agitation rate was set at 150 RPM. Cell 
culture media and feeding strategy were matched to the 5L STR conditions (see section 
2.2.3 for a detailed description). 
4.2.3 Shear Study Comparison 
Cell culture material was harvested at the 5L scale once the viability had reached 
approximately 75%. Samples of the material were loaded into a rotating shear device 
(Boychyn et al., 2004; Hutchinson et al., 2006; Levy et al., 1999; Tait et al., 2009). High and 
low shear (equivalent to maximum energy dissipation rates of 0.37x106 Wkg-1 and 0.019x106 
Wkg-1 respectively) were applied to the material, with each condition examined in triplicate. 
Particle size distributions obtained pre and post exposure to high and low shear of each 
material batch were normalised and compared. 
4.2.4 Cell Culture Harvest 
All 5L STR harvests were performed on days 13 to 14 of culture, once the viability has 
declined to ~70%. The 70 L STR harvests were performed daily between day 7 and day 14 
of culture, where 3L of cell culture material was removed per daily harvest. 
4.2.5 Induced Cell Apoptosis 
On day 13 of the cell cultures, approximately 300 mL of cell culture material was removed 
from the 5L STR, aliquoted into 50 mL falcon tubes and washed with a sterile phosphate 
buffered saline solution (PBS, Sigma-Aldrich, Gillingham, Dorset, UK). The sedimented cells 
were then incubated on ice for 2 hours, then maintained at 37°C for up to 24 hours prior to 
use. Samples were monitored in the first 6 hours post apoptosis induction by staining using 
the Annexin V-FITC/7ADD kit PN IM3546 (Beckman Coulter, High Wycombe, UK) and 
processed using a Coulter Epics XL-MCL Flow Cytometer (Beckman Coulter, High 
Wycombe, UK). Apoptosis data was collected and analyzed using EXPO 32 ADC XL Color 
software (Beckman Coulter, High Wycombe, UK). Samples were analyzed using 488 nm 
excitation and detected using 525 nm and 675 nm band-pass filters for Annexin V and 7-
ADD (7-amino-actynomycin D) respectively, and collected for 300s (10,000 events). On the 
Chapter 4 
74 
 
day of harvest the required volume of the dead cell stock was calculated based on cell 
concentration and viability measurements of both the harvest material and the dead cell 
stock, obtained using a ViCellTM (Invitrogen, Paisley, UK). 
 
4.2.6 Cell concentration 
Cell culture material was concentrated post-harvest, using an Asahi Kasei Bio-Optimal MF 
SLTM module, area 0.005 m2 (Asahi Kasei Medical Co., Tokyo, Japan). The module was run 
in TFF mode using the AKTA crossflow system (GE Healthcare, Little Chalfort, UK) as well 
as a manually controlled peristaltic pump for permeate flow control. The feed was circulated 
at 240mL/min and permeate was collected at a constant flowrate of 3.5mL/min, until the 
target concentration factor was achieved. The starting and final concentration volumes (VS 
and VC respectively in equations 4.1 & 4.2) were calculated based on the starting (DS) and 
desired (DR) cell concentrations,  as well as the spike volumes of the product (IgGSP and 
impurity spikes (HCPSP, DNASP) and the dead cell stock spike (DCSP) required (Figure 4.1). 
                                                                                                                              
(4.1) 
      
                                                      (4.2) 
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4.1.1 Impurity and Product Concentration 
Fully purified IgG1 and flowthrough fraction post Protein A chromatography was kindly 
provided by Lonza Biologics. The flowthrough fraction was used to produce the HCP spike 
stock solution while the fully purified IgG1 was used to create the product stock solution. 
Both the HCP and IgG1 fractions were concentrated to approximately 50g/L using a 
Vivaspin®20 (Sartorius, Epsom, UK) with 5,000 and 50,000 MWCO filters respectively. Post 
treatment concentrations of the HCP stock were confirmed using the BCA assay (Fisher 
Scientific, Loughborough, UK). The IgG1 was quantified by measuring absorbance at 
280nm. All analytical methods applied in this chapter can be found in sections 2.4.7 and 
2.4.8. 
4.3 Results and Discussion 
4.3.1 Analysis of cell culture test material (CCTM) 
A representative set of mimic feeds to primary recovery, termed cell culture test materials 
CCTM were generated to create a wide range of cell culture conditions. The range of 
conditions generated match current cell concentration ranges as well as those reported to be 
high cell concentration conditions (20-100x106 cells/mL). The methodology used is 
summarised in Figure 4.1 and involved harvesting low cell concentration cell culture 
(<10x106 cells/mL) material produced in a stirred tank bioreactor and concentrating it using a 
tangential flow filtration step. An apoptotic cell stock was also created which may be used as 
a cell stock to achieve required cell viability conditions. Product and HCP stocks were also 
created by concentrating a GS-CHO cell line derived IgG1 and impurities. These were used 
to achieve target product and impurity concentrations for the selected conditions. The 
resultant CCTM samples were characterised in terms of the key variables of cell culture 
materials when used for primary recovery studies. The methodology was analysed across 
the two scales used to generate the cell culture material, the consistency of the final material 
was also assessed. 
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Figure 4.1: Schematic illustrating the template methodology used to produce the cell culture test material CCTM, 
with independent control of cell concentration, cell viability, HCP, and IgG1 concentrations. This methodology was 
used to achieve a range of high cell concentrations, viabilities, titre, and HCP concentrations by using cell culture 
material harvested from an STR at the 5L and 70L sales at a cell concentration <10 × 106 cells/mL and a titre of <1 
g/L. The cell cultures were harvested and concentrated using TFF, to achieve the target CCTM cell concentration. 
When required apoptosis induction was used to generate a dead cell stock which when spiked was able to provide 
the target viability of the CCTM. HCP and IgG1 originating from the GS-CHO cell line were spiked into the CCTM to 
achieve the target impurity and product concentrations. 
 
4.3.2 Impact of the Cell Material Source  
Cell culture material was produced at bench (5 L) and pilot scales (70 L). Cell growth, 
viability profiles and the average specific productivity during scale up were predominantly 
maintained within one standard deviation of the bench scale results for the majority of the 
runs (Figure 4.2). However, an apparent drop in viability was detected at the 70 L scale after 
250 hours of cell culture. 48 hours later the viability was once again within one standard 
deviation of the 5 L scale average. This inconsistency after 250 hours of cell culture is likely 
due to poor sampling technique, as suggested by the rapid restoration of the viability back to 
the expected range. This can often be caused by insufficient flushing of the sample tube 
prior to sampling. 
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Figure 4.2: Cell culture growth curves comparing the cell culture growth profiles achieved at two scales. Average 
viable cell concentration at the 5L scale calculated using data from 5 biological replicates ( ) and cell viability ( ) 
is shown throughout a 14 day culture period. Average viable cell concentration at the 70L scale calculated using 
three technical replicates ( ) and cell culture viability ( ) is shown. Dotted lines above and below the average 
lines indicate ±1 standard deviation of the repeat 5L cultures and error bars indicate ±1 standard deviation from a 
single 70L scale run. NOTE: individual 5L run results are plotted in Appendix B. 
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Figure 4.3A:Cell culture IgG4 titre curves achieved at the 5L scale, where the average of 5 repeated cell cultures is 
shown (x) as well as the upper and lower bounds of one standard deviation shown using the black dotted lines. Cell 
culture titre curve for the 70L scale is calculated using one run repeat, and an average of triplicate samples is 
shown (x). The error bars represent one standard deviation. B: Specific productivity calculated for five 5L scale cell 
culture runs compared to that obtained at the 70L is shown. 
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The IgG4 production seen at the 5L scale was comparable to that at the 70L scale between 
0 and 120h. Post 120 hours the titre reached using the 5L system was approximately 20-
30% higher than at the 70L scale (Figure 4.3A). However, the cell specific productivity at 
both scales is within one standard deviation of the batch to batch variation seen at the 5L 
scale (Figure 4.3B). Therefore the titre difference is due to a decrease in the integral viable 
cell count (IVCC) throughout the culture which translates to this small decrease in the overall 
titre. A decrease in the IVCC can be explained by the implementation of a single use bag at 
the 70L scale as opposed to the glass tank at the 5L scale. The impact of leachables in the 
single use system could have been the cause. Vessel material as well as other potential 
differences such as the volumetric power input have been recommended to be maintained 
during scale up (Nienow, 2013a; Nienow 2013b). Neither were maintained in this case and 
this may have had an effect on cell specific productivity observed in figure 4.3B.  
Cell shear sensitivity profiles of the cell culture materials were also compared. This was 
carried out by subjecting cell culture material harvested from both the 5L STR and the 70L 
SUB at equivalent viabilities of ~75% to conditions of no, low and high shear (Figure 4.4A, B 
and C). Prior to the application of shear three populations of cellular material could be 
observed at both scales. The 0-7µm region showing small diameter cell debris, 7-12µm 
region showing apoptotic cell populations and 12-30µm region showing live cells. As low 
levels of shear were applied a shift towards smaller particle sizes was observed, as well as 
an increase in the apoptotic cell population. The decrease in cell size as a response to 
applied stress conditions has been observed previously (Tait et al., 2009; Tarrant et al., 
2012). In addition cell damage is expected as shear is applied, causing some of the cells to 
burst, and subsequently the observed shift in cell size. The change in particle size 
distribution profiles between no shear and low shear yielded similar profiles at 5 and 70 L 
scales. 
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Figure 4.4 (A): Particle size distributions of cell culture material harvested at 70–75% viability at the 5-L (black line) 
and the 70L (dotted line) scales prior to the application of shear. Average particle size distributions of each sample 
were obtained (n = 5). Measurements where variation was >10% were discarded and the measurement was 
repeated. (B) Particle size distributions at the two scales post low shear application (0.019 × 106 W/kg). (C) Particle 
size distributions post high shear application (0.37 × 106 W/kg). 
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A decrease in live cell population was observed when high levels of shear were applied 
(0.37x106 W/kg), along with a concomitant increase in apoptotic and cell debris populations. 
For the high shear condition, the decrease in the live cell population observed at the 70 L 
scale was found to be significantly different to that at the 5 L scale (p value = 0.002). The 
apoptotic and the debris populations between the scales were found also to be significantly 
different (p value < 0.0001). However, these differences in live, apoptotic and cell debris 
populations between the scales likely indicates a higher level of susceptibility to shear for the 
material generated at the 70 L scale.  The impact or the validity of this difference is not clear 
as the statistical significance of the data are low, it’s therefore recommended to be explored 
further and to be addressed on a case-by-case basis.  . 
4.3.3 Generation of mimic feed profiles to primary recovery 
In order to create mimic feed profiles with different cell concentrations and viabilities, it was 
necessary to decouple the control of these factors. Different viabilities were achieved 
through spiking in material from an independently generated apoptotic cell stock. This 
section illustrates the capabilities of the proposed method for achieving target conditions. To 
achieve a reduction in the viability of the material generated using the 5 L STRs, apoptosis 
was induced in a portion on the cell culture, creating an apoptotic cell stock. A similar 
method has been shown previously to induce apoptosis early in the culture period (Fransen 
et al., 2011). A sample of the cell culture material was removed from each culture batch prior 
to harvest and apoptosis induced in these fractions using cold shock. Apoptosis staining 
showed a rapid increase in the dead cell population and a decrease in the live cell 
populations over the course of the following 6 hours (Figure 4.5A).  
 Overall, a decrease to <20% cell viability was achieved within 7 hours of apoptotic 
induction. Independent control of cell concentration and viability was demonstrated during 
the production of the cell culture test material (Figure 4.5B and C). Batches designated “X” 
and “Y” cell culture material produced in 5 L STRs were harvested on day 14, at viabilities of 
65% and 71% and cell concentrations of 8x106, 8.5x106 cells/mL respectively. Post 
processing, cell concentrations of 100x106 cells/mL were achieved for both batches, while 
simultaneously achieving different target viabilities of 40% for X and 60% for Y, as shown in 
Figure 4.5A and B. No significant differences in cell viability beyond that attributable to 
measurement variability were observed during these cell concentration stages. 
The generated apoptotic cell stock was spiked into the concentrated material to achieve the 
target culture viability levels. Due to the difference in volumetric addition of the apoptotic cell 
stock derived solution a calculated degree of over-concentration was necessary to achieve 
the final target cell concentrations for cultures X and Y of 220x106 and 130x106 cells/mL 
respectively. The degree of over-concentration included the volume compensation for the 
IgG1 and the HCP spike volumes.  Sample-to-sample variation in both cell concentration and 
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viability measurements of up to 10% were observed. This was considered to be within the 
expected measurement variation as dilutions of 50 to 80 times were required to obtain 
readings within the detection range of the ViCellTM. 
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Figure 4.5: (A) Apoptosis induction during the production of a dead cell stock using cold shock is shown. % live 
( ) and dead ( ) cell populations were measured using FACS staining using the Annexin V-FITC/7ADD kit. 
Comparison of total cell concentration (B) and cell viability (C) achieved in two batches of CCTM generated at the 
5-L scale at three key stages of the CCTM methodology. Light grey bars represent Batch X with targeted low 
viability (40%), and a high cell concentration of 100 × 106 cells/mL and a concentration factor of ∼28. Dark grey 
bars represent Batch Y with targeted medium viability (60%),  a high cell concentration of 100 × 106 cells/mL and a 
concentration factor of ∼15. 
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4.3.4 Consistency of mimic feed profiles to primary recovery 
The consistency of the CCTM manufacturing methodology was found to vary for each of the 
target variables. Achieving the target total cell concentration was found to be, within 10% of 
the target cell concentration. Outliers observed at the higher target cell concentrations of 
100x106 cells/mL (Figure 4.6A) were most likely due to the increase in measurement error 
when using the ViCellTM for high cell concentrations. Viability showed greater variability at 
low levels of target cell viability. As cells began to break down, the accuracy of the trypan 
blue method decreased, and the apparent total cell count fell. The percentage viability figure 
consequently became less consistent and representative (Figure 4.6B). No dead cell stock 
addition was required for the 70 L SUB material, as the cell viability reduced during the cell 
concentration stage of the CCTM production. This reduction in viability during the 
concentration step is consistent with the particle size distribution data (Figure 4.4A, B and C) 
suggesting that the material produced at the 5 L scale may be less shear sensitive than that 
produced at the 70 L scale. In addition, the 70 L scale material was produced during the 
course of a cell culture starting from day 7 to day 14. It has previously shown that day 5-7 
cell culture is more susceptible to shear damage and that the susceptibility decreases in the 
following days (Tait et al., 2009). Apoptotic and non-viable cells have been theorised to be 
more robust due to the increased porosity of the cell membrane. As a result of this reduction 
there is a limit to the viability it was possible to achieve post concentration, as the final 
viabilities were below the target by 15-20%. HCP and titre concentrations were increasingly 
variable as the target concentrations increased (Figure 4.6C and D). This is also likely to be 
due to the increase in dilution factors required to quantify effectively the HCP and the IgG1 
concentrations once titre exceeds 10g/ L.  The HCP spike consistency was observed to be 
consistent. The total HCP concentration was kept within 10% batch-to-batch variation.  
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Figure 4.6: Box plots showing the range in achieved conditions versus the target value for the CCTM. Three target 
combinations of (A) cell concentration, (n = 8–10), (B) viability, (n = 8–10), (C) HCP concentration (n = 5–8), and 
(D) titre (n = 5) were tested. These were manufactured using cell culture material generated at 70L scale. The box 
represents the 25th hand the 75th percentiles, the median is indicated with a black line, the mean with the star. The 
whiskers represent data within 1.5 of the interquartile range. 
 
IgG1 and HCP profiles were also compared in these three CCTM material batches (Figure 
4.7Ai-Ci). IgG1 and HCPs across the molecular weight and pI spectrum were shown to be 
present in the HCP stock.  Some level of inconsistency in the individual isoform volumes 
were observed, but the overall diversity in the HCP population between the three batches 
was consistent. By adoption of these methods it was possible to expose the subsequent 
processing technologies to a consistent IgG1 and HCP population within the feed material. 
It has been shown previously that towards the end of the culture period mammalian cell 
culture material typically contains three distinct populations within the particle size 
distribution: live cell, apoptotic cell and debris populations (Tait et al., 2009). Consistency in 
particle size distributions of the final CCTM material as well as the HCP population was 
compared to ensure that the material was as far as possible representative of true cell 
culture material (Figure 4.7Aii-Cii). In terms of particle size distribution, three populations 
were observed across the three CCTM batches tested. The large peak at >10µm includes 
the majority of live cells, the smaller population between 5-10µm in particle size represents 
the apoptotic cell population and the low volume fraction population with a particle size of 
<5µm represents cell debris. Particles <3µm were below the detection limit of the instrument 
and therefore have not been quantified. All three populations were present in the particle 
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size distributions, and also present in a typical cell culture material originating in an STR. On 
the basis of this finding it may be calculated that the CCTM methodology provided a 
consistent and representative feed material input to primary recovery operations in terms of 
particle size distribution.  
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Figure 4.7: Comparison of CCTM profiles generated using culture material from three 5-L STR cultures in terms of (Ai-Ci): HCP profiles, including the IgG1 product and (Aii-Cii): 
equivalent particle size distributions, where % volume fraction of the solids was calculated based on an average measurement of five repeat samples. 
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4.4 Conclusions 
This chapter set out to develop and demonstrate an experimental methodology for the 
creation of a mammalian cell culture test material (CCTM). Cell concentration, cell viability, 
product and impurity concentrations were each manipulated to achieve a range of cell 
culture test conditions to provide a controlled set of key variables in the cell culture feed to 
primary recovery. Generation of CCTM material at selected worst case as well as a range of 
other conditions was shown successfully. Key cell culture parameters effecting primary 
recovery operation performance including cell concentration, cell viability, product and HCP 
concentrations were successfully decoupled.  An apoptosis induction by cold shock method 
was applied to create an apoptotic cell population which was used to reduce the viability to 
selected target conditions. The method was applied to cell culture material originating from 
bench and pilot scales. Data showed that the ability to target conditions accurately using this 
method decreased as higher target concentrations were set. It is likely that this feature is, to 
an extent, an artefact of some of the analytical techniques applied when assaying very high 
concentrations. The CCTM methodology, created in this work, was able to preserve the 
expected three distinct particle size populations for live, apoptotic and debris cells with a low 
batch-to-batch variation. In addition, the selected HCP stock was found to provide a wide 
variety of HCPs varying in molecular weight and pI, thus providing a basis for determining 
specific HCP removal capability of a particular unit operation during CCTM application.  
Overall, the CCTM method was found to decouple the selected variables in the cell culture 
feed to downstream operations, while providing consistent material which is representative 
of typical cell culture material in terms of key features such as particle size distribution and 
HCP population. The accurate replication of these features make this methodology suitable 
for application in primary recovery and purification unit operation studies to which they will 
be applied in the next chapter. Having developed a suitable method to produce test material 
which matches the criteria identified in Chapter 3, it is now possible to begin to test primary 
recovery technologies for their potential to cope with high cell concentration, high titre 
conditions expected in the future. 
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5. Chapter 5: Technology Screening for Robust Development of Primary Recovery 
Strategies for High Cell Density Cultures Using Ultra Scale-Down Models 
5.1 Introduction 
The two previous chapters focused on defining the likely future demands on primary 
recovery operations. This was achieved by identifying the current targets for cell culture 
operations and developing a suitable method to produce test material representative of 
future cell culture material in terms of high cell concentration, high titre conditions as well as 
varying impurity loads and viability. These provided the key tools required to begin the 
development of an experimental framework which would allow the screening of primary 
recovery technologies in a systematic manner, providing a reliable measure of their practical 
and economic performance. This chapter describes the screening framework and its 
application to assess primary recovery technologies for their ability to cope with future cell 
culture feed profiles. 
Primary recovery operations in mammalian cell culture processes have typically been 
designed to provide high levels of solids removal collectively aiming to remove solids >0.1-
0.2 µm in diameter. Centrifugation combined with depth filtration stages have been 
described as the current workhorses of primary recovery (Liu et al., 2010; Shukla et al., 
2007; Yavorsky et al., 2003) in large-scale manufacturing, typically achieving 98-99% solids 
removal prior to sterile filtration stages. However as cell culture performance has improved 
dramatically, primary recovery and purification operations have been facing increasingly 
challenging feed streams, and it is unclear whether current unit operations can continue to 
provide adequately robust processing options in the future.  
Most mammalian cell culture processes used today employ centrifuges fitted with 
hermetically-sealed feed zones, which reduces the levels of shear exposure. However, 
energy dissipation levels still reach 0.019 x106 Wkg-1, which in some cases results in 
significant cell breakage, and subsequently impacts depth filter area requirements (Boychyn 
et al., 2004). The key parameter causing variation in solids removal performance at a fixed 
cell concentration is the cell culture viability at harvest.  Generally, efficient solids removal 
can be achieved at viabilities >50% (Iammarino et al., 2007).  For cell culture material with 
lower viabilities centrifugation is often considered to be more challenging, due to the 
increased number of cell debris in the processing stream. 
 
At the turn of the century, cell concentrations by mammalian cell culture required relatively 
low centrifugal discharge frequencies and the contribution to product loss was considered 
minimal, especially when compared to those experienced in microbial processes (Maybury 
et al., 2000). Since then, maximum cell concentrations have increased by over 100 fold 
(1x106 cells/mL to >100x106 cells/mL) and average processes now reach 10-20 fold higher 
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titres (>10 g/L) (Clincke et al., 2011). Subsequently the solids content of the high cell 
concentration harvest streams is approaching  >10% v/v. Centrifuge efficiency at such high 
solids contents is generally lower and there is a need to desludge the centrifuge more 
frequently, potentially leading to a greater degree of product loss than previously witnessed 
(centrifugation unit operation is discussed in more detail in section 1.3.1). 
 
Depth filtration has primarily been used for solids removal of supernatant post centrifugation, 
and in some cases (generally at scales <2,000 L) to process material directly from cell 
culture. Most available depth filters use charged filtration media and have been 
demonstrated to achieve a level of DNA and host cell protein (HCP) removal (Charlton et al., 
1999; Yigzaw et al., 2006). Depth filters tend to be followed by absolute pore size rated 
filters (typically 0.45 µm, 0.2 µm or 0.1 µm) which ensure the removal of solid particulates as 
well as some endotoxins and a degree of viral removal from the cell culture harvest material 
(Gerba and Hou, 1985). Together these steps ensure a particle-free product solution, which 
can then proceed successfully to packed bed chromatography steps.  
 
A wide range of alternative technology options for primary recovery have been previously 
identified including flocculation (Salt 1995; Barany and Szepesszentgorgyi 2004; Milburn et 
al., 1990; Habib et al., 2000; Riske et al., 2007), acid precipitation (Lydersen et al., 1994; 
Westoby et al., 2011), expanded bed absorption (Draeger and Chase 1991; Lutkemeyer et 
al 2001; Poulin et al., 2008), counter current tangential chromatography (Shinkazh et al., 
2011) and alternating tangential flow filtration (Schirmer et al., 2010). Although these 
operations are expected to bring benefits in the future, current limitations in terms of 
practical application were reported for example potential issues with flocculent presence in 
the bulk drug substance, low product yields and highly sensitive operational performance 
(Shukla et al., 2007; Habib et al., 2000). Tangential flow microfiltration (TFF) options, on the 
other hand, have been suggested in the past to deliver high processing rates without 
adverse effects on cell viability (van Reis et al., 1982). This advantage can potentially play a 
key role in reducing cell damage during primary recovery of high cell concentration cell 
culture feeds, subsequently reducing potential impurity releases. Hollowfibre membranes 
have primarily been used in mammalian cell perfusion cultures, but are typically not 
considered for batch type harvest operations. The membrane costs of TFF can be lower 
than the cost of typical depth filtration media, especially where single use modules are 
required, as the TFF membrane media tends to be reusable (van Reis 2001). 
 
This chapter focuses on evaluating both current and alternative primary recovery 
technologies in terms of their robustness and ability to cope with predicted future feed 
profiles. Cell culture test materials (CCTM) described in the previous chapter (chapter 4), 
were used for this purpose. The technologies were evaluated based on the following 
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performance criteria: solids removal, yield and impurity removal. Selected current and 
alternative technologies were then ranked using a multi-attribute decision-making (MADM) 
technique and the successful candidates were assessed further using an economic 
evaluation and facility fit criteria.  
 
The results discussed in Chapter 3 highlighted the increase in demand on solids removal as 
well as a demand for achieving host cell protein (HCP) and DNA removal prior to purification 
operations.  The results also confirmed a high probability of a change in the feed to primary 
recovery, where an increase in titre and cell concentration of up to 20 g/L and 100x106 
cells/mL respectively were considered likely in the next 12 years. This chapter will focus on 
firstly identifying some current and alternative technologies with the potential to cope with 
the future feed to primary recovery, then discuss the results obtained from screening these 
technologies at the identified worst case conditions, identified by quantifying expert opinion 
as described in Chapter 3. 
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5.2 Materials and Methods 
A list of technologies which are currently used as well as those which carry probable 
potential to improve primary recovery operations in the future were identified (see Table 5.1). 
When choosing the technologies, their potential to achieve impurity reduction was 
considered as well as their availability for implementation.  
Table 5.1: Current and alternative primary recovery technology systems used in the screening study with 
corresponding specification description and experimental conditions. 
  
System Specification Description Conditions 
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Centrifugation 
 
Disc-Stack 
CSA-1 mimic 
(Westfalia) 
USD set up, 
mimicking a 
hermetically 
sealed feed 
zone, at  a 100 
L/h feed flowrate 
Depth filtration 
Pre-filter Media 
(3M) 
05 SP: 2-10µm 
typical particle 
removal, charged 
 
USD set up 
Constant 
pressure, 
100 mbar 
10 SP: 1-5µm 
typical particle 
removal, charged 
30 ZA: 1-2µm 
typical particle 
removal 
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 Tangential Flow 
Microfiltration 
Bio-Optimal  
MF-SLTM 
(Asahi Kasei) 
0.4 µm pore size, 
polysulphone 
hollowfibre, 
graduated pore 
structure 
Constant flux, 
30LMH 
Tangential Flow Anion 
Exchange membrane 
QyuSpeed DTM 
(Asahi Kasei) 
0.2 µm nominal 
pore size, anion 
exchange 
membrane 
Constant flux 
filtration mode at 
30LMH 
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Table 5.2: Primary recovery screening study conditions consisting of worst case values for key cell culture variables 
 
 
 
 
 
 
Note: The values were determined using results of a survey compiling expert opinion on the likely future cell culture 
feed profiles to primary recovery. Additionally, a low viability was selected to provide a challenging case for the 
selected technologies. 
 
The identified technologies were then used for primary recovery of the worst case scenario 
for potential future cell culture material, i.e. high cell concentration, high titre and high 
impurity load as well as low viability material (see Table 5.2). Technology performance 
results were collected and used to carry out an initial technology performance assessment 
followed by an economic assessment of the technologies. At this stage technologies which 
met the assessment criteria were carried forward into a design of experiments study to 
further assess the remaining technologies (see Figure 5.1). This chapter will focus on part 1 
of the framework, and part 2 will be discussed in the following chapter. 
Potential Technologies 
for Future 
Implementation
Screening Study
(Single Worst Case 
Condition)
Technology 
Performance 
Assessment
Economic Assessment Selected Candidates
DoE
(Centre Composite 
Design)
Economic Assessment
Primary Recovery 
Technology Strategy
PART 1
PART 2
 
Figure 5.1: Overview of the integrated experimental and economic framework for primary recovery technology 
screening.  
 
5.2.1 Cell Culture and Cell Harvest 
Cell culture was carried out in 5L STRs (B. Braun BIOSTAT B-DCU control unit, Sartorius, 
Epsom, UK) and harvested on day 13. Total cell concentrations at harvest were ~9x106 
Cell Concentration 
(x106cells/mL) 
Titre (g/L) 
HCP Concentration 
(µg/mL) 
Viability (%) 
100 20 20,000 40 
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cells/mL with an average viability of 77%. The harvested material was used to generate cell 
culture test materials with the representative most challenging set of target conditions (Table 
5.2). The CCTM generation is discussed in detail in the previous chapter. The cell culture 
harvest was concentrated and spiked with the volumes of IgG1 and a HCP stock to create 
the required conditions. Apoptosis induced cell stock was added to the CCTM in order to 
achieve the target viability of 40%. 
 
5.2.2 Primary Recovery Methods 
Technologies were selected to represent current and alternative primary recovery options 
(Table 5.1). Three centrifugation (hemetically-sealed disc-stack centrifuge) and primary 
depth filtration options (05SP, 10SP and 30ZA media options) were selected to represent 
the current options, and two tangential flow filtration options (Bio-Optimal MF-SLTM and 
QyuSpeedDTM) to represent the alternative options. The CCTM were then used as feed to 
these unit operations. The methodology and the running conditions applied in each case are 
described in section 2.3. 
 
5.2.3 Technology Assessment 
A weighted sum multi-attribute decision making (MADM) technique (DeGarmo et al., 1988; 
Farid et al., 2005; George et al., 2007; Pollock et al., 2013) was used to combine the 
performance data into a single metric. Initially, the calculated technology performance values 
for each attribute were normalised to a 0-1 scale, where the zero value represented the 
worst case performance result and value of one represented the best case performance 
result.  
 
(5.1) 
 
where PA is the actual figure for a performance attribute (e.g., solids removal), Pmin is the 
minimum value achieved by the technologies and Pmax is the maximum value achieved by 
the technologies for the same performance attribute. The normalised values were then 
weighted using a ratio of 3:2:1 for the performance attributes of solids removal to DNA 
removal to HCP removal. This ratio was selected based on a survey carried out to quantify 
industry opinion on demands facing primary recovery operations in the future (see section 
3.3).  The subsequent sum of the weighted values for each technology leads to an overall 
rank figure (OR) from which technology performances can be compared. 
 
(5.2) 
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where ωi is the weighted value and the Ni is the normalised value each corresponding to the 
performance of metric i. The resultant OR also has a value between zero and one, therefore 
representing the least and the most efficient option for a given scenario respectively. 
Selection criteria of the current typical minimum performance in terms of solids removal, 
yield and impurity removal were used as cut off criteria for technology performance. 
 
5.2.4 Economic Evaluation 
The economic evaluation was focused on the primary recovery stages only using the same 
worst case input conditions as were generated in the practical experiments (Table 5.1, Table 
5.2). These were combined with the sizing data collected during the experimentation and 
further assumptions (Table 3 and 4) to calculate equipment duties required, kg product 
outputs per batch, capital investment and cost of goods (COGPR) outputs for the primary 
recovery operations for three scale scenarios: 2,000 L, 10,000 L and 20,000 L production 
scales. A detailed process economics model was built in Excel (version 2010) that integrated 
mass balance, design and cost equations so as to generate the key performance metrics for 
the different primary recovery strategies. The mass balance and design equations 
accounted for features such as the impact of the cell concentration on the number of 
centrifugation discharges required (calculated based on the centrifuge model used to obtain 
experimental data) and the resulting yield loss. Experimental results were used as inputs for 
worst case filter throughputs and flux likely to be achieved. The cost equations were similar 
to those detailed in Farid et al., 2007. 
 
5.2.5 Economic Evaluation Assumptions 
Primary recovery operations were defined as those activities involved in the processing of 
cell culture material during cell culture harvest until the completion of the sterile filtration 
stage prior to chromatographic purification. Sizing data including throughput, yield and solids 
removal were collected using the experimental set up described in Table 5.2. This was 
combined with additional scenario constraints to provide the final sizing outputs. The 
scenario constraints included a target processing time of 6 hours. In addition, details on 
equipment performance at the selected scale were constricted to specific equipment 
choices. This included a choice of Alpha Laval BTAX215H and Alpha Laval BTAX205 
centrifuges, lenticular mobile skids for depth filtration, 8 m2 and 5 m2 modules for the Bio-
Optimal MF SLTM and the QSDTM options respectively. 
 
Production was assumed to consist of 17 batches per year, with a process length assumed 
to be 20 days. The COGPR comprised of both the direct and indirect costs for primary 
recovery operations only, assuming use of an existing facility. The direct costs included 
materials (e.g. filters, single use materials etc.), labour costs (including operational labour) 
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and WFI costs. The indirect costs included depreciation of 10% per annum over 10 years 
based on the capital investment. Capital investment was calculated on reusable equipment 
(e.g., filtration skids, centrifuge units etc.) and auxiliary equipment (e.g., pumps) using Lang 
factors shown in Table 5.3, Table 5.4 and Table 5.5.  
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Table 5.3: Key assumptions and calculations used to construct the process economics model. 
Unit Operation Inputs Source Outputs Calculations 
Centrifugation    
Cell culture volume, VT Scenario input   
Wet mass per cell, MWC Experimentally determined Cell mass in the feed TCD x VT x MWC 
% of solids fraction remaining, SR Experimentally determined using particle 
size distribution 
Solids mass in the sediment ST (100-SR)/100 
Centrifuge models available: 
- Alpha Laval BTPX-205 
- Alpha Laval BTAX215H 
 
Scenario input 
 
  
Solids holding capacity, SH    
Dewatering level – 50% Manufacturer’s specification Mass of liquor in the sediment, 
MLW 
0.5(SH) 
Number of centrifuge units, U Facility specification, = 1 specified unit Number of discharge operations,  
NP 
(ST/SH)/NU 
Maximum feed flowrate, QCin Manufacturer’s specification Total liquor loss in the sediment 
VW 
((N= x VW)-(ST/ρS)) x U 
Product is only lost in the liquor fraction of the 
sediment 
Assumption Processing time, tPCent VT/(UxQCin) 
Depth Filtration    
Product mass in, mPin Input from centrifugation calculations Volume in, VDFin 
 
VT  - VW 
 
Throughput Vmax Experimentally determined   
Safety factor SF Assumption = 1.5 Total membrane area required, 
ADF 
(VDFin/Vmax) x SF 
 
Membrane area per module, AM Manufacturer’s specification 
 
Number of modules required, Nm ADF/AM 
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Number of modules per skid, NMSK Manufacturer’s specification Number of skids required, NSK Nm/NMSK 
Hold up volume per module VDFhup Manufacturer’s specification 
 
Permeate volume, VDFp VDFin-( VDFhup x Nm) 
Unit specific product concentration yield, YCP Experimentally determined Product Yield, YDF mPin /(mPin/ VDFin x 
(YCP/100) x VDFp) 
Skid size: length and width, l,w Manufacturer’s specification   
Minimum space required for operation, OPA Assumption = 1m Floor space required, AFSP ((l+ OPA)x(w+ OPA)) x NSK 
 
 
 
 
 
 
TFF 
   
Cell culture volume, VT Scenario input   
Throughput, T Experimentally determined   
Safety Factor, SF Assumption = 1.5 Total membrane area required, 
ATFF 
(VT/T) x SF 
Membrane area per module, AM Manufacturer’s specification Number of modules required, Nm ATFF/AM 
Number of modules per skid, NMSK Manufacturer’s specification Number of skids required, NSK Nm/NMSK 
Hold up volume per module VTFFhup Manufacturer’s specification Permeate volume, VTFFp (ATFF/AM) x VTFFhup 
Unit specific product concentration yield, YCP Experimentally determined Product Yield, YTFF mPin /(mPin/ VDFin x 
(YCP/100) x VTFF) 
Skid size: length and width, l,w Manufacturer’s specification   
Minimum space required for operation, OPA 
 
Assumption = 1m Floor space required AFSP ((l+ OPA)x(w+ OPA)) x NSK 
Cost of Goods Model Breakdown 
Cost Category Value 
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Direct Cost Materials:  
Filter Modules 
Sterile Filters 
Tubing 
Miscellaneous Materials 
Labour 
Operating Labour 
WFI 
f(utilisation) 
Indirect Cost Maintenance 
Depreciation 
General Utilities (HVAC) 
0.1xCapital investment x Project duration 
Capital investment/Depreciation period x Project duration 
Cost per unit area x Facility size x Project duration 
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Table 5.4: Key cost assumptions used in the construction of the process economic model. 
 
 
 
Resource Specification £/Unit Unit 
Equipment 
Stainless steel vessel 
2,000 L 65,700 
£/unit 10,000 L 71,500 
20,000 L 174,200 
Peristaltic pump 2,000 L/h 2,750 £/unit 
Alpha Laval BTX-205 
centrifuge 
2,500L/h 150,000 £/unit 
Alpha Laval BTAX 
215H centrifuge 
12,000L/h 577,420 £/unit 
Depth Filtration Rig 
Standalone Rig 
System 
20,000 £/unit 
TFF Rig Mobile skid 30,000 £/unit 
Labour  
Operating labour 
Single operator with 
maximum shift length 
of 8h 
300 £/h 
Materials 
Depth Filtration 30ZA 
modules 
3.2m2 per module 400 £/module 
TFF: Bio-Optimal MF-
SL modules 
8m2 per module 9,847 
£/module 
TFF: QSD modules 5m2 per module 20,520 
WFI 
Generated in-house 
assumed 
100 £/L 
Tubing  10 £/m 
Sterile filter 0.22 µm 200 £/m2 
Chapter 5 
99 
 
 
Table 5.5: Bioprocess facility capital investment factors and corresponding Lang factor included in the indirect cost 
calculations. 
Lang Factor Description 
Cent&30ZA TFF 
Base Case 
Reusable 
Technology 
Total Equipment Purchase Cost (inc. utilities) - 1 
Pipework & installation - 0.9 
Process control - 0.37 
Instrumentation - 0.6 
Commissioning - 0.07 
Equipment Validation - 0.06 
Contingency factor - 1.15 
Lang factor 1.00 3.45 
 
5.3 Results and Discussion 
5.3.1 Primary Recovery Technology Performance 
The performance of three centrifugation and depth filtration options (05SP, 10SP and 30ZA 
media) as well as two tangential flow filtration unit options (Bio-Optimal MF-SLTM and 
QSDTM) were investigated when challenged with the most demanding cell culture material 
conditions (see Figure 5.2). A USD set up was used to mimic the characteristics of a disk-
stack centrifuge operating with a hermetically-sealed feed zone and a feed flowrate of 100 
L/h. The centrifuged material was then passed onto the USD depth filtration set up using a 
0.28 cm2 depth filter disc of each of the three media types at a constant pressure of 100 
mbar. The resultant filtrate was compared to the material which passed through the single 
fibre set up of the Bio-Optimal MF-SLTM module (4 cm2) and the QSDTM (6 cm2) at 30 LMH 
constant flux. Comparisons were made in terms of solids removal, yield and levels of 
impurity removal achieved. 
 
Initially solids removal was measured using OD measurements and subsequent calculation 
of the % solids removal, but this proved unreliable due to the high levels of fine particles 
generated during the USD centrifugation step. Therefore solids removal for the USD 
centrifugation step was further analysed by dry cell weight measurement of the supernatant 
compared to the feed and was also normalised using the supernatant passed through a 0.22 
µm filter. This presented a more reliable measure of the centrifugation performance. Solids 
removal was measured for the depth filtration options using the OD measurement 
methodology and was used as a rough filter performance indicator. Direct comparison 
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between centrifugation and depth filtration solids removal capacities was not made due to 
the differences in the quantification techniques applied. 
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Figure 5.2: Primary recovery technology performance under the worst case screening study conditions generated 
using the CCTM in terms of % yield performance ( ), %DNA removal performance ( ), %solids removal ( ) and 
% HCP removal ( ). The worst case screening study conditions are summarised in Table 5.1. 
 HCP release into the supernatant stream was also observed, indicating high levels of cell 
damage due to shear. The particle size distribution data (see Figure 4.4Error! Reference 
source not found.) of the feed material and the supernatant also showed an increase in 
particles between 2-5 µm in diameter, and the presence of some particles between 5-10 µm 
in diameter. An absence of particles with diameters above 10 µm in the supernatant stream, 
was observed. The 30ZA option however provided the highest degree of solids removal 
compared to the 5SP and 10SP options, as it has the smallest nominal pore size. However, 
breakthrough occurred during filtration and this increased the sample pool OD.  A ~10% total 
HCP removal was observed when using all three media types, as well as substantial DNA 
removal of 15-20% and 63% DNA removal using the SP and the ZA media respectively. The 
observed difference in removal was expected and can be explained by the positive charge 
provided by the ZA media compared to the SP. The low HCP removal observed using the 
depth filtration medium is within the current reported literature range for a single medium 
containing filtration device (Yigzaw et al., 2006). The DNA removal using the ZA medium 
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also falls within the expected range reported in literature (Dorsey et al., 1997, Charlton et al., 
1999). 
 
The Bio-Optimal MF-SLTM and the QSDTM options achieved >99% solids removal, however 
their performance differed in terms of impurity removal levels. Operating with the Bio-
Optimal MF-SLTM provided a ~50% DNA removal compared to >99% DNA removal using the 
QSDTM and HCP removal of 15 and 20% respectively. The Bio-Optimal MF-SLTM media is 
however uncharged and therefore was not expected to result in a high level of DNA removal. 
However high cell mass within the hollowfibre may have resulted in entrapment of DNA due 
to a combination of physical particle retention and non-specific binding to the cellular matter. 
The QSDTM was expected to achieve a high level of DNA removal due to the high charge 
capacity provided by the diethylamine (DEA, NH((CH2CH3)2) ligands grafted to the 
polyethylene (PE) membrane material (Shirataki et al., 2011). A 99% removal of DNA has 
not been previously reported using centrifugation and depth filtration combinations. 
However, specific benefits of DNA removal at the earlier stages of the process are not 
clearly communicated and would benefit from quantification as part of future work. 
 
In terms of particle size distribution, the Bio-Optimal MF-SLTM showed the lowest presence 
of solids across the particle size range. The QSD, BioOptimal as well as the centrifugation 
and 30ZA options showed an overall low solids content, with the solids fraction remaining 
below 3%.  
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Figure 5.3: Particle size distributions of samples post solids removal using the different primary recovery 
technology options. (A) supernatant fraction post USD centrifugation, (B) permeate fraction post centrifugation 
followed by depth filtration using 05SP media, (C) permeate fraction post centrifugation followed by depth filtration 
using 10SP media, (D) permeate fraction post centrifugation followed by depth filtration using 30ZA media, (E) 
permeate fraction post tangential flow filtration using Bio-Optimal MF-SLTM, (F) permeate fraction using QSDTM in 
tangential flow filtration mode. 
5.3.2 HCP Removal Profile 
One of the key functions of the unit operations following the solids removal/clarification 
stages is HCP removal. Protein A typically removes ~95-99% of HCPs (Ghose et al., 2005). 
However, HCP reduction prior to Protein A may have benefits in terms of Protein A resin 
lifetime. In addition, specific HCP removal may still be a concern for some processes or 
cases where upstream batch-to-batch variability may cause expression of HCPs which are 
particularly difficult to remove.  Therefore, the HCP removal potential of each technology 
option was investigated further in order to gain an understanding of the types of HCPs these 
technologies tend to remove. 2D PAGE gels of the starting material and post primary 
recovery operations were run in triplicate. HCP normalised spot volumes were compared to 
the CCTM gels in four gel areas numbered Q1-Q4 (Figure 5.4A), representing different pI 
and molecular weight combinations (low pI and low molecular weight; high pI and low 
molecular weight; low pI and high molecular weight; high pI high molecular weight). Spot 
increases and decreases were calculated relative to the CCTM gels and included any new 
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spots which were not originally found on the CCTM gel images (Figure 5.4B). This method 
was used to indicate any specific areas of HCP removal which a particular technology can 
provide. Highest spot number decreases were seen in the low molecular weight and high pI 
region across all the technologies (Q4). Centrifugation & 30ZA, Bio-Optimal MF SLTM and 
QSDTM options also showed higher HCP removal in the Q3 region. Highest spot increases 
were observed in the Q1 region for all the technologies except the centrifugation & 30ZA 
option. The centrifugation and 30ZA option showed higher net spot decreases than 
increases across all the quadrants. 
A dark line of unresolved lower pI HCPs can be seen on the feed material gel (Figure 5.4A). 
Due to the poor resolution these were not quantified, but a significant reduction of this region 
was observed post QSDTM application and some reduction was observed post Bio-Optimal 
MF-SLTM application (see images in Appendix C).  
 
Changes in HCP spot volumes during primary recovery operations have been documented 
previously (Tarrant et al., 2012; Tarrant et al., 2014). Work was also carried out to identify 
the HCPs which showed a significant change in volume between the operations (Hogwood 
et al., 2015). Although such identification shows the relevance of the findings reported in this 
thesis, it also highlights that the presence of specific HCPs is highly cell line dependent. 
Therefore, this type of comparison is suitable as part of a method applied for technology 
selection and is recommended to be carried out with the cell line of interest. 
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Figure 5.4: 2D PAGE gel analysis of CCTM feed and samples post primary recovery using each of the selected technologies. The gels were divided into 4 quadrants based on gel coordinates. A: 
2DPAGE gel of the CCTM feed divided into four quadrants - (Q1) low pI and low molecular weight region, (Q2) high pI and low molecular weight region, (Q3) low pI and high molecular weight 
region, (Q4) high pI and high molecular weight region. B: Increases ( ) and decreases ( ) in the normalised spot volumes compared to the CCTM feed in each quadrant using SameSpots 
software. 
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5.3.3 Technology Assessment 
An MADM additive weighting technique was used to assess the practical findings and quantify the 
overall performance by considering the performance attributes taken together. A potential scenario for 
the selection criteria was then explored, where yield and purity targets were selected based on the 
current platform processes as well as literature data.  
Solids removal, DNA reduction and HCP reduction results were normalised based on the minimum 
and maximum values for each attribute to obtain a rating value between zero and one (Table 5.6). 
The example values for a current platform are also shown. The ratings were then obtained for each 
technology and each of the selected performance attributes. An overall purity weighted score was 
then obtained and compared across the technologies ( 
Table 5.7). These results reflected the practical data, where the QSDTM displayed the highest score, 
followed by Bio-Optimal MF-SLTM, the centrifugation plus 30ZA, centrifugation plus 10SP and finally 
centrifugation & 05SP option. Based on the normalised weighted score of the “current operational 
level” selected, centrifugation & 05SP as well as centrifugation & 10SP options were seen to fall 
below the desired level, while centrifugation & 30ZA, Bio-Optimal MF-SLTM and the QSDTM options 
performed above the set base line. Additional minimum yield criteria was then also implemented and 
set to be 90% (Figure 5.5). As a result the Bio-Optimal and the QSDTM technologies met both of the 
set criteria while the centrifugation and 30ZA option met the target purity criteria but not the yield 
criteria. Centrifugation and the 10SP option met the yield criteria but not the purity criteria and the 
centrifugation and the 05SP option met neither of the criteria. If reducing the acceptable yield criteria 
to 80% is possible centrifugation and 30ZA option would not be ruled out. Accounting for this 
possibility we did not rule out the centrifugation plus 30ZA option at this stage.  
 
Table 5.6: Values representing typical existing operational performance for primary recovery technologies. These were 
combined with the projected technology performance results to obtain normalised technology performance ratings using 
minimum and maximum values in respective performance categories. 
 
Performance attribute 
Current 
operational 
performance 
 
Min value (%) 
 
Max value (%) 
Solids removal (%) 98 43 100 
DNA Removal (%) 30 15 62 
HCP Removal (%) 10 9 17 
 
A sensitivity analysis was performed on the weighting ratio of DNA:HCP removal to determine the 
impact on the ranking of the technologies. Figure 5.5 illustrates that if the HCP removal score is 
considered more important than DNA removal (DNA:HCP removal weighting ratio ˂ 0.75), the 
normalised weighted score of the centrifugation plus 30ZA option falls below the acceptable threshold 
values. The ranking of centrifugation plus 05SP and centrifugation plus 10SP options also switches at 
a DNA:HCP removal ratio below 0.25 where centrifugation plus 10SP option scores fall below the 
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05SP alternative. These trends are driven by the very small differences in HCP removal performances 
of the technologies and the much greater differences in DNA removal performances. 
 
Table 5.7: Normalised performance ratings (0-1) for each primary recovery technology option. 
Primary 
recovery 
options 
Solids removal 
rating 
DNA removal 
rating 
HCP Removal 
Rating 
Overall 
Weighted Score 
Normalised 
Weighted Score 
Current 
Operation Level 
1.0 0.0 0.1 3.1 0.5 
Centrifugation 
plus 05SP 
0.0 0.2 0.3 0.7 0.1 
Centrifugation 
plus 10SP 
0.0 1.0 0.0 2.0 0.3 
Centrifugation 
plus 30ZA 
0.6 0.8 0.3 3.5 0.6 
Bio- Optimal MF-
SLTM 
0.4 1.0 0.7 4.0 0.7 
QSDTM 1.0 1.0 1.0 6.0 1.0 
Note: The normalised values were calculated, using minimum and maximum performance data obtained experimentally.  
Performance categories were weighted 3:2:1 (solids removal: DNA removal: HCP removal) in order to obtain a normalised 
weighted score for each technology. 
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Figure 5.5: Primary recovery technology performance scores calculated using an MADM additive weighting technique. The normalised weighted score was calculated for purity by assuming a 3:2:1 
weighting ratio of solids removal : DNA removal : HCP removal. These scores are presented for centrifugation and 05SP depth f iltration media option ( ), centrifugation and 10SP depth filtration 
media option ( ), centrifugation and 30ZA depth filtration media option ( ), Bio-Optimal-MF-SLTM option ( ), and the QSDTM option ( ). The scores were plotted against the yield result 
obtained in terms of product concentration. Technology performance targets were applied based on existing processes to obtain a yield target and a purity target for technology selection. B: 
Sensitivity analysis on score weighting was performed by altering the DNA : HCP weighting ratio. Normalised weighted score for the selection criteria rating based on current operational 
performance. 
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5.3.4 Economic Evaluation 
In order to compare the economic impact of the primary recovery technology selection, the cost of 
goods was calculated for the primary recovery operations defined as all activities post cell culture 
harvest, not including Protein A purification operation and beyond. 
 
Throughput data for the three depth filtration options and the Bio-Optimal MF-SLTM and the QSDTM 
was used in the comparison.  The Bio-Optimal MF-SLTM was found to provide the highest capacity of 
> 110 L/m2, followed by the 05SP, 10SP QSDTM and 30ZA media (101, 88, 82, 32 L/m2 respectively). 
This is consistent with a previously reported throughput range seen in the SP filtration media when 
processing high cell concentration material (Pegel et al., 2011).  
 
This data together with the unit operation assumptions and the performance data presented in the 
previous section provided the inputs to the cost of goods model (Table 5.1). Based on the technology 
performance results, economic outcomes are presented for those technology options which fulfilled 
one or more performance target criteria (i.e. centrifugation and 30ZA; Bio-Optimal MF-SLTM; QSDTM). 
The centrifugation and 30ZA media option achieved the lowest kg/batch output of product, when 
compared to both of the TFF options (see Figure 5.6A). Based on model evaluation, this low output 
was found to be due to the yield losses expected during the large scale centrifugation operation. At 
such high solids concentrations, the number of discharge operations required by the selected 
centrifuge models, reduced the overall step yield from ~90% to 30-40% at the three scale scenarios. 
This had a considerable impact on the cost of goods (RMU/g) output (Figure 5.6B), across the scales 
where the centrifugation and 30ZA option is the most costly followed by the QSDTM and the Bio-
Optimal MF-SLTM. The RMU/g figures were benchmarked against a commercially available software, 
which yielded results within the same order of magnitude.  
 
The space required to facilitate the use of the equipment required was also investigated (Figure 
5.6C). The centrifugation & 30ZA media was found to require > 200 m2 of floor space to 
accommodate the skids at the 20,000 L scale, which totalled 23 units. A current 20,000 L facility was 
used as a benchmark to provide facility fit constraints. It can accommodate 10 skids for primary 
clarification filters and 10 skids for secondary clarification filters (as the current worst case scenario). 
The space required to accommodate the 30ZA primary clarification skids at the 20,000 L scale at the 
set scenario conditions was more than double this. Although the number of skids required to 
accommodate the QSDTM option was also high, secondary filtration prior to the sterile filters is not 
required, and would fit into this hypothetical facility. The Bio-Optimal MF-SLTM option required 
approximately a quarter of this floor space. This indicates that in cases where existing facilities are 
used for new processes or alternative unit operations, the TFF options may prove to be more easily 
accommodated. 
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Material costs dominate the COGPR/batch in all technology cases across the scales (Figure 5.7A). 
The QSDTM option had the highest cost per batch, which is approximately double the cost of the 
centrifugation and 30ZA option and over three times the cost of Bio-Optimal MF-SLTM. This is due to 
the high cost per module, as the technology is designed and priced to compete with anion exchange 
resins and membranes (Table 5.4). The QSDTM module cost comprises 80% of the total COGPR/batch 
compared to the 60-70% in the centrifugation and 30ZA and Bio-Optimal MF-SLTM cases (Figure 
5.7B). In addition, WFI costs make up 10-20% of the batch cost in the case of the TFF options 
compared to 2% in the case of centrifugation and 30ZA.  
 
The lowest cost operation across the scale scenarios is the Bio-Optimal MF-SLTM, due to the high 
throughput it achieves and the relatively low cost of the modules compared to the QSDTM. Although 
increasing membrane reusability beyond 50 times significantly reduces the RMU/g output, a 
reusability of 10 times was selected for these scenarios to represent a suitable option for a CMO. 
However, options including centrifugation can benefit from economies of scale once a larger 
centrifuge model is required (scales >5,000L).  
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Figure 5.6: Kilogram per batch output (A), COGPR/g (B) and floor space required (C) for the primary recovery technology 
options at three scale scenarios of 2,000 L, 10,000 L and 20,000 L.  Analysis based on experimental performance at the 
selected worst case feed to primary recovery conditions, assuming 17 batches per year production at each scale. Cost of 
goods (COGPR/g) account for primary recovery costs only. Floor space considerations assumed a minimum of 1m operational 
space around each unit.   Results are presented for the centrifugation & 30ZA option ( ;  ),   Bio-Optimal MF-SLTM  option 
( ; ),;   QSDTM option ( ; ). In C, the numbers above the bars indicate the number of filtration skids required in each 
given scenario. An example of an existing current worst case primary recovery space requirement for a 20,000L process is 
indicated for primary clarification (
 
 ) and primary and secondary clarification collectively (
 
 ). 
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Figure 5.7: A: Comparison of COGPR breakdown at each scale scenario on a category basis for indirect costs ( ), material 
costs ( ) and labour costs ( ), for the primary recovery operations only.  B: Material and WFI costs breakdown at the10,000 L 
scale scenario. 
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5.4 Conclusions 
Using a combination of cell culture test materials (CCTM), ultra scale-down technologies, multi-
attribute decision-making methods, process economics and facility fit considerations,  this chapter has 
demonstrated a methodology and results for achieving a screening of current and alternative primary 
recovery technologies. The example technologies tested using this method included three 
centrifugation and depth filtration options (using 05SP, 10SP and 30ZA media), and two alternative 
tangential flow filtration options (using Bio-Optimal MF-SLTM and QSDTM hollowfibre modules). HCP 
removal levels in the range of 10-20% were reached across all the tested technologies, however 
removal of specific HCP groups varied. Up to 99% DNA removal was achieved using the QSDTM, with 
lower levels of DNA removal using the other options. 
 
MADM analysis as well as selection based on current technology performance criteria showed that 
only two options met the yield and purity criteria: Bio-Optimal MF-SLTM and the QSDTM. The 
centrifugation and the 30ZA option met the purity criteria but not the yield criteria. The options were 
further evaluated based on their economic performance. This showed the centrifugation and 30ZA 
option to be the least cost-effective across the 2,000 L, 10,000 L and 20,000 L scale scenarios and 
not fit the facility constraints set based on a typical existing large-scale facility. The Bio-Optimal MF-
SLTM option was the most cost-effective option across the 2,000-20,000 L scales of operation.  
Economic and MADM analysis of the alternative technologies has been used to predict robust primary 
recovery options for the future. The QSDTM was found to provide greater capability for DNA removal 
prior to purification operations, however remained a costly alternative. The Bio-Optimal MF-SLTM 
offered a similar level of solids removal but was more cost-effective.  
 
These findings provided a single extreme data point, initially defining and assessing the potential of 
the technologies to cope with worst case scenarios. The outcome prioritised the two alternative 
technologies to investigate further in the next study, which focused on further exploring their 
performance over a range of cell culture conditions between the current and the future worst case 
condition. The next chapter outlines part 2 of the framework, which focuses on mapping Bio-Optimal 
MF-SLTM and QSDTM performance as a function of key cell culture variables. 
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6. Chapter 6: Effects of key variables in mammalian cell culture broth on primary 
recovery by tangential flow microfiltration 
6.1 Introduction 
The previous chapter identified two alternative technologies Bio-Optimal MD-SLTM and 
QSDTM (both tangential flow filtration options) with the potential to provide robust primary 
recovery options for the future. Both options fulfilled performance and economic screening 
selection criteria under the worst case scenario. However, current cell culture conditions are 
10-20 fold lower than the worst case conditions tested and therefore may not require a 
switch to the identified technologies for the moment. To understand the point at which a 
technology change to either of the alternatives becomes viable, this chapter focuses on 
mapping the performance of the alternatives as a function of the cell culture variables.  
 
Cell concentration and cell viability have been previously shown to impact tangential flow 
filtration performance in terms of throughput prior to solids breakthrough. The need for 
robust performance at a range of cell concentrations and viabilities has been identified in 
Chapter 3 (see section 3.3.1), where the cell concentration range of interest was concluded 
to be 20x106 - 100x106 cells/mL. Robust performance at low viabilities was also identified to 
be a desirable function for a robust primary recovery step. Low viability has been defined in 
the literature to be <50%, where accurately detecting viabilities below 40% is increasingly 
difficult (Immarino et al., 2007). Low viability conditions in the previous chapters have been 
defined as ≤40%. This will therefore continue to be the definition of low viability, and high 
viability conditions will be defined as ≥90%.  
TFF performance in terms of yield has been a concern especially in cases of high 
concentration of protein, specifically product. The concentration factor which can be 
achieved by a TFF system as well as the yield are largely limited by the system dead 
volume. Microfiltration membranes are designed to allow product transmission through the 
membrane to the permeate, however product loss can still occur by product retention on the 
membrane, or by non-specific binding to the cell matter in the retentate. Product loss can be 
decreased by washing the retentate with additional buffer and recovering unbound product 
remaining in the retentate (Rao et al., 2012). For the purposes of a base level assessment, 
product yield will be calculated without the implementation of any yield improvement 
techniques to provide a baseline for each TFF technology performance. 
The cell culture variables most likely to impact TFF have been identified to include cell 
concentration (solids load), and particle size profile (determined by cell viability). As TFF 
performance can be described by Darcy’s Law (see section 1.3.3), fluid viscosity can 
decrease flux through the membrane, thus negatively impacting on the TFF performance. 
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Any increase in fluid viscosity can be caused by an increase in protein concentration 
(including the product) due to increased protein production or a decrease in cell viability. The 
worst case scenarios discussed in the previous chapters have involved high titre, high 
impurity cases. Therefore titre and host cell protein concentrations will also be included in 
the design of experiments as separate factors.  
This chapter aims to describe the performance and COG achieved by Bio-Optimal MF-SLTM 
and QSDTM as a function of key cell culture variables, where the data can be used to identify 
cell culture conditions which would necessitate a change in technology. Measured 
responses were selected to capture key metrics indicating TFF performance. These involved 
throughput as well as product concentration in the permeate and HCP concentration in the 
permeate. Significant factors were identified and correlations to link these factors to the 
responses were built using Design Expert 8.0 Software. The correlations for each 
technology type were incorporated into the economic model described in Chapter 5 (see 
sections 5.2.4 and 5.3.4). COG values for a range of cell concentration and product titre 
scenarios were calculated at the 2,000 L scale. The COG values were benchmarked against 
worst case performance results predicted using experimental data obtained for the 
centrifugation and depth filtration (30ZA) combination. The most cost effective technology 
option for each cell concentration and product titre combination was calculated to allow for a 
formation of a technology strategy for given aims of cell culture performance in terms of cell 
concentration and titre combinations. 
6.2 Materials and Methods 
6.2.1 Experimental Overview 
Technology options selected based on the screening study and economic analysis 
described in Chapter 5 were, including QSDTM and Bio-Optimal MF-SLTM carried forward into 
a centre composite four factorial DoE design in order to obtain correlations relating key cell 
culture variables to the technology performance outputs (see Figure 6.1). These correlations 
along with assumptions described in Chapter 5 (see sections 5.2.4) were used to perform a 
detailed economic assessment and map the COG for the technology options across the 
selected ranges of cell culture inputs. 
Key cell culture variables with the potential impact on tangential flow filtration operation 
performance were identified to include cell concentration, viability, cell culture titre and HCP 
concentration. These were selected as the factors for the DoE design further described in 
section 6.2.2. Cell culture material with the required variable combinations was generated 
using a 70 L SUB prepared as described in see section 2.2.3. The CCTM material was then 
processed using QSDTM and Bio-Optimal MF-SLTM. 
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Figure 6.1: Overview of the integrated experimental and economic framework for primary recovery technology 
strategy formation. Part 1 of the methodology was described in Chapter 5 providing selected technology candidates 
including centrifugation and 30ZA, Bio-Optimal MF-SLTM and QSDTM options. This chapter will describe Part 2 of the 
experimental framework presenting results for the primary recovery technology strategy. 
 
6.2.2 Design of Experiments Approach 
A centre composite approach for a four factorial design, where the factors included cell 
concentration in the range of 20-100x106 cells/m, IgG1 titre (5-20 g/L), HCP concentration 
(4,000-7,000 µg/mL) and cell culture viability (90-40%) (see Table 6.1). The experimental 
runs were ordered in decreasing order of viability, thus allowing the production of material for 
the entire set of experimental runs using a single 70L SUB cell culture run.   
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Table 6.1: DoE design target value inputs used for Bio-Optimal MF-SLTM and QSDTM experiments. These were 
carried out during the course of one 50 L STR cell culture and therefore were not randomised but were placed in 
descending order of viability conditions. A model verification point was randomly selected. This data point was not 
used for model generation, however was obtained in the same cell culture run as the remaining 23 run conditions.  
Run 
Cell 
concentration 
(x10^6 
cells/mL) 
Titre (g/L) 
HCP 
Concentration 
(µg/mL) 
Viability (%) 
1 100 20 7,000 90 
2 20 20 4,000 90 
3 100 5 4,000 90 
4 20 5 7,000 90 
5 60 12.5 5,500 65 
6 60 12.5 5,500 65 
7 60 12.5 5,500 65 
8 60 12.5 5,500 65 
9 100 5 7,000 40 
10 20 20 7,000 40 
11 100 20 4,000 40 
12 20 5 4,000 40 
Model Verification 
Point 
40 7 5000 50 
 
During the course of the cell culture 2 L of material per day were harvested through the 
harvest line of the 70 L SUB between day 6 and day 14 of the fed-batch culture. The 
harvested cell culture broth was then processed to produce a CCTM corresponding to the 
experimental run conditions described in Table 6.1 using the CCTM methodology described 
in section 4.2. 
Due to the high concentration of the CCTM material produced, large dilution factors were 
required to obtain cell number and viability readings when using the ViCellTM. Thus resulted 
in a higher level of variability in readings than would be typically expected. Therefore 
percentage solids readings were also obtained for the starting material and related to the 
total cell concentration readings. The percentage solids for each experimental run was 
ultimately used as an input for DoE analysis in order to reduce noise within the analysis. 
However, throughout this chapter all inputs and correlations obtained through this analysis 
are related back to total cell concentration (see Figure 6.2), as this is a more relevant metric 
to describe mammalian cell culture properties.  
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Figure 6.2: Total cell concentration (TCD) measured using the ViCellTM versus % Solids (v/v) measured using 
centrifugation of a 5mL cell culture volume. This standard curve was generated and used to convert TCD inputs to 
Design Expert 7.0 Software to obtain equations for each response. All economic result outputs were converted back 
to TCD to provide a more comprehensive set of results. 
Twelve small scale modules of Bio-Optimal MF-SLTM and QSDTM were prepared individually 
by wetting the membrane using purified water for a period of 30 minutes. Water flux of each 
membrane was then tested at a TMP of 0.1 bar and membrane resistance was calculated 
for each module and compared to ensure comparability between the modules. Initial cell 
culture volumes of 43 mL and 65 mL were used for Bio-Optimal MF-SLTM and QSDTM 
respectively. These were calculated based on a maximum throughput for both modules of 75 
L/m2 and a yield of 70%. The dead volumes for Bio-Optimal MF-SLTM and QSDTM were 
measured to be 13 mL and 19.5 mL respectively. The modules were run as described in 
section 2.3.3. Permeate fractions were obtained and OD was monitored to ensure no 
breakthrough occurred. IgG1, HCP and DNA concentration was measured as well as the 
throughput through the membrane. The responses were analysed using the Design Expert 
9.0 Software, where the correlations obtained were used to predict the model verification 
point conditions (see Table 6.1). These were compared to the results obtained in practice. 
Post result analysis of the responses, the correlations obtained were used to model IgG1 
and throughput results as a function of the significant factors identified in the analysis. The 
inputs and the correlations were incorporated into the economic model used in Chapter 5 
(see section 5.2.4). COG outputs were calculated for Bio-Optimal MF-SLTM and QSDTM for a 
single scale scenario of 2,000 L, as this would most appropriately represent a maximum 
likely scale of operation for high cell concentration, high titre processes. Economic model 
assumptions are described in section 5.2.5. 
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6.3 Results and Discussion 
6.3.1 50L Cell Culture Material Generation 
Cell culture material was produced at pilot scale (70 L) using the previously described in 
section 2.2.3 . Cell growth, viability profiles were compared to the previously discussed cell 
culture data obtained at the 5 L and 70 L scales (see Figure 4.2). Cell growth during the 
second run of the 70 L SUB was kept within 10% of the standard deviation of the 5 L scale 
and the previous 70 L results (see Figure 6.3). Cell viability was kept within standard 
deviation of the 5 L and the 70 L scale result obtained previously. A 10% higher maximum 
cell count was achieved at the same running conditions which may indicate a higher average 
cell count at the 70 L scale or a greater batch-to-batch variability. In order to determine 
reasoning for this event a higher number of experimental runs will be required. 
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Figure 6.3: Cell culture growth comparison at 5 L scale and 70 L scales. An average of 5 cell cultures at 5 L scale 
using BIOSTAT B-DCU glass STRs is shown, where viable cell concentration is shown using  ;viability using ; 
and the standard deviation is indicated using . Two repeat 70 L cell cultures were carried out using the 70 L 
CultiBag STR SUB where the viable cell concentration of run 1 is indicated using ; and run 2  ; viability run 1 
 and viability run 2 .   
6.3.2 Models for TFF performance based on cell culture conditions using DoE 
One TFF module was used per experimental condition. Therefore twelve of each type of 
TFF modules were compared in terms of water flux prior to use. Membrane resistance 
between the modules used for the study were found to be within 9% and 25% for the Bio-
Optimal MF-SLTM and QSDTM respectively. The two-fold higher variability in the QSDTM 
modules is most likely due to module number 1 originating from a different lot of membrane 
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material, therefore the variability includes batch-to-batch variation, whereas the Bio-Optimal 
MF-SLTM modules originated from the same manufacturing lot. 
Bio-Optimal MF-SLTM performance was analysed with respect to cell concentration, viability 
IgG1 titre and HCP load (see Table 6.2). Design Expert 8.0 was used to determine the 
significant factors affecting each measured response, including throughput, IgG1 
concentration in the permeate, HCP concentration in the permeate. Significant factors for 
throughput through the membrane were found to be total cell concentration (converted to % 
solids) and cell viability, where throughputs of over 85 L/m2 were possible at the 2-4% solids 
(equivalent to 10-20x106 cells/mL) range at cell viabilities of 70-90% and 20L/m2 at the worst 
case 20% solids (equivalent to 90-100 x106 cells/mL) and <40% viability (see Figure 6.4). 
ANOVA results for the throughput model indicate high significance of both factors as well as 
the overall model (see Table 6.3). The normal plot versus residuals, as well as predicted 
versus actual results are shown in Appendix E. 
Cell concentration and viability have been previously identified to be significant in affecting 
membrane throughput in TFF operations (Stressmann and Moresoli, 2008) and in some 
cases are set as harvest criteria during cell harvest to ensure robust performance of the 
primary recovery step. Typical filtration sizing techniques include a safety factor which is 
applied to the required membrane area for a given scale. Cell concentration was found to 
have a 10 fold effect on the decrease in throughput compared to cell viability (see Table 
6.2). Therefore for a specific process and cell line, where a range of cell concentration at 
harvest is within ±5x106 cells/mL from the average typically obtained, cell viability is not 
predicted to impact throughput significantly, in cases where membrane area has been sized 
using a safety factor of >40%. For tightly controlled processes where cell viability is not 
expected to fall below 60% membrane performance is not predicted to be effected when a 
safety factor of >20% is used. 
Initial IgG1 and HCP concentrations in the CCTM were found to be significant factors in 
determining their respective concentrations in the permeate (see Table 6.3). The percentage 
of product and HCP transmitted through the Bio-Optimal MF-SLTM membrane under the 
explored set of conditions was constant at each of the starting concentrations, independent 
of cell concentration or the starting cell culture viability. Results were also compared to a 
control sample, which showed no significant decrease in IgG1 or HCP concentrations, thus 
suggesting potential protein adsorption to the membrane, or retentate material. Due to the 
high concentration and apparent cell damage of the retentate material, methods used for 
protein and product quantification were deemed insufficient to carry out a mass balance on 
the protein and product concentrations. In the scope of this study moderate but not 
optimised process conditions were selected in order to maintain constant flux and shear 
during processing. In the case that Bio-Optimal MF-SLTM is selected for primary recovery 
operation, further optimisation work will be required to increase product transmission through 
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the membrane. Both factors and models generated for these responses were shown to be 
significant based on ANOVA results given in Table 6.5 (for plots of residuals as well as 
predicted versus actual results see Appendix E). 
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Figure 6.4: Contour plot of the two factors %solids and cell viability which effect throughput of the Bio-Optimal MF-
SLTM. Actual % solid and viability values of the feed material to the Bio-Optimal MF-SL were used as opposed to the 
target conditions. Average values calculated from triplicate measurements using the ViCellTM were used for viability 
and volume measurement pre and post centrifugation was used to obtain % solids. 
 
Table 6.2: Correlations each of the responses calculated using the DoE design applied to the Bio-Optimal MF-SLTM. 
The equations were used to predict Bio-Optimal MF-SLTM performance at given cell culture conditions within the 
range used to generate the correlations. 
Responses for Bio-Optimal MF-SLTM Equation Used to Predict Performance 
Throughput(L/m2) =f(TCD, Viability) 
Throughput = 83-4.2x( %Solids)+0.4x (%Viability) 
Cell concentration (cells/mL) = %Solids/0.172 
[IgG1]Permeate (µg/mL)=f(Titre) [IgG]Permeate=472+0.6x(Titre) 
[HCP]Permeate (µg/mL)=f([HCP] [HCP]Permeate=1707+0.6x[HCP] 
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Analysis of the QSDTM module results in terms of throughput identified cell viability as a 
single significant factor (see Table 6.4). Maximum throughput achieved using this module at 
high viability of ≥90% was 90L/m2, decreasing to a minimum of 4L/m2. Although filter 
capacity can depend on solids load, pore blocking mechanisms also vary depending on feed 
particle size distribution (van Reis and Zydney, 2001). A decrease in cell viability during 
filtration typically causes a decrease in the average particle size, which may cause 
increased pore blocking at this membrane size (0.2µm), to a greater degree than in the case 
of the Bio-Optimal MF-SLTM (0.45µm). However, to explore this further membrane pore size 
should be included as a factor in the experimental design. The throughput achieved by the 
QSD is lower than typically advertised by TFF technology suppliers (140-200L/m2) (Mehta, 
2006). However, the reported figures were generated using 10 fold lower cell concentrations, 
and therefore are not representative in this case. 
IgG1 and HCP concentrations in the permeate were found to be dependent on the starting 
concentration of the respective components, as in the case of Bio-Optimal MF-SLTM. 
However, transmission of HCPs and the IgG1 was found to be greater (70% as opposed to 
60% for the Bio-Optimal MF-SLTM) and also independent of the starting concentration. This 
may be due to the discussed potential difference in the pore blocking mechanism or the 
membrane material. Both models were found to be significant with P values of <0.001 (see 
Table 6.5). See Appendix E shows plots of actual results versus predicted as well as the 
plots of residuals for each factor. 
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Table 6.3: Summary of ANOVA results for the selected model best fitting the results for each of the given responses for both 
the Bio-Optimal MF-SLTM and QSDTM. All selected models as well as the factors within each model are significant where 
significance was defined by a Prob>F value of <0.05. 
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Table 6.4: Correlations each of the responses calculated using the DoE design applied to the QSDTM. The equations were used 
to predict QSDTM performance at given cell culture conditions within the range used to generate the correlations. 
Responses for QSDTM Equation Used to Predict Performance 
Throughput(L/m2) =f(Viability) Throughput = 9.3+0.98x(%Viability) 
[IgG1]Permeate (µg/mL)=f(Titre) [IgG1]Permeate=-102+0.7x(Titre) 
[HCP]Permeate (µg/mL)=f([HCP] [HCP]Permeate=740+0.7x[HCP] 
 
The correlations derived using experimental data for each factor were tested using the predictive 
function of the Design Expert 8.0 software and the data obtained for the model verification point 
during the course of the experimental run. Models used to describe the Bio-Optimal MF-SLTM were 
found to be within 21% of the experimental data within the range of the model (see Table 6.5). The 
QSDTM model was found to be within 15% of the experimental data, where the highest variability was 
seen in the HCP transmission data. One of the limitations of the implemented design is its inability to 
check for curvature in the area outside the tested points. Although centre points are present in both 
designs, some unknown curvature may still be present within the described area and could be a 
potential cause for the higher percentage variation values e.g. throughput and [HCP]Permeate in the 
case of Bio-Optimal MF-SLTM or [HCP]Permeate in the case of the QSDTM. 
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Table 6.5: Summary of the experimental Vs model predicted values for the Bio-Optimal MF-SLTM and QSDTM models calculated 
for each of the selected responses. 
Bio-Optimal MF SLTM Responses Experimental versus Predicted (%) 
Throughput (L/m2) 21 
[IgG] Permeate (µg/mL) 0.5 
[HCP] Permeate (µg/mL) 25 
QSDTM Responses Experimental versus Predicted (%) 
Throughput (L/m2) 1 
[IgG] Permeate (µg/mL) 1 
[HCP] Permeate (µg/mL) 15 
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6.3.3 Economic Assessment 
In order to analyse the potential of the selected technologies for future primary recovery operation the 
two identified TFF technologies were assessed on their economic viability by modelling their 
performance at the 2,000L scale of operation, at the cell concentration, product titre, viability and 
impurity concentration ranges expected to be reached in the future. Correlations derived from the 
experimental data, described in section 6.3.2 were used to calculate membrane sizing requirements 
in each cell culture scenario in conjunction with assumptions described in sections 5.2.4 and 5.2.5 to 
complete the economic assessment.  
COG generated for the Bio-Optimal MF-SLTM and QSDTM were compared to the COG generated by 
the centrifugation and 30ZA depth filtration model, where inputs included the 20-100x106 cells/mL cell 
concentration range and low cell viability scenarios. COG ratios of the TFF option to centrifugation 
and depth filtration option were calculated for each of the alternative technologies at 40% cell viability 
centrifugation and 30ZA option (see Figure 6.5).When comparing the COG values and throughput for 
centrifugation & 30ZA to Bio-Optimal MF-SLTM, the Bio-Optimal MF-SLTM showed a higher COG than 
centrifugation &30ZA option for cell concentrations below 60x106 cells/mL, however, for cell 
concentrations >60x106 cells/mL Bio-Optimal MF-SLTM was the more economically viable option. The 
QSDTM COG was 3-4 fold higher than that predicted for the centrifugation & 30ZA option at cell 
concentrations below 50x106 cells/mL and 2-fold higher at 50-80x106cells/mL. However, the option 
becomes economically viable once cell concentrations exceed 80x106cells/mL. In both cases 
centrifugation and 30ZA COG becomes increasingly less efficient with increasing cell concentration, 
due to the yield losses encountered as a result of solids discharge during centrifugation. The 
centrifuge used to model yield losses for the 2,000L scale of operation was selected to represent an 
average current design (Alfa Laval BTPX-205). However, alternative centrifuge designs which may be 
implemented in the future could significantly reduce the yield loss at this stage e.g., KSep 
technologies may provide an alternative to the classic solids discharge mechanisms potentially 
allowing for a reduction in yield loss (Ko and Bhatia, 2012).  
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Figure 6.5: Calculated COG ratios for 40% cell viability, the explored range of cell concentrations and titre at the 2,000L scale comparing A: Bio-Optimal MF-SLTM : Centrifugation & 30ZA option and 
B: QSDTM : Centrifugation & 30ZA option.  
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Bio-Optimal MF-SLTM and the QSDTM COG was compared for a range of cell viabilities at a fixed cell 
concentration of 60x106 cells/mL (see Figure 6.6). The impact of viability on the Bio-optimal MF-SLTM 
COG is lower than that on QSDTM COG.  The material costs of the QSDTM modules was 2-fold higher 
(see section 5.2.5). Hence, any impact on performance arising as a consequence of an increase of 
the surface area results in a significant increase in COG compared to the Bio-Optimal MF-SLTM 
option.  In order to achieve equivalent COG for the Bio-Optimal MF-SL and QSD modules a cell 
culture process may be operated  at a product titre of >14g/L for the Bio-Optimal MF-SL and a titre of 
10-14g/L and a viability of >60% or a titre of 18-20g/L at the low viability range of 30-40%. 
Titre increases are typically achieved via a combination of cell concentration and cell specific 
productivity increases (see section 3.3.1). The lowest cost primary recovery options for the 
combinations of cell concentrations and titres possible to achieve in the future were calculated for the 
worst case viability of 40% (see Figure 6.7). All options with COG values within 0.05 RMU/g were 
stated as viable for a given specific cell concentration and viability combination. Centrifugation and 
30ZA option has the lowest COG for harvests of cell concentrations below 60x106 cells/mL. The Bio-
Optimal MF-SLTM data matches the COG of the centrifugation and 30ZA option between 60x106 and 
80x106 cells/mL, however for titres of <8g/L Bio-Optimal MF-SLTM is the lowest cost option. At cell 
concentrations of >80x106 cells/mL and titres of >12g/L the QSDTM option matched the Bio-Optimal 
MF-SLTM COG, making both options equally viable.  
Current cell culture harvest strategies tend to specify harvest criteria in terms of cell viability to ensure 
the success of the primary recovery step to follow as well as other reasons which may be product or 
cell line specific (e.g. product stability).   It may therefore be argued that the QSDTM, although 
sensitive to changes in cell viability could act as a future proof robust option, as its performance was 
least sensitive to changes in cell concentration. For cases where a change in technology is 
significantly less desirable than the cost of the primary recovery step, QSDTM may provide a single 
technology option which will be viable across the cell concentration and titre ranges explored in this 
study. 
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Figure 6.6: Cost of goods (RMU/g) modelled for a range of cell viability and titre scenarios at the 2,000L scale for a 60x106 cells/mL cell concentration scenario. A: Bio-Optimal MF-SLTM; B: QSDTM. 
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Figure 6.7:  Summary of economically viable technologies at the given cell concentration and titre ranges. Economically viable 
technology is defined as the lowest COG at the given scenario, all viable options within a 0.05 RMU/g range are shown for 
each scenario.  
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6.4 Conclusions 
This final chapter has presented a second successful scale up run of the 70 L Sartorius CultibagTM 
single use bioreactor. Peak viable cell count during the course of the batch exceeded the expected 
cell count obtained at the 5 L scale, however more runs would be required to determine whether a 
higher average cell concentration is achieved consistently at the 70 L scale. 
 
The material generated at the 70L scale produced cell culture test material for a DoE study used to 
identify correlations for the significant key cell culture variables which affect Bio-Optimal MF-SLTM and 
QSDTM performance. The correlations were than used to calculate COGs for combinations of cell 
concentration, titre and impurity concentrations for conditions currently seen in mammalian cell culture 
and those expected over the next decade (2,000 L scale scenario).  
 
Bio-Optimal MF-SLTM throughput performance was found to be affected by a combination of total cell 
concentration and viability, where cell concentration had a fourfold higher impact on throughput and 
impacted directly the membrane area required. IgG1 and HCP concentrations in the permeate were 
independent of cell concentration or viability and depended on starting protein concentration in both 
cases of the product and impurity, where 60 % of the starting HCP and IgG1 concentrations were 
found in the permeate. QSDTM throughput performance was directly dependent on cell viability and 
did not correlate significantly with cell concentration. However further experiments would be 
recommended to confirm the absence of curvature in the explored design space. 70% of HCP and 
IgG1 was found to be present in the permeate, suggesting lower potential product loss in the case of 
QSDTM when compared to the Bio-Optimal MF-SLTM. All found correlations were tested using 
randomly selected experimental conditions within the tested range. All of the QSDTM and Bio-Optimal 
MF-SLTM correlations were found to be within 25% of the predicted range. 
 
COG was calculated for the two alternative TFF options at the full range of cell concentration, viability 
and titre combinations tested and benchmarked against the COG calculated for the centrifugation and 
30ZA option. The comparison showed the centrifugation and 30ZA option to be the most cost 
effective across the titre range at cell concentrations <50x106 cells/mL For the Bio-Optimal MF-SLTM 
option it was equally cost effective at cell concentrations of 60-90x106 -80x106 cells/mL and more cost 
effective than the centrifugation and depth filtration option at titres less than 8g/L. Once cell 
concentrations exceed 80x106 cells/mL the Bio-Optimal MF-SLTM was most cost effective at the lower 
titre ranges and QSDTM becomes equally as cost effective once titres exceed 12 g/L. Finally, it may 
also be argued that the single future proof technology, independent of cost would be the QSDTM as its 
performance is not dependent on cell concentration, and therefore would provide a robust option for 
processes where the harvest viability is controlled. 
 
Implementing the use of a new technology not previously employed in the process is classed as a 
major process change. Obtaining approval for such a change will typically require a substantial 
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validation and supporting data package. The next chapter will discuss the validation considerations 
involved when implementing these sets of changes to existing processes.  
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7. Chapter 7: Validation Considerations in Implementation of Major Process Changes to 
Exiting Processes 
Process validation strategies as well as validation of process changes have been driven 
towards the implementation of continuous improvement through risk management and quality 
by design approaches since the publication of the “Guidance for Industry- Process Validation: 
General Principles and Practices” by the FDA (Scott, 2011). In addition, the new guidance 
documents produced by the International Conference on Harmonisation Technical 
Requirements for Registration of Pharmaceuticals for Human Use (ICH) address process 
validation issues in ICH Q7 (Good Manufacturing Practice), ICH Q8 (Pharmaceutical 
development) and ICH Q11 (Development and Manufacturing of Drug Substances). These 
guidelines provide a basis of drug registrations in the EU, US and Japan, and highlight that 
qualification efforts alone are no longer sufficient without established process control over the 
course of the process lifetime. 
Changes to existing manufacturing processes can include minor, moderate and major 
changes recording categories. A major change carries the potential to adversely affect the 
identity, strength, quality, purity or potency of a drug product. Making such a change requires 
approval from the FDA, prior to the distribution of the resulting product material. Thus a “Prior 
Approval Supplement No 314.70(b)” must be submitted. In order to identify the potential 
impact of the process change, an assessment of the effects of the change must first be 
carried out. This includes the assessment of the change on the product conformance to 
specification in terms of the listed acceptance criteria. Once the material is deemed to 
continue to meet specification, additional testing is recommended to assess the change effect 
on product identity, quality, strength or effectiveness. During the course of performing the 
additional testing product equivalence of the product before and after the change must be 
demonstrated.  
Currently, the manufacturing costs of biopharmaceutical products are far outweighed by the 
R&D costs involved in the search for a successful drug candidate and the manufacturing 
process continues largely to define the drug product, despite drive towards the QbD 
approach. This means that risk can be carried through to GMP drug manufacture stages in 
cases where high uncertainty within the processing strategy exists.  
As primary recovery and purification operation performance can be highly dependent on cell 
culture, it becomes very important to ensure the robustness of the downstream strategies. 
One of the ways in which this could be achieved is by developing a highly robust primary 
recovery stream which can cope with the likely variance produced by the variability in cell 
culture operations, and consequently keep the purification of the resultant product stream 
functioning consistently and reliably.  
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This thesis has discussed primary recovery strategies in the context of implementation in a 
contract manufacturing organisation (CMO), producing a range of biological products for a 
wide range of companies from small biotech to big pharma. Typically, production contract 
lengths and production scale may vary; some customers may only need production for one 
Phase of a clinical trial, and may want to transfer the process to their own facility at a later 
stage, whereas other projects may require large scale manufacture.  
Chapter 6 identified two tangential flow filtration options for primary recovery with the potential 
to provide cost effective technology options for the future. The validation package required for 
their implementation in place of a current processing options would depend on whether they 
are applied as a single use or reusable technology. Single-use equipment is increasingly 
recognised as an advantageous option for CMO use (Fuller and Pora, 2008), however, re-
using the TFF technologies up to 5-10 times significantly reduces the COG (see section 
6.3.3). 
Assuming that the selected TFF technology will be re-used up to 10 times, cleaning validation 
studies will be required. In addition, reusability studies of the TFF option at small scale would 
be required as well as a validation at large scale. In addition, the TFF modules used for the 
purpose of the studies described in this thesis, have been designed to be sterilised using a 
70% ethanol rinse cycle and hold. Steam sterilisation cannot be used due to the adhesives in 
the construction of the modules not being able to withstand the sterilisation temperature. This 
may be considered less reliable to autoclaving, and require a more extensive validation data 
package. 
Re-using the TFF filters would require leak testing and filter integrity testing to be verified at 
end of each batch run which would increase the post processing activity times. Having to 
carry out a leak or integrity testing at the end of each run introduces an additional 
contamination risk by introducing additional solution and material handling stages. Although 
leachables and extractables testing is associated with single-use equipment, the validation 
effort associated with this may still apply to this unit operation as safety will still have to be 
demonstrated. 
Three to four pressure sensors would be required for a reliable module operation during 
processing, which are not currently a part of the system. These would also have to be 
installed and verified prior to use. The key pressure sensors required for operation include the 
feed and the permeate pressure sensors, without these being fully functional the unit 
operation cannot proceed reliably. A plan to mitigate the risk associated with their failure 
should be included in the control strategy (e.g. a procedure to change pressure sensors 
during processing, include spare sensors prior to start of a batch etc). Single use pressure 
sensors could potentially serve as a viable option as they can be purchased as part of the 
single-use flow path, pre-validated and thus changed after each run. 
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A separate validation issue which applies to primary recovery operations in general includes 
defining control point criteria for material release for further processing. As cell culture 
material can be highly variable, it is important to ensure a consistent output by the primary 
recovery unit operations to reduce potential batch failure. For example, it may be easier to 
ensure consistent solids removal specification during primary recovery by introducing 
appropriate safety factors during filter or membrane sizing, however if impurity removal 
specification is introduced, it may be more difficult to meet if changes in impurity profile or 
load are detected. However, if specific changes to the impurity profile or load have been 
found to influence the Quality Target Product Profile (QTPP) they must be part of the control 
strategy and included in the control point criteria. 
The following section will provide an overview of the conclusions drawn throughout the 
chapters of this thesis. It will also propose additional future work which would strengthen the 
arguments presented to date. 
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8. Chapter 8: Conclusions & Future Work 
The continuing trend of rising mammalian cell culture densities and titres in the 
biotechnology industry has been increasing the strain on primary recovery operations 
bringing into question the limit to the current technologies and the search for suitable 
alternatives for implementation. Choosing a suitable technology for an existing platform 
process is difficult, particularly with long term robust performance in mind. The overall 
methodology and results discussed in this thesis have created a structured approach to the 
testing and selection of primary recovery technologies based on providing robust processing 
of cell culture material expected over the next decade.  
 
8.1 Overall Conclusions 
The first aim of this thesis, described in Chapter 3, was to identify current and future 
demands on primary recovery operations by surveying expert opinion. This survey was 
carried out successfully in order to quantify the current and expected trends in cell culture, 
primary recovery and purification operations.  
The results of the survey agreed with the literature in confirming that primary recovery and 
purification constraints have been experienced. Based on this the survey also highlighted 
the need for impurity removal to be a capability of the desired primary recovery technology 
as well as solids removal. In addition, a general increase in demand for new technologies 
across the biotechnology sector was also identified. 
Expected titre and cell concentration ranges were also identified for the future cell culture 
feed to primary recovery based on expert opinion, which was confidence waited and 
averaged across the surveyed population.  Expected titre in 2020 was estimated to be in the 
range of 10-20 g/L with an expected cell concentration projected to be in the range of 50-
100x106 cells/mL. The upper limits of these ranges were then used throughout the following 
chapters as a worst case for the cell culture material that the technologies would face in the 
future.  
Priority criteria for impurity removal targets for the primary recovery technologies were 
identified. HCP removal was identified as the primary concern, followed by DNA and product 
aggregate removal.  
Chapter 4 aimed to develop and demonstrate an experimental methodology for the creation 
of a mammalian cell culture test material (CCTM), consistent with the anticipated profile in 
the next decade. Cell concentration, cell viability, product and impurity concentrations were 
each manipulated to achieve a range of cell culture test conditions to provide a controlled set 
of key variables in the cell culture feed to primary recovery. Key cell culture parameters 
including cell concentration, cell viability, product and HCP concentrations were successfully 
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decoupled. The CCTM method was found to decouple the selected variables in the cell 
culture feed to downstream operations, while providing consistent material which is 
representative of typical cell culture material in terms of key features such as particle size 
distribution and HCP population. The accurate replication of these features made this 
methodology suitable for application in primary recovery studies to test the potential for the 
technologies to cope with the high cell concentration, high titre conditions expected in the 
future. 
Chapter 5 aimed to use a combination of cell culture test materials (CCTM), ultra scale-
down technologies, multi-attribute decision-making methods, process economics and facility 
fit considerations,  to demonstrate a methodology and results for achieving a screening of 
current and alternative primary recovery technologies. The example technologies tested 
using this method included three centrifugation and depth filtration options (using 05SP, 
10SP and 30ZA media), and two alternative tangential flow filtration options (using Bio-
Optimal MF-SLTM and QSDTM hollowfibre modules).  
 
MADM analysis as well as selection based on current technology performance criteria 
showed that only two options met the yield and purity criteria: Bio-Optimal MF-SLTM and the 
QSDTM. The centrifugation and the 30ZA option met the purity criteria but not the yield 
criteria. The options were further evaluated based on their economic performance. This 
showed the centrifugation and 30ZA option to be the least cost-effective across the 2,000 L, 
10,000 L and 20,000 L scale scenarios and not fit the facility constraints set based on a 
typical existing large-scale facility. The Bio-Optimal MF-SLTM option was the most cost-
effective option across the 2,000-20,000 L scales of operation.  
 
Chapter 6 presented a DoE study which was used to identify correlations for the significant 
key cell culture variables which affect Bio-Optimal MF-SLTM and QSDTM performance. The 
correlations were than used to calculate COGs for combinations of cell concentration, titre 
and impurity concentrations for conditions currently seen in mammalian cell culture and 
those expected over the next decade (2,000 L scale scenario).  
 
Bio-Optimal MF-SLTM throughput performance was found to be affected by a combination of 
total cell concentration and viability, where cell concentration had a fourfold higher impact on 
throughput and impacted directly the membrane area required. QSDTM throughput 
performance was directly dependent on cell viability and did not correlate significantly with 
cell concentration. However further experiments were recommended to confirm the absence 
of curvature in the explored design space. All of the QSDTM and Bio-Optimal MF-SLTM 
correlations were found to be within 25% of the predicted range. 
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The COG comparison showed the centrifugation and 30ZA option to be the most cost 
effective across the titre range at cell concentrations <50x106 cells/mL. For the Bio-Optimal 
MF-SLTM option it was equally cost effective at cell concentrations of 60-80x106 cells/mL and 
more cost effective than the centrifugation and depth filtration options at titres less than 8 
g/L. Once cell concentrations exceed 80x106 cells/mL the Bio-Optimal MF-SLTM was most 
cost effective at the lower titre ranges and QSDTM became equally as cost effective once 
titres exceed 12 g/L. Overall, it was argued that the single future proof technology, 
independent of cost would be the QSDTM as its performance is not dependent on cell 
concentration, and therefore would provide a robust option for processes where the harvest 
viability is controlled. 
 
8.2 Future Work 
Proposal 1 
CCTM material was shown to be representative of some key features of mammalian cell 
culture including particle size distribution and the range of host cell proteins it provides. 
However, the material is expected to be limited in its comparability to true high cell 
concentration cell culture material, each variable of interest has been individually altered, as 
opposed to being caused by a realistic scenario. There is scope for a comparative run 
testing the primary recovery of CCTM material versus high cell concentration material.  It is 
proposed that the high cell concentration material is generated using the same cell line as is 
used for the CCTM material generation. The CCTM material would be made up to mimic the 
high cell concentration culture as closely as possible, in terms of cell concentration, titre and 
HCP concentration. Particle size distributions, HCP populations and titre are recommended 
to be compared between the two material sets. In addition to this, shear sensitivity of the 
cells is also recommended to be compared. This is proposed to be carried out using a shear 
device, which can provide consistent shear for the testing both materials. Particle size 
distribution prior and post shear exposure should be compared. This would expose any 
effects of the culture method on cell robustness and subsequently question whether the 
CCTM should be produced using the same or similar cell culture techniques in order to 
result in material adequately representative for primary recovery operations.  
Proposal 2 
Method validation studies are also recommended in order to explore the robustness of the 
DoE design used to derive correlations for the performance of the Bio-Optimal MF-SLTM and 
the QSDTM in Chapter 6. Although reliability data for the CCTM material described above 
would strengthen the case for the use of the correlations, it would not provide sufficient data 
to show that the use of high cell concentration material from a different origin would not 
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result in alternative performance profile in either technology. This may be an issue for two 
factors: 
- The use of CCTM versus true high cell concentration material 
- The use of an alternative cell line for the generation of the high cell concentration 
material. 
It is therefore recommended to explore both options by using material produced in proposal 
1 for the comparison of the Bio-OptimalTM and QSDTM performance at a single cell culture 
condition. A separate experimental would be required to test the two options using an 
alternative cell line. 
Proposal 3 
The identified primary recovery technologies have been assessed based on direct 
application for cell removal, as well as impurity removal. Achieving impurity removal earlier 
in the process was aimed at reducing the burden on downstream operations, however this 
theoretical benefit has not been fully explored. A further study is recommended, aimed at 
quantifying the impact of the change in the primary recovery step on protein A resin lifetime, 
as well as impurity removal in the bulk drug product. This would help to create an even more 
complete analysis of the process consequences of adopting technology advances. 
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10. Appendices  
10.1 Appendix A 
 
Mammalian cell processing industry trends and their impact on primary recovery 
 
Daria Popova, EngD Researcher with Lonza Biologics and UCL 
Academic supervisors: Nigel Titchener-Hooker & Suzanne Farid 
Industrial supervisor: Ashley Westlake 
Significant increases in cell culture titres have resulted in higher cell concentrations, product 
masses and impurity loads. This has increased strain on both primary recovery and 
purification operations. This is especially a challenge in facilities which have been designed 
to cope with lower titres and cell concentrations.  This survey is part of the UCL–Lonza 
EngD collaboration on assessing and improving the current performance of primary recovery 
operations when used in processing of high cell concentration feed streams. The research 
will greatly benefit from interviews with experts in different processing areas so as to gain a 
complete and accurate overview of the current and potential future pressures on primary 
recovery. We are seeking your input to gain insight into the following trends: 
 
 Increase in CMO popularity and its effect on the current capacity at Lonza, 
highlighting the operating area which experiences most capacity constraints.  
 Effect of increases in titre, cell concentration and impurity levels over the recent 
years 
 Consequences of decrease in clarification efficiency 
 Future expectations in terms of customer demand and its effect on future processing 
 The impact of increasing titres and cell concentrations on the future requirements of 
each processing area 
 Changing future regulatory demands  
 
 
The survey will be carried out in an interview form and should take no longer than 20-30 
minutes. The questionnaire consists of 12 questions, most of which are multiple choice, 
however discussion and additional comments are most welcome. Any stated figures or 
values disclosed during the process will remain confidential. During analysis any exact 
values will be desensitised. If you are interested, the results of the survey can be emailed to 
you when the study is complete. 
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FOR EACH QUESTION PLEASE ALSO INDICATE YOUR CONFIDENCE RATING  as 
H/M/L where 
H = high confidence based on data/experience,  
M = medium confidence based on gut feeling,  
L = low confidence based on a guess 
 
 
1. In production using mammalian cell culture, which processing areas have you 
experienced operational constraints over the last 2 years?  
 
(You are welcome to tick more than one box) 
 
i. Cell culture 
 
ii. Primary recovery 
 
iii. Purification 
 
iv. Other (Please specify)  
 
v. None have been experienced 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Confidence (H,M,L) 
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2.  
a. In your experience have you observed an increasing customer interest in 
alternative unit operations to those you currently offer? 
 
i. Yes  
 
ii. No 
 
 
 
b. If yes, which are most commonly requested? 
 
i. Alternative cell culture options 
 
  Please tick if you are referring to perfusion culture 
 
ii. Flocculation options 
iii. Precipitation 
iv. Cell settling/ sedimentation 
v. Expanded Bed Adsorption 
vi. Protein A alternatives   (Please specify) 
 
 
vii. Other primary recovery options  (Please specify) 
 
 
viii. Other purification options   (Please specify) 
 
 
 
 
 
Confidence (H,M,L) 
 
 
 
 
 
 
 
 
 
 
 
Confidence (H,M,L) 
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3. Do you feel there is pressure to limit cell concentrations due to operational 
constraints experienced in downstream operations? 
 
i. Yes  
 
ii. No 
 
 
 
 
4. What maximum cell concentrations do you expect to achieve over the next 
decade? 
 
i.   Please Specify  
 
 
 
 
5. What maximum mAb titres do you expect to achieve over the next decade? 
 
ii.   Please Specify  
 
 
 
 
 
 
 
Confidence (H,M,L) 
 
 
Confidence (H,M,L) 
 
 
Confidence (H,M,L) 
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6. What cell culture strategies do you expect will allow you to achieve the higher cell 
concentrations and titres? 
 
(You are welcome to tick more than one box) 
 
 
i. Fed- batch stirred tank reactor 
 
ii. Perfusion stirred tank reactor 
 
iii. Alternative media 
 
iv. Alternative feeding strategy 
 
v. Alternative cell line 
 
vi. Other                  
 
(Please specify) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Confidence (H,M,L) 
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7. Titre increases are usually due to increases in cell concentrations or specific 
productivities or a combination of both. Please rank the following routes to 
achieving a 2-fold increase in titre from 4g/L to 8g/L for a particular cell line in 
order of likelihood, where 1 is the most likely and 5 the least likely? 
  
a. 2-fold increase in cell density  
 
b. 2-fold increase in specific productivity  
 
c. Increases in both cell density and specific productivity 
 
 
 
 
 
8. What cell density levels could cause operational constraints in these recovery 
options? 
 
(You are welcome to tick more than one box) 
 
  
Cell density (cells/mL) Confidence 
(H,M,L) 
 
3x10
6 
5x10
6 
1x1
07 2x107 5x107 N/A 
i. 
 
Recovery by depth  
filtration alone 
       
ii
. 
 
Recovery by 
centrifugation  
& depth filtration 
       
 
 
 
 
 
 
 
Confidence (H,M,L) 
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9. Assuming the current purification capacity, what % removal of each impurity 
would be desirable from a primary recovery stage so as to avoid constraints in 
purification? 
 
(You are welcome to tick more than one box) 
 
    
% Removal 
1-
10% 
10-
20% 20-40% 
i HCP    
ii Aggregates    
iii DNA    
iv 
Other-  Please 
state: 
   
v.  
Other-  Please 
state: 
   
 
 
 
Confidence (H,M,L) 
 
 
Appendix A 
154 
 
 
10. Please rank the following cell culture induced impurities in order of difficulty of 
removal, where 1 is the simplest to remove and 5 is the most difficult. 
 
  Rank 
i HCP  
ii Aggregates  
iii DNA  
iv Other-  Please state:  
v Other-  Please state:  
 
 
 
 
11. If no changes are made to purification for the next 5 years, what HCP levels would 
cause operational constraints in chromatography operations? 
 
(You are welcome to tick more than one box) 
 
  
HCP load  1,000,000 (ng/mg) 
N/
A 
Confiden
ce (H,M,L) 
Titre (g/L) 1 2 5 10 
Absolute HCP 
load (ng/mL) 
1,000,00
0 
2,000,00
0 
5,000,00
0 
10,000,00
0 
 
i. Protein A       
ii. AEX       
iii. CEX       
 
 
 Confidence (H,M,L) 
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12. What factors do you believe will lead to increases in HCP levels? 
 
(You are welcome to tick more than one box) 
 
i. Low viability cell culture 
 
ii. High shear during centrifugation 
 
iii. High cell density of the culture 
 
iv. High titre 
 
 
 
 
 
 
 
 
 
 
 
 
Confidence (H,M,L) 
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13.a. With improvements in PAT technologies and assays, do you envisage the 
regulatory authorities imposing changes to lot release specifications? 
 
 
i. Yes 
 
ii. No 
 
iii. Don’t know 
 
 
 
 
 
 
 
b.  If Yes, please indicate what changes may be expected 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Confidence (H,M,L) 
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14.a. With new assays for HCP detection giving higher readings, is it likely to lead 
to higher demands on recovery and purification? 
 
i. Yes 
 
ii. No 
 
iii. Don’t know 
 
 
 
 
 
 
 
b. If yes, please state the key problem you think this would cause for your current 
processing. 
 
 
 
 
 
 
Confidence (H,M,L) 
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10.2 Appendix B 
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Figure 10.1: Viable cell concentration (VCD) and titre curves achieved using the 5 L STR described in section 
4.3.1.VCD for fed batch run 1( ), fed batch run 2 ( ), fed batch run 3 ( ), fed batch 4 (X), fed batch run 5 ( ). 
IgG4 titre achieved during the course of the respective batches are shown for fed batch 1 ( ), fed batch 3 ( ), fed 
batch 4 (*), fed batch 5 ( ). 
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10.3 Appendix C 
B C
F
A
D E
 
Figure 10.2: Example 2D PAGE images used for image analysis and comparison of HCP removal across the 
primary recovery technologies tested. The images shown include the cell culture test material used to test the 
primary recovery technologies (A); centrifugation and 05 SP depth filtration medium option (B); centrifugation and 
10 SP depth filtration medium option (C); centrifugation and 30ZA depth filtration option (D); Bio-Optimal MF-SLTM 
option (E); QSDTM option (F). 
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10.4  Appendix D 
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Figure 10.3: Statistical diagnostic charts for the throughput response of Bio-Optimal MF-SLTM under the selected 
model conditions. A: Normal plot of studentised residuals. B: A plot of throughput predicted by the selected model 
versus the actual experimental results. 
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Figure 10.4:  Statistical diagnostic charts for the IgG1 concentration in the permeate response of Bio-Optimal MF-
SLTM under the selected model conditions. A: Normal plot of studentised residuals. B: A plot of IgG1 concentration 
in the permeate predicted by the selected model versus the actual experimental results. 
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Figure 10.5: Statistical diagnostic charts for the HCP concentration in the permeate response of Bio-Optimal MF-
SLTM under the selected model conditions. A: Normal plot of studentised residuals. B: A plot of HCP concentration 
in the permeate predicted by the selected model versus the actual experimental results. 
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Figure 10.6: Statistical diagnostic charts for the throughput response of QSDTM under the 
selected model conditions. A: Normal plot of studentised residuals. B: A plot of throughput 
predicted by the selected model versus the actual experimental results. 
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Figure 10.7: Statistical diagnostic charts for the IgG1 concentration in the permeate response of QSD
TM under the 
selected model conditions. A: Normal plot of studentised residuals. B: A plot of IgG1 concentration in the permeate 
predicted by the selected model versus the actual experimental results 
 
Appendix E 
165 
 
Design-Expert® Software
[HCP] Permeate
Color points by value of
[HCP] Permeate:
8471
2123
Externally Studentized Residuals
N
o
rm
a
l 
%
 P
ro
b
a
b
il
it
y
Normal Plot of Residuals
-2 0 2 4 6
1
5
10
20
30
50
70
80
90
95
99
Design-Expert® Software
[HCP] Permeate
Color points by value of
[HCP] Permeate:
8471
2123
Actual
P
re
d
ic
te
d
Predicted vs. Actual
2000
3000
4000
5000
6000
7000
8000
9000
2000 3000 4000 5000 6000 7000 8000 9000
A
B
 
Figure 10.8: Statistical diagnostic charts for the HCP concentration in the permeate response of QSDTM under the 
selected model conditions. A: Normal plot of studentised residuals. B: A plot of HCP concentration in the permeate 
predicted by the selected model versus the actual experimental results. 
 
 
 
